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Abstract 
In the thesis presented here, novel co-crystals of two active pharmaceutical ingredients 
(APIs), i.e. paracetamol and furosemide are presented. Co-crystals are molecular complexes 
in which two or more components are held together through non-covalent interactions. The 
work on co-crystals was aimed to investigate and identify robust hydrogen bonds and primary 
structural motifs which can be used to predict the solid-state assembly in related molecular 
complexes. 
The Database mining based on retro-synthetic approach followed by co-crystal screening 
using mechano-chemical and crystallisation methods in conjunction with high-throughput 
powder X-ray analysis led to the discovery of four novel co-crystal forms of paracetamol. The 
study shows that a balance between the retrosynthetic approach and database screening of 
supramolecular synthons provides a useful approach for targeted co-crystal synthesis. 
 The ability of charge transfer hydrogen bonding interaction to drive the assembly of 
molecules in co-crystals was investigated. This led to the synthesis of a series of isostructural 
host-guest complexes of furosemide. It has been discovered that charge transfer interaction 
drives the crystal packing arrangement in presence of other hydrogen bonding interactions. 
The ability of two component physical mixture to form ternary co-crystals has been 
investigated. Systematic synthesis with careful selection of components based on simple 
geometric principles led to the discovery of a series of ternary co-crystals stabilised through a 
novel two-dimensional hydrogen-bonded network, which serves a prototype for a new family 
of ternary co-crystals. This has enabled a targeted approach for the selection and synthesis of 
new ternary co-crystals with control over symmetry and gross structural features. The study 
demonstrates that networks that maintain their dimensionality and integrity provide a degree 
of predictability in the crystal packing arrangements in the solid state.  
 
III 
 
 
Acknowledgements 
I take this opportunity to express my sincere gratitude to my supervisor Prof. Anthony Vivian 
Powell and my co-supervisor Dr. Arno Kraft for their constant support and guidance 
throughout the course of this study. 
I wish to thank my industrial collaborator, Dr. Stephen Watt from Solid Form Solutions for 
allowing me to use their thermal instruments. 
Support from the Scottish Funding Council and Heriot-Watt University is greatly 
acknowledged. 
Finally, I would like to thank all my lab mates in the Solid State Chemistry Group. 
 
 
  
IV 
 
Table of Contents 
Abstract 
Acknowledgements 
Research thesis submission form 
Table of contents 
List of abbreviations  
 
Chapter 1: Introduction.   
1.1. Introduction .......................................................................................................................... 1 
1.2. The nature and types of intermolecular interactions ............................................................ 1 
1.2.1. Ionic bonds .................................................................................................................... 2 
1.2.2. Hydrogen bonds ............................................................................................................ 2 
1.2.2.1. Discovery of the hydrogen bond ............................................................................ 2 
1.2.2.2. Definition of hydrogen bond .................................................................................. 3 
1.2.2.3. Types of hydrogen bonds ....................................................................................... 5 
1.2.3. van der Waals interactions ............................................................................................ 6 
1.2.3.1. Distinction between weak hydrogen bond and van der Waals interaction ............ 7 
1.2.4. Halogen bonding ........................................................................................................... 8 
1.2.5. π–π interactions ............................................................................................................. 9 
1.3. Supramolecular synthon..................................................................................................... 12 
1.3.1. Types of synthons ....................................................................................................... 14 
1.4. Graph-set analysis of intermolecular interactions.............................................................. 14 
1.5. Crystal engineering ............................................................................................................ 15 
1.5.1. Molecular assemblies formed by intermolecular interactions .................................... 16 
1.5.2. Appendage structures .................................................................................................. 16 
1.5.3. Zero-dimensional networks ........................................................................................ 17 
1.5.4. One-dimensional hydrogen-bonded networks ............................................................ 18 
1.5.5. Two-dimensional hydrogen-bonded networks ........................................................... 19 
1.5.6. Three dimensional hydrogen-bonded networks .......................................................... 22 
1.5.7. Three-dimensional hydrogen bonding networks in binary systems ........................... 23 
1.5.8. Host-guest assemblies ................................................................................................. 24 
1.5.8.1. Tunnel type inclusion complexes with directionally bonded hosts ..................... 25 
V 
 
1.5.8.2. Tunnel type inclusion complexes with van der Waals bonded hosts................... 25 
1.5.8.3. Tunnel type two-component host network .......................................................... 26 
1.5.8.4. Clathrate inclusion compounds ............................................................................ 27 
1.6. Co-crystals or molecular complexes in the context of the pharmaceutical industry ......... 28 
1.6.1. Pharmaceutical co-crystals .......................................................................................... 29 
1.6.1.1. Hydrate formation ................................................................................................ 30 
1.6.1.2. Chemical Stability ................................................................................................ 31 
1.6.1.3. Dissolution rate .................................................................................................... 31 
1.6.1.4. Bioavailability ...................................................................................................... 32 
1.6.1.5. Co-crystals with improved solubility profiles...................................................... 32 
1.7. Salts .................................................................................................................................... 33 
1.8. Undesirable forms of APIs................................................................................................. 33 
1.8.1. Polymorphism ............................................................................................................. 34 
1.8.2. Solvates ....................................................................................................................... 34 
1.8.3. Chiral drugs ................................................................................................................. 35 
1.8.4. Solid-state transformations ......................................................................................... 35 
1.8.5. Solvent-mediated transformations .............................................................................. 35 
 
Chapter 2: Experimental methods. 
2. Co-crystal synthesis .............................................................................................................. 37 
2.1. Mechano-chemical methods of co-crystallisation ......................................................... 37 
2.2. Crystallisation from solution.......................................................................................... 37 
2.3. Powder X-ray diffraction ............................................................................................... 38 
2.4. X-ray diffraction ............................................................................................................ 41 
2.4.1. Background ............................................................................................................. 41 
2.4.2. Structure factor and electron density ...................................................................... 43 
2.4.3. The phase problem .................................................................................................. 44 
2.4.4. Solutions to the phase problem ............................................................................... 44 
2.5. Least-squares refinement ............................................................................................... 47 
2.6. Single crystal X-ray diffraction (SXRD) ....................................................................... 48 
2.7. Spectroscopic methods................................................................................................... 51 
2.7.1. Nuclear Magnetic Resonance (NMR) ..................................................................... 51 
VI 
 
2.7.2. Infrared spectroscopy .............................................................................................. 52 
2.8. Thermo analytical methods ............................................................................................ 53 
2.8.1. Differential Scanning Calorimetry (DSC) .............................................................. 53 
2.8.2. Thermogravimetric Analysis .................................................................................. 53 
2.9. Cambridge Structural Database in crystal engineering .................................................. 54 
 
Chapter 3: Crystal Engineering Methods for the Synthesis of Paracetamol Co-crystals. 
3.1. Introduction ........................................................................................................................ 55 
3.2. CSD analysis ...................................................................................................................... 61 
3.3. Results and discussion ....................................................................................................... 65 
3.3.1. Co-crystal (1) [(paracetamol)1-(trans-1,4-diaminocylcohexane)0.5] ........................... 65 
3.3.2. Co-crystal (2) [(paracetamol)2.0-(1,2-di(4-pyridyl)ethylene)1.0-(MeOH)1.0] ............... 70 
3.3.3. Co-crystal (3) [(paracetamol)2.0-(1,2-di(4-pyridyl)ethane)2.0] .................................... 75 
3.3.4. Co-crystal (4) [(paracetamol)4.0-(1,4,8,11-tetraazacyclotetradecane)1.0] .................... 79 
3.4. Discussion .......................................................................................................................... 83 
3.5. Conclusion ......................................................................................................................... 87 
 
Chapter 4: Hydrogen-Bonded Host-Guest Complexes of Furosemide. 
4.1. Introduction .................................................................................................................... 88 
4.2. Results and discussion ................................................................................................... 92 
4.2.1. Crystal structure description of molecular complex (5) [(furosemide)1-
(imidazole)1] ..................................................................................................................... 92 
4.2.2. Crystal structure description of molecular complex (6) [(furosemide)1-
(piperazine)1]..................................................................................................................... 96 
4.2.3. Crystal structure description of molecular complex (7) [(furosemide)1-(1,4,8,11-
tetraazacyclotetradecane)0.5] ........................................................................................... 100 
4.2.4. Crystal structure description of molecular complex (8) [(furosemide)1-(1,2-bis(4-
pyridyl)ethane)0.5] ........................................................................................................... 104 
4.2.5. Crystal structure description of molecular complex (9) [(furosemide)1-(1,2-di(4-
pyridyl)ethylene)0.5] ........................................................................................................ 109 
4.2.6. Crystal structure description of molecular complex (10) [(furosemide)1-(4,4’-
bipyridyl)0.5] .................................................................................................................... 112 
4.3. Discussion .................................................................................................................... 118 
VII 
 
 
Chapter 5: A Robust Two-Dimensional Hydrogen-Bonded Network for the Predictable 
Assembly of Ternary Co-crystals.  
5.1. Introduction ...................................................................................................................... 122 
5.2. Co-crystal (11) [(furosemide)1- (4,4’-bipyridyl)0.5] ......................................................... 125 
5.2.1. Synthesis of co-crystal (11) ...................................................................................... 125 
5.2.2. Crystal structure of co-crystal (11) ........................................................................... 126 
5.3. Co-crystal (12) [(furosemide – bipyridyl – DMSO (1-1-1)] ............................................ 128 
5.3.1. Crystal structure of co-crystal (12) ....................................................................... 128 
5.4. Co-crystal (13) [(furosemide – bipyridyl – MeOH (1-1-1)] ............................................ 132 
5.4.1. Synthesis of co-crystal (13) ...................................................................................... 132 
5.4.2. Crystal structure of co-crystal (13) ........................................................................... 133 
5.5. Co-crystals (14) [(furosemide – bipyridyl – ethanol (1-1-1)]; (15) [(furosemide – 
bipyridyl – 2-propanol (1-1-1)]; and (16) [(furosemide – bipyridyl – 1-butanol (1-1-1)] ...... 137 
5.5.1. Mechanochemical synthesis of ternary co-crystals (14), (15), and (16) ................... 137 
5.6. Co-crystals (17) [(furosemide – 4,4’-bipyridyl – ethylene glycol (1-1-0.5))]; (18) 
[(furosemide – 4,4’-bipyridyl – 1,4-butanediol (1-1-0.5))]; (19) [(furosemide – 4,4’-bipyridyl 
– hydroquinone (1-1-0.5))] ..................................................................................................... 144 
5.6.1. Crystal structure of co-crystal (17) [(furosemide – 4,4’-bipyridyl – ethylene glycol 
(1-1-0.5))]............................................................................................................................ 145 
5.6.2. Crystal structure of co-crystal (18) [(furosemide – 4,4’-bipyridyl – 1,4-butanediol (1-
1-0.5))] ................................................................................................................................ 149 
5.6.3. Crystal structure of co-crystal (19) [(furosemide – 4,4’-bipyridyl – hydroquinone (1-
1-0.5))] ................................................................................................................................ 153 
5.7. Conclusion ....................................................................................................................... 156 
 
Chapter 6: Conclusions and Further Work. 
6.1. Conclusions ...................................................................................................................... 159 
6.1.1. Molecular complexes of paracetamol ........................................................................... 159 
6.1.2. Molecular complexes of furosemide ............................................................................. 160 
6.1.3. Proton transfer ............................................................................................................... 160 
6.1.4. The asymmetric two-dimensional hydrogen bonded network ...................................... 161 
6.2. Further work..................................................................................................................... 162 
VIII 
 
6.3. Concluding remarks. ........................................................................................................ 163 
 
References 
Appendices 
Publications 
 
  
IX 
 
List of Abbreviations 
 AIM – Atoms in molecules 
APIs – Active pharmaceutical ingredient  
NCEs – New chemical entities 
CCF – Co-crystal formers 
OX – S-oxiracetam 
RH – Relative humidity 
NFLX – Norfloxacin 
R&D – Research and Development 
1D, 2D, 3D – One, two and three dimensional 
PXRD – Powder X-ray diffraction 
SXRD – Single crystal X-ray diffraction  
ATR - Attenuated total reflectance 
IR – Infrared 
DSC – Differential scanning calorimetry  
TGA – Thermogravimetric analysis 
CSD – Cambridge Structural Database 
CIF – Crystallographic Information File 
PAC – Paracetamol 
BPEA – 1,2-bis(4-pyridyl)ethane 
BPEE – 1,2-di(4-pyridyl)ethylene  
Cyclam – 1,4,8,11-tetraazacyclotetradecane 
DMSO – Dimethyl sulphoxide 
FUR – Furosemide  
IM – Imidazole  
PIP – Piperazine 
BIPY – 4,4’-bipyridyl 
 
1 
 
Chapter 1: Introduction. 
1.1. Introduction 
Intermolecular interactions in molecular crystals are responsible for the extraordinarily 
specific way in which molecules interact to form a highly ordered crystalline material. These 
intermolecular interactions referred to as molecular recognition events are significant features 
of biological and chemical systems. The ensemble of intermolecular interactions ultimately 
defines the physical properties and reactivity of any given solid. Therefore understanding the 
intermolecular interactions has attracted interest from scientists in various disciplines, ranging 
from solid-state chemists to protein crystallographers, theoreticians and crystal engineers. A 
better understanding of the intermolecular interactions is imperative for efficient co-crystal 
synthesis. This introduction chapter will discuss the types of intermolecular interactions, 
outline the use of dimensional solids in the context of the crystal engineering challenges, in 
particular co-crystals, explain the relevance of co-crystals in the pharmaceutical industry and 
provide examples related to enhancing the properties of pharmaceutical compounds.  
 
1.2. The nature and types of intermolecular interactions 
All molecules possess the potential for some type of intermolecular interactions.
1
 When two 
atoms or molecules come together, the interactions between them could be attractive or 
repulsive depending on the mutual orientation of the two molecules. When these interactions 
are attractive they contribute to the stability of the molecules. However, the interaction 
between two atoms is not always attractive; it becomes repulsive after a certain distance and 
the curve of the interaction energy follows the Morse-like shape curve.  In the literature, for 
molecular crystals, there are many classifications of intermolecular interactions.
2
 An 
intermolecular interaction consists of the following energy components (1) exchange-
repulsion; (2) electrostatic interactions; (3) polarisation interactions; and (4) dispersion 
interactions. The interactions can be represented in an analytical form and are interdependent 
on each other to a certain extent. The intermolecular interactions relevant to the work 
presented here can be classified into 
1. Ionic bonds. 
2. Hydrogen bonds. 
3. van der Waals interactions. 
4. Halogen bonding. 
5. π–π interactions. 
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1.2.1. Ionic bonds  
Ionic bonds are observed in molecular crystals in which at least one of the components 
possess a net charge. The simplest case involves two atoms with opposite signs, such as 
X
+
···Y
-
 bond. The prototypical example is the NaCl crystal containing Na
+
···Cl
-
 interactions. 
Ionic bonds also exist in crystals where only one of the species involved possesses a net 
charge while the other is a neutral component; examples of such types are the ion-solvent 
interactions. These interactions are characterised as charge-induced hydrogen bonds.
3
 In ionic 
bonds, the total interaction energy is dominated by the electrostatic term. In ion-ion 
interactions, the total interaction energy is dominated by the charge-charge term, while in ion-
neutral interactions the total interaction energy is dominated by the charge-dipole or charge-
quadrupole terms, depending on the nature of the neutral species involved. 
 
1.2.2. Hydrogen bonds  
1.2.2.1. Discovery of the hydrogen bond 
The influence of the hydrogen bond was observed in gaseous, liquid and solid state long 
before it was identified and given a name. A literature survey of the late 19
th
 and early 20
th
  
century shows references which, in retrospect, could be perceived as evidence of hydrogen 
bonding. The terms Nebenvalenz (near valence) and innere Komplexsalzbildung were used by 
German chemists Werner
4
, Hantzsch
5
 and Pfeiffer
6
 to describe both inter- and intramolecular 
hydrogen bonds. 
 
According to Linus Pauling, the concept of the hydrogen bond can be attributed to M. L. 
Huggins, as well as W. M. Latimer and W. H. Rodebush. Latimer and Rodebush
7
 published a 
paper which contained the statement that “the hydrogen nucleus held by two octets constitutes 
a weak bond”. In a paper entitled the Electronic Structure of Atoms, Huggins8 stated that “a 
positively charged kernel containing no electrons in its valence shell (i.e. H
+
) reacting with an 
atom containing a lone valence pair can form a weak bond”. 
 
In the late 1920s and early 1930s crystal structures of NaHF2
9
, urea
10
, and NH4F2 began to 
appear but nothing was mentioned about hydrogen bonding. None of the authors used the 
term hydrogen bond in their original publications. It was Pauling in 1931 who wrote a general 
paper on the nature of chemical bond, where he possibly for the first time used the term 
hydrogen bond. This paper was the precursor to his famous book Nature of the Chemical 
Bond
11
 where he introduced the concept of hydrogen bonding to the chemical world. He noted 
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that “under certain conditions an atom of hydrogen is attracted by rather strong forces to two 
atoms instead of only one, so that it may be considered to be acting as a bond between them”. 
This he called the hydrogen bond. 
 
1.2.2.2. Definition of hydrogen bond  
Hydrogen bonds are of fundamental importance in chemistry and biology. The hydrogen bond 
usually lies in the energy range between covalent bonds and van der Waals interactions. The 
weakest of the hydrogen bonds are difficult to be distinguished from the van der Waals 
interactions, while the strongest of hydrogen bonds are energetically stronger than some of the 
weak covalent bonds. Therefore, in molecular crystals there exists a continuum of energy 
going form covalent bonds to hydrogen bonds to van der Waals interactions. An 
intermolecular interaction X-H···A is called a hydrogen bond if (1) it constitutes a local bond 
and (2) X-H acts as a proton donor to A. The X-H group is called the proton donor and the A is 
called a proton acceptor. In this definition the hydrogen bond is in principle viewed as an 
incipient proton transfer reaction. The above definition incorporates the acid-base properties 
of the donor X-H and acceptor, A groups. This definition of a hydrogen bond excludes the van 
der Waals contacts, agostic interactions and does not set a threshold value for an interaction to 
be called a hydrogen bond, provided the above two conditions are satisfied. In the simplest 
case, the donor interacts with one acceptor. However, complex situations like bifurcated and 
trifurcated hydrogen bonds arise when one donor is hydrogen-bonded to two or three acceptor 
groups, or an acceptor is bonded to more than one donor group. Theoretically a hydrogen 
bond is possible between two, three or more acceptors. However, in practice hydrogen bonds 
with more than three acceptor groups are rarely observed experimentally due to steric 
hindrance.  
 
The above definition of a hydrogen bond requires the evidence for the existence of a bond 
between the H···X groups. Identifying the evidence for the existence of a bond is at times 
problematic, especially in cases involving weak interactions. One criterion for the existence of 
a bond is based on atoms in molecules theory (AIM).
12
 The AIM theory requires the molecule 
to be energetically stable and must possess at least one critical point between the atoms. This 
method of ascertaining the existence of a bond requires some computation on the 
experimentally observed structures. Other, readily available criteria for the existence of the 
bond are based on analysing the geometrical features of the hydrogen bond and these provide 
evidence directly from the structure.  
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Evidence of intermolecular bond directly from crystal structures: 
1. The evidence for the existence of intermolecular bonds is based on empirical observations. 
This criterion is based on the electrostatic nature of the X-H···A hydrogen bond, the dipole 
X-H donor group prefers to align with the negative acceptor group A so as to minimize the 
interaction energy. Ideally the interaction energy will be at a minimum when the angle 
made by the X-H···A interaction is close to 180
o
. The tendency of the angle made by the X-
H···A interaction to be close to 180
o
 is considered as a criterion for the evidence of a strong 
hydrogen bond and can be readily measured in any crystal structure. 
2. The evidence of an intermolecular bond can be obtained by measuring the percentage 
contraction from the van der Waals cut off radii. The shorter the H···A distance in X-H···A 
interactions, the greater the percentage contraction of van der Waals cutoff radii. It must 
me mentioned that hydrogen bonds possess long range distances and in some cases 
especially weak interactions like C-H···O and C-H···N the H···O/N distance can be 
greater than the sum of van der Waals radii. In such cases, other complementary criteria 
must be considered. 
3. Evidence of the presence of an intermolecular hydrogen bond can also be obtained from 
spectroscopic data. For example, the presence of a hydrogen bond manifests itself with a 
decrease in the value of X-H stretching frequency (νX-H) in the infrared spectrum when 
compared to a free X-H bond; this is called a red-shifted hydrogen bond. At this place it is 
appropriate to mention that in some unconventional hydrogen bonds an increase in the X-H 
stretching frequency is noticed when compared to a free X-H bond. These are called blue 
shifting hydrogen bonds. 
4. In cases where the above criteria do not give concrete proof, especially in interactions 
involving weak C-H···O and C-H···N contacts, evidence for the existence of 
intermolecular interactions can be obtained by calculation and inspection of Hirshfeld 
surfaces. The Hirshfeld surfaces provide direct visual evidence for the existence of the 
hydrogen bonds. An X-H···A interaction is represented by a different colour on the 
calculated Hirshfeld surface. Strong interactions have intense red colours, while weak 
interactions are represented as light colours. 
The factors that determine the existence of a bond are also the properties of the hydrogen 
bonds. In addition to the above factors, one of the important properties of hydrogen bonds is 
cooperativity. Accordingly, the energy of a series of m interlinked hydrogen bonds is larger 
than the sum of the m isolated hydrogen bonds. Functional groups, like the alcohols which can 
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act simultaneously as donors and acceptors form extended chains or rings in which the 
individual hydrogen bonds enhance each other's strength due to mutual polarisation.  
In addition to these, in suitable π–systems, charge flow due to polarised hydrogen bonds 
increases the strength of the hydrogen bonds, which are referred to as charge assisted 
hydrogen bonds. 
 
 1.2.2.3. Types of hydrogen bonds  
Given the importance of the hydrogen bonds in organic crystal engineering, these are divided 
into three categories based on their strength. The three categories as suggested by Jeffrey are 
(a) strong (b) moderate and (c) weak hydrogen bonds.
2
 Hydrogen bonds which have an 
interaction energy between 4 to 14 kcal mol
-1
 are referred to as moderate hydrogen bonds. 
The hydrogen bonds that have the interaction energy stronger than 14 kcal mol
-1
 are called 
strong hydrogen bonds, while the ones that have the interaction energy less than 4 kcal mol
-1
 
are called as weak hydrogen bonds. Table 1.1 shows the three different types of hydrogen 
bonds as proposed by Jeffrey.  
 
Strong hydrogen bonds are sub-divided into three types based on the nature of the donor-
acceptor groups, these are (a) neutral···neutral hydrogen bonds, formed between the donor 
and acceptor groups possessing no net charge and the dominant electrostatic term is made up 
of dipole-dipole interactions; (b) charge···charge hydrogen bonds, here the dominant 
electrostatic term is the stronger charge-charge component; (c) neutral···charge hydrogen 
bonds, in which the electrostatic component is dominated by the charge – dipole term.  
 
Moderate hydrogen bonds are generally formed between neutral donor and acceptor groups, 
i.e. of the type O-H∙∙∙O and N-H∙∙∙O interactions. These hydrogen bonds have an interaction 
energy that lies between 4-14 kcal mole
-1
. In these hydrogen bonds, the donor  atoms (X) are 
more electronegative relative to hydrogen and the acceptor A atoms have lone-pair unshared 
electrons in a X-H···A hydrogen bond. These are the most common type of hydrogen bonds 
found in nature and are also called normal hydrogen bonds. 
 
 
Weak hydrogen bonds are formed between weak donors and strong acceptors (eg. C-
H···O=C), between strong donors and weak acceptors (N-H···Ph, O-H···Se) and between 
weak donor–weak acceptors (C≡C-H···C≡C) groups and possess interaction energy less than 
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4 kcal mol
-1
. The first systematic study on C-H···O interactions was done by Sutor in 1962.
13
 
Sutor assumed van der Waals distance in a H···O contact to be 2.6 Å and repeatedly observed 
very short C-H···O distances in theophylline (d = 2.25 Å), caffeine (d = 2.12 Å) and uracil (d 
= 2.20, 2.27Å). She called these interactions as C-H···O interactions which were a subject of 
debate for a long time and is historically called the Sutor–Donohue controversy. 
 
Table 1.1: Types of hydrogen bonds. 
 Strong Moderate Weak 
Interaction type Strongly covalent Mostly electrostatic Electrostatic/dispersion 
Bond lengths (Å) 
H···A 
1.2 – 1.5 1.5 – 2.2 > 2.2 
Lengthening of X-H 
(Å) 
0.08 – 0.25 0.02 – 0.08 <0.02 
X-H versus H···A X-H~H···A X-H<H···A X-H<<H···A 
X···A [Ǻ] 2.2-2.5 2.5-3.2 >3.2 
Directionality Strong Moderate Weak 
Bond angles [
o
] 170-180 >130 >90 
Bond energy [kcal/mol] 15-40 4-15 <4 
Effect of crystal 
packing 
Strong Distinctive Variable 
Relative IR shift ΔνX-H 
[cm
-1
] 
25% 10-25% <10% 
 
1.2.3. van der Waals interactions  
Van der Waals interactions form the extreme end of the attractive forces between molecules. 
Weak attractive forces between uncharged atoms or molecules are collectively referred to as 
van der Waals forces. These forces arise from the electrostatic attraction of the nuclei of one 
molecule for the electrons of a different molecule. The repulsions between the electrons and 
the nuclei of the two molecules counteract the electrostatic attractions, but there is always a 
small net attractive force. Van der Waals forces are short-range forces, that is, they are only 
significant when the molecules are very close to one another. There are two types of van der 
Waals forces: dipole-dipole interactions and London (or dispersion) forces. 
1. Dipole-Dipole Interactions: These interactions arise because of the electronegativity 
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property of the atoms, molecules become polar which gives rise to a net dipole moment. 
The net dipole moment of a molecule is the resultant of the vector addition of the 
individual bond dipoles in the molecule. The larger the dipole moment of a molecule, the 
greater the dipole-dipole interactions between molecules.  
2. London or Dispersion forces: A fluctuating dipole moment in one atom induces a 
temporary dipole moment in a nearby atom in such a way that there is a net attraction 
between the two rapidly fluctuating dipoles. This attractive force between a pair of rapidly 
fluctuation dipoles whose electronic motions are correlated is called the London dispersion 
force, named after Fritz London. The strength of the dispersion force depends on how 
easily the electron cloud of the atom or molecule can be distorted or polarized.  
 
1.2.3.1. Distinction between weak hydrogen bond and van der Waals interaction  
The difference between a weak hydrogen bond and van der Waals interaction can be 
understood by analysing different types of C-H···O interactions. It is well recognised that C-
H groups can act as weak hydrogen bond donors. The C-H donor strength depends on the 
hybridisation of the carbon atom involved and follows the trend C(sp)-H > C(sp
2
)-H > C(sp
3
)-
H. While the bonds formed by acidic C-H groups (alkynes) are moderately strong, those that 
involve weakly polarised C-H groups are much weaker.  
 
The main structural feature that distinguishes hydrogen bonds from van der Waals 
interactions is the directionality of the hydrogen bonds. The hydrogen bonds tend to exist in 
linear geometry or close to linear geometry whereas van der Waals contacts are isotropic.  
 
The angular characteristics of the weak C-H···O hydrogen bonds are retrieved from 
Cambridge structural database (CSD), for those involving C(sp)-H, C(sp
2
)-H, C(sp
3
)-H in 
conjunction from data with those for van der Waals contacts of the type C-H···H-C. The 
details are given in Table 1.2. Table 1.2 shows the gradual decrease in the directionality of C-
H···O interactions with decreasing C-H polarisation, but is still clearly different from the 
perfectly isotropic C-H···H-C contacts.    
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Table 1.2: Data showing difference between C-H···A hydrogen bonds and C-H···H-C 
contacts. 
Contact type Mean (H···A) (Å) Mean X···A(Å) Mean X-H···A(
o
) 
HC C H O C  2.360(4) 3.312(2) 152.0(2) 
2HC CH2 O C  2.670(1) 3.561(2) 143.1(1) 
2HC CH3 O C  2.761(6) 3.590(7) 137.1(7) 
2HC CH3 H C  2.500(2) 3.246(4) 128.6(3) 
 
1.2.4. Halogen bonding  
The term “halogen bond refers to an attractive interaction between a halogen atom X and an 
atom or a group of atoms in different molecules(s), where there is evidence of bond 
formation”.14 Analogous to hydrogen bonding interactions, energetic and directional 
behaviours are observed in halogen bonding interactions. 
To understand halogen bonding, we should consider the anisotropic distribution of electron 
density around the halogen atom as shown in Figure 1.1. It is observed that for the halogen 
bonds chlorine (Cl), bromine (Br) and iodine (I) a positive electrostatic potential develops on 
the outer surface of the halogen atom, centered along the intersection of the covalently bonded 
C-X axis, while there is a negative electrostatic potential throughout the halogen atom. The 
positive electrostatic potential is referred to as a “σ–hole”. The presence of the positive 
regions on halogen atoms is responsible for the halogen atoms acting as lone pair acceptors in 
molecular crystals. The term halogen bonding refers exclusively to the ability of halogen 
atoms to act as electron acceptors. It must be mentioned that organofluorine almost never acts 
as a hydrogen bond acceptor.
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Figure 1.1: Anisotropic distribution of electron density around the halogen atoms. The 
halogen atom shows a negative electrostatic potential and maximum radius along the 
equatorial region and positive electrostatic potential and minimum radius along the polar 
region. 
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All halogen···halogen interactions show directional preferences. These directional preferences 
of halogen···halogen interactions are divided into two types  
(a) type-I (θ1 = θ2) and  
(b) type-II
16
 (θ1 =180
o
 and θ2 = 90
o
) (Scheme 1.1), where θ1 and θ2 are the C-X···X-C 
angles (X = Cl, Br, I).  
Type-I interactions (scheme 1.1(a)) symmetrical interactions, and occur whilst possessing a 
crystallographic inversion centre in crystal structures. Type-II interactions (scheme 1.1(b)) are 
unsymmetrical halogen···halogen interactions and usually occur around a screw axis or glide 
plane and are explained using the anisotropic model presented above. It has been observed 
that the possibility of formation of type-II interactions increases as the halogen atom becomes 
more polarisable, i.e. moving down the group from chlorine to iodine.
17
 It has been recently 
noticed that X···X contacts in hexachlorobenzene (C6Cl6) and its isostructural analogues 
(C6Br6 and C6I6) cannot be grouped into either of the above two types. The packing 
arrangement in these crystal structures is governed by using the trimer motif shown in scheme 
1.1(c).
18
 The trimer motif is known to act as a supramolecular synthon.
19
 
 
Scheme 1.1: Halogen···halogen interactions, (a) type –I and (b) type – II (c) the trimer 
synthon 
 
1.2.5. π–π interactions 
Non-covalent interactions between aromatic moieties play a significant role in determining 
the structure and properties of molecular assemblies in Chemistry, Biology and Material 
Science. The π–π interactions constitute one of the important classes of non-covalent 
interactions. 
In a given molecule more than one type of π–π interaction can exist. Understanding the nature 
of π–π interactions in substituted benzene rings is fundamental in crystal engineering and 
material science. π–π interactions in substituted benzene rings occur in various geometries 
10 
 
shown below (Figure 1.2). Typically the aromatic rings are arranged in a face–to–face 
(sandwich configuration) or an offset face–to–face20 (parallel - displaced) geometry (Figure 
1.2), or slipped by a certain angle (α) (Figure 1.3). However, structures that are near–
sandwich configurations are observed in some crystal structures. Another common interaction 
motif between benzene rings is the edge-to-face or perpendicular (T-shaped) configuration. 
Intermediate configurations between parallel and perpendicular-type configurations are 
frequently observed in chemical/biological systems. 
H
Sandwich T-shaped Parallel-displaced  
Figure 1.2: Prototypical π-π configurations observed in benzene dimers. 
 
 
H H
HH
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Figure 1.3: Face-to-face/center-to-edge with a slip angle (α) (left) and face-to-face/center-to-
center (right) geometries in aromatic systems. 
 
An electrostatic model of the nature of π–π interactions in substituted aromatic rings was 
proposed by Hunter and Sanders.
21
 In this model, for each contributing carbon atom in the π 
system, Hunter and Sanders placed a +1 charge at each carbon nucleus and a -1/2 charge 
above and below the plane of aromatic ring, representing the π–cloud. According to Hunter 
α 
H H 
H H 
H H H H 
H H 
H H 
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and Sanders model, the electron–withdrawing substituents reduce the negative quadrupole 
charge from the negatively charged π–clouds, favouring the formation of parallel displaced 
face – to – face and/or sandwich configurations. While the electron donating groups increase 
the negative charge of the π–cloud, which may favour the formation of a T-shaped 
configuration. These rules for stacking interactions prevailed until sophisticated computations 
were available. Theoretical calculations on mono–substituted benzene dimers indicated that 
both the electron-withdrawing and electron-donating groups increase the attraction between 
the benzene rings leading to the formation of a sandwich-type orientation.  It is noticed that 
the attraction is due to the strong attractive London dispersion term contributing to the 
interaction energy, which overcomes the repulsive/unfavourable electrostatic term leading to 
the formation of a sandwich type orientation.
22,23
 When the two electron clouds overlap, the 
diffuse electron clouds do not repel each other as compared to the point charges. The electron-
to-nucleus attraction terms slightly outweigh the sum of electron to electron and nuclear to 
nuclear repulsion terms leading to the formation of a sandwich orientation in substituted 
benzene rings.  
N N N
N
Aligned Anti-aligned
(Py)2 (Py)2
N
(Bz) - (Py)(Bz)2
 
Figure 1.4: Sandwich configurations of the benzene, benzene-pyridine, and pyridine 
dimmers. 
 
Many naturally occurring aromatic heterocyclic compounds possess at least one heteroatom in 
the π system. There can be four possible configurations in a system containing one benzene 
and one pyridine. These systems generally form the sandwich geometries shown in Figure 
1.4. From the possible sandwich geometries, the anti-aligned pyridine dimer is the most stable 
configuration while the aligned pyridine dimer is the least stable geometry in the sandwich 
arrangement. This is due to the dipole-dipole interactions that exist between the aligned 
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pyridine dimers. Theoretical calculations have shown that the electrostatic term is attractive 
for all the four model sandwich complexes shown in Figure 1.4 with the benzene-pyridine 
sandwich geometry being the most stable. It has been noticed that the dispersion term, while 
being favourable for the formation of the benzene dimer, is the least favourable for the 
pyridine dimer, with values for benzene-pyridine combination falling in between. More 
theoretical calculations are required in order to understand the interactions between 
substituted pyridine moieties. The other types of π–π interactions i.e. the cation–π and anion–
π are not of interest to the thesis presented here and hence are not mentioned. 
Arene–arene interactions between various substituted aromatic rings represent an important 
class of supramolecular synthon in organic crystal engineering. These synthons have been 
extensively used for the design and synthesis of molecular complexes. Arene–arene 
interactions in cooperation with other interactions such as hydrogen bonding interactions are 
used for the synthesis of supramolecular architectures.
24
 
 
1.3. Supramolecular synthon  
The term “synthon” was first coined by E. J. Corey in 1967 in an article entitled “General 
methods for the construction of complex organic molecules”.25 A synthon is described as an 
identifiable design element and incorporates both geometric and chemical recognition features 
of the molecules. Desiraju extended the term synthon in the supramolecular context and called 
it a supramolecular synthon which is defined as “structural units within supermolecules which 
can be formed and/or assembled by known or conceivable synthetic operations involving 
intermolecular interactions”.26 Examples of some supramolecular synthons commonly 
studied in supramolecular chemistry are shown in Scheme 1.2. 
 
The association of supramolecular synthons uniquely defines a crystal structure. 
Supramolecular synthons can be used in a retrosynthetic approach to predict the crystal 
packing arrangements in related crystal structures. The retrosynthetic process for predicting 
the crystal packing arrangement effectively involves analysing a number of related crystal 
structures and identifying supramolecular synthons in which a given functional group or 
combination of functional groups can participate. While some synthons are sufficiently 
dominant and may invariably occur in the presence of a particular functional group, it is 
challenging to identify and reproduce combinations of supramolecular synthons in related 
crystal structures. This happens because of the following reasons. 
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1. Since all the hydrogen bonding/ intermolecular interactions are weak, a small increase in 
the molecular functionality will increase the number of possible and competing 
supramolecular synthons very quickly.  
2. Structural interference from remote molecular functionalities may be fickle and 
unpredictable.  
3. The final and perhaps the most difficult to handle is the interference from the hydrocarbon 
residue, though this hydrocarbon core is generally considered not to be a functional group 
in molecular chemistry, it is known to exhibit supramolecular functionality by participating 
in non-covalent interactions.  
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Scheme 1.2: Commonly occurring supramolecular synthons. 
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1.3.1. Types of synthons   
Supramolecular synthons can be divided into two distinct categories: 
Supramolecular homosynthons (Scheme 1.2) that are composed of identical complementary 
functional groups also referred to as self-association motifs. Examples are carboxylic acid 
dimers, amide dimers, etc. 
Supramolecular heterosynthons (Scheme 1.2) composed of different but complementary 
functional groups such as acid-amide, acid- pyridine, etc. It is quite well documented that 
some of the supramolecular heterosynthons are preferred over the corresponding 
supramolecular homosynthons. 
 
1.4. Graph-set analysis of intermolecular interactions 
Analysis of hydrogen-bonded networks in molecular solids may be achieved using graph 
sets.
27
 The analysis of hydrogen bonding networks is based on the fact that complex hydrogen 
bonding networks can be reduced to combinations of simple patterns. The simple patterns 
observed in molecular crystals are designated as chains (C), rings (R), intramolecular 
hydrogen-bonded patterns (S), and other finite patterns (D) (Scheme 1.3). The hydrogen 
bonds in molecular crystals are described by these pattern designators followed by a subscript 
representing the number of hydrogen–bond donors (d), and a superscript representing the 
number of hydrogen bond acceptor groups (a), while the number of participating atoms are 
represented by a number n, within parentheses as (n). 
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1
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4  
Scheme 1.3: Pattern designators in hydrogen-bonded systems. 
 
Based on the number and complexity of the hydrogen-bonded network present in a crystalline 
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compound different pathways of graph set analysis can be followed. These are unitary, binary, 
ternary or higher levels of graph set analysis. In the thesis presented here the unitary level of 
graph analysis are used. 
 
1.5. Crystal engineering   
Crystal engineering of molecular solids is concerned with the rational design of functional 
molecular solids.
28
 Co-crystal synthesis is imperative for effective crystal engineering and 
vice versa. The term crystal engineering was first introduced by Pepinsky in 1955.
29
 The 
concepts of crystal engineering have been applied by chemists, solid-state chemists in 
particular, theoreticians, crystallographers, and protein crystallographers. Schmidt was 
amongst the first to implement the concepts of crystal engineering to organic solid-state 
photochemistry.
30
 Thomas while reviewing organic solid-state photochemical reactions noted 
that the reactivity of organic compounds in the solid state is governed by the molecular 
orientation and stacking sequences in the crystal structures.
31
 The term crystal engineering is 
defined as “the understanding of intermolecular interactions in the context of crystal packing 
arrangements and utilisation of such understanding in the design and synthesis of new solids 
with desired properties”. Crystal engineering depends on the use of non-covalent interactions 
to assemble molecules in the solid state; an effective control of non-covalent interactions is 
required for effective crystal engineering. Initially, crystal engineering work focussed on 
systems containing purely organic compounds, which in recent years has been extended to 
inorganic systems. Drawing an analogy between intermolecular bonds and covalent bonds, 
Lehn noted that an intermolecular bond in a supermolecule is analogous to a covalent bond in 
a molecule.
32
 Following this argument, Dunitz stated that “a crystal is a supermolecule par 
excellence”.33 This statement in essence states that a crystal represents a higher level of 
complexity when compared to molecules with the crystallisation process being the 
supramolecular reaction. The ability to build crystal structures from the molecular structures 
would therefore require a complete understanding of the crystallisation process. 
Understanding the crystallisation process is the ultimate aim of crystal engineering, this would 
then allow the prediction of crystal structures from molecular structures and the synthesis of 
higher order crystals. The rational synthesis of higher order crystals is necessary if we are to 
ever understand the enormously complex molecular recognition process in biological systems. 
Understanding intermolecular interactions in terms of molecular recognition units lies at the 
heart of crystal engineering. 
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1.5.1. Molecular assemblies formed by intermolecular interactions  
One of the principal challenges in crystal engineering or molecular co-crystal synthesis is to 
predict the crystal structure and property of molecular solids from the molecular structure of 
the constituent components.
34
 In this context, molecular solids stabilised through predefined 
solid state structures can find important applications for developing new solids. Predefined 
molecular structures are usually conceived though hydrogen bonding interactions. Many 
design strategies for the synthesis of molecular complexes or co-crystals are based on utilising 
the complementary nature of hydrogen bonding interactions.
35
 Combinations of hydrogen 
bonding interactions can lead to the formation of a wide variety of molecular assemblies. 
These can be categorized into 0D, 1D, 2D and 3D molecular architectures, host guest 
assemblies and appendage structures. The hydrogen bonding interactions in these complexes 
can be homomeric or heteromeric and involve neutral or charge-assisted interactions.  These 
networks can serve as modules in the design and synthesis of molecular materials. In addition, 
robust supramolecular modules significantly reduce the number of possible solid-state 
packing motifs.  
 
1.5.2. Appendage structures  
Appendage structures are formed in systems containing more than one component. In these 
structures, one component forms a hydrogen-bonded network, to which the other component 
is appended through hydrogen bonding interactions without being part of the network formed 
by the first component. The simplest examples of appendage structures is the complex formed 
by formic acid with hydrogen fluoride.
36
 The structure shows chains of hydrogen-bonded 
formic acid molecules to which H-F molecules are appended through F-H···O and C-H···F 
hydrogen bonds (Scheme 1.4).  
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Scheme 1.4: Structure of formic acid····hydrogen fluoride. 
17 
 
1.5.3. Zero-dimensional networks 
Molecular complexes are said to have zero–dimensionality when the components in a crystal 
are hydrogen-bonded to from a discrete group. Molecular complexes stabilised though zero-
dimensional networks are observed in systems containing one two and three component 
systems.  
Zero-dimensional hydrogen-bonded networks in unitary systems: 
Benzoic acid is a prototypic example of a solid stabilised though a homomeric zero-
dimensional network. The carboxylic acid groups form a cyclic 𝐑𝟐
𝟐(8) motif through two O-
H···O interactions (Scheme 1.5). 
O
O H O
OH
 
Scheme 1.5: Hydrogen bonding in benzoic acids. 
 
Zero-dimensional hydrogen-bonded networks in binary co-crystals: 
An example of a zero-dimensional hydrogen-bonded network in a binary system is shown in 
Scheme 1.6. The co-crystal contains two components, cinnamic acid (A) and isonicotinamide 
(B).
37
 The two components arrange in an A-B-B-A arrangement to form a discrete zero-
dimensional network. The supermolecule is stabilised through acid-pyridine and amide-amide 
supramolecular synthons (Scheme 1.6). The robustness of the network is demonstrated by the 
synthesis and structure solution of a series of binary co-crystals stabilised through acid-
pyridine and amide-amide supramolecular synthons, suggesting that it is an example of a 
high-yielding supramolecular reaction.  
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Scheme 1.6: Discrete zero-dimensional network observed in co-crystals of cinnamic acid and 
isonicotinamide.
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Zero-dimensional hydrogen bonding network in ternary co-crystals: 
Ternary co-crystals were synthesised from known supramolecular synthons using the Scheme 
1.7.
38
 The rationale for the synthesis of ternary co-crystals is based on the findings of Etter 
and Frankenback,
39
 where they noticed that the best hydrogen bond donor will preferentially 
hydrogen bond to the best acceptor. An extension of this observation is that the second best 
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donor preferentially hydrogen bonds to the second best acceptor. This preference of donors 
and acceptors has been tested and proved by synthesising and analysing a series of ternary co-
crystals.
38
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Scheme 1.7: Rationale for the construction of ternary co-crystals.
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1.5.4. One-dimensional hydrogen-bonded networks  
The simplest one–dimensional (1-D) hydrogen-bonded networks formed by molecular solids 
are wires, chains, tapes or ribbons. One dimensional hydrogen-bonded networks are observed 
in many unitary and binary systems.
40
 The requirement for forming a one-dimensional 
hydrogen-bonded network is that its components should be able to form two hydrogen bonds. 
These can be homomeric or heteromeric hydrogen bonds. 
The formation of robust 1-D hydrogen-bonded aggregates in a series of nitro-anilines was 
reported by Panunto et al.
41
 The nitro-anilines arrange in the solid state via head-to-tail 
hydrogen bonding interactions between the amino donors and nitro acceptors (Scheme 1.8) to 
form one-dimensional chains. In these structures the hydrogen bonding pattern clearly 
contains chains with rings as links. The hydrogen bonds are symmetrically independent. The 
bifurcated hydrogen bonds at the unitary level can be represented by the 𝐑1
2(4) motif. The 
chain pattern is designated by the complex binary notation 𝐂1
2(8). This notation does not 
uniquely describe the pattern in these crystals. In such cases, where the pattern is described as 
“chain of rings” the notation 𝐂1
2(8)[𝐑1
2(4)] is used. In this notation the ring description is 
appended in square brackets to the chain description.   
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Scheme 1.8: One-dimensional network in nitro-anilines. 
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An example of 1-D wires are the binary molecular complexes formed between the dications 
of 1,2-bis(2’-tetrahydropyrimidyl) ethane and terephthalate and isophthalate dianions (Figure 
1.5).
42
 Robust one dimensional tapes are observed in the 1:1 co-crystals of 5,5-
diethylbarbituric acid and substituted tris(amino)pyrimidines (Scheme 1.9).
43
 The presence of 
the bulky substituents on the pyrimidine groups prevents the formation of 2-D layers in favour 
of rosette network. 
 
1.5.5. Two-dimensional hydrogen-bonded networks  
Two–dimensional molecular networks based on hydrogen–bonding interactions are formed by 
components containing three or more hydrogen bonding functionalities. The networks formed 
can be either homomeric (formed between identical molecules) or heteromeric (formed 
between different components). The formation of planar two-dimensional hydrogen bonding 
networks leaves a void space in crystal structures. However, the voids in crystal structures are 
interpenetrated by symmetrically equivalent 2-D hydrogen-bonded networks.  The 
interpenetration occurs in order to maximise packing. The prototypical example of a 
homomeric two-dimensional network is pure trimesic acid (1,3,5-benzenetricarboxylic 
acid).
44
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1,2-bis(2'-tetrahydropyrimidyl)ethane
isophthalate
terephthalate   
Figure 1.5: Molecular diagrams of dications of 1,2-bis(2’-tetrahydropyrimidyl) ethane 
and terephthalate and isophthalate dianions and the corresponding crystal structures showing 
the formation of 1-D wires. 
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Scheme 1.9: One-dimensional tapes observed in co-crystals of 5,5-diethylbarbituric acid and 
substituted tris(amino)pyrimidines. 
 
Trimesic acid crystallises through hydrogen bonds between the carboxylic acid groups to 
form a two-dimensional honey comb structure (Scheme 1.10). The voids formed by the two-
dimensional arrangement are interpenetrated by other symmetry-equivalent networks. 
However, recently crystals of trimesic acid without interpenetration of two-dimensional 
networks leading to the formation of 1-D channels were isolated form a solution of diethyl 
ether in presence of pyrene molecules.
45,46
 The pyrene molecules act as guests by occupying 
the channels formed by the trimesic acid molecules.  
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Scheme 1.10: Two-dimensional honeycomb arrangement in the crystal structure of trimesic 
acid. 
 
An early example of a robust two-dimensional hydrogen-bonded network in molecular 
crystals is reported by Gong et al
47
 in a series of substituted sulphamide molecules. The 
rationale for the synthesis is based on utilising the geometry of the tetrahedral shaped 
sulphamide group. It is noticed that despite the different size and nature of the substituents the 
robust two-dimensional hydrogen-bonded network (Scheme 1.11) prevailed in all compounds. 
A 2-D network formed by the sulphonamide groups arranges around a plane with the 
substituents hanging above and below the plane resulting in the formation of a three-
dimensional crystal organised through van der Waals interactions. 
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Scheme 1.11: Robust two-dimensional network in related sulphamide molecules.
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1.5.6. Three dimensional hydrogen-bonded networks  
Molecular crystals with 3-D networks are intriguing due to the fundamental and practical 
issues. Three-dimensional molecular networks are structurally similar to inorganic zeolites. 
While the zeolite networks are stabilised through strong metal-oxygen bonds, 3-D open 
framework molecular networks are not very stable due to the relatively weak nature of non-
covalent interactions. In addition, the formation of 3-D open network structures requires the 
molecules to possess empty space, which is against the principle of close packing. However, 
three-dimensional molecular networks can be stabilised by trapping suitable guest or solvent 
molecules thereby restricting interpenetration of symmetry-equivalent networks. The early 
examples of such hydrogen-bonded molecular networks are adamantane-1,3,5,7- 
tetracarboxylic acid
48
 and methanetetracarboxylic acid (Scheme 1.12).
49
 Both compounds 
form diamondoid networks though hydrogen bonding between the carboxylic acid groups. 
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Scheme 1.12: Molecular diagrams of methanetetracarboxylic acid and adamantane-1,3,5,7-
tetracarboxylic acid. 
 
Both structures possess pseudo-tetrahedral topologies. Topologically similar diamondoid 
networks are observed in crystal structure of tetrakispyridone (Scheme 1.13).
50
 
 
Scheme 1.13: Molecular structures of tetrakispyridone, compound exhibiting diamondoid 
networks. 
 
1.5.7. Three-dimensional hydrogen bonding networks in binary systems  
Topologically similar adamantoid networks are observed in 1:1 complexes of diamines and 
quinones.
51
 The rationale for the synthesis of co-crystals is based on the complementary 
hydrogen bonding nature of alcohols and amines. The formation of a 1:1 complex is driven by 
the 50% increase in the number of hydrogen bonds observed in the individual components of 
alcohols and amines. The molecular complexes of p-phenylenediamine, benzidine with 
hydroquinone and 4,4’-dihydroxybiphenyl form super-diamond lattices through the formation 
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of O-H···N hydrogen bonds. The super-tetrahedral lattice formed by these linear dialcohols 
and linear diamines is shown in Figure 1.6.  
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Figure 1.6: Super-tetrahedral lattice observed in molecular complexes of dialcohols and 
diamines. 
 
1.5.8. Host-guest assemblies  
Host-guest assemblies are the complexes that are composed of two or more molecules or ions 
held together in a unique structural relationship by non-covalent forces.
52
 A necessary 
requirement to classify complexes as host-guest assembly is that the host and the guest are 
distinguishable from one another. Generally in a host-guest assembly, the larger component 
forms an array which includes the guest molecules. In host-guest complexes two different 
types of arrangements are observed. 
1. The tunnel type inclusion complexes.53 
2. The clathrate type host-guest arrangement.54 
In the first type the guests are included in the tunnels formed by the host molecules and can be 
in mutual contact with one another. In the second type the guest molecules are separated from 
one another while being included in the cages formed by the host molecules. 
In both the tunnel and clathrate types, the interactions between the host compounds can be 
divided into two types: (i) in which the host molecules interact through directional hydrogen-
bonding interactions; (ii) complexes in which the host molecules interact through non-
directional van der Waals interactions. Similar types of interaction can be observed between 
the host and the guest molecules. In host-guest assemblies, the host network can be made up 
of one or two components with other components occupying the guest positions. 
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1.5.8.1. Tunnel type inclusion complexes with directionally bonded hosts  
The first among the tunnel type inclusion complexes are the crystalline adducts formed by 
urea.
55
 Urea forms crystalline hexagonal complexes with a series of homologous n-paraffins
32
 
and rhombohedral complexes
56
 with other bulkier guests. However, depending on the 
crystallisation conditions, urea forms both hexagonal and rhombohedral complexes with 
certain guests. Examples of guests which form hexagonal inclusion complexes with urea 
include
57
 n-paraffins, alcohols, ketones, ethers, thioethers, esters, carboxylic acids. 
Rhombohedral inclusion complexes of urea are less common when compared to the 
hexagonal structure types. Dioxane, trioxane, acetone, 2,15-dimethylhexadecane, 2,18-
dimethylnonadecane and 2,19-dimethyleicosane are among the guest molecules which form 
rhombohedral inclusion complexes with urea. Thiourea
58
 and selenourea
59
 form isostructural 
rhombohedral complexes similar to that of urea, with guest molecules such as n-paraffins, 
alcohols, ketones and halogen-containing compounds.
60
 The structures of the inclusion 
complexes of urea are based on forming a hexagonal cross-section with the urea molecules 
forming four hydrogen bonds between the N-H and C=O groups. The structure types of 
compounds formed though directional interactions are called tectons.
61
  
One example of a molecular tecton formed though hydrogen bonding interactions is the 
structure shown in Scheme 1.14. The results demonstrate that the 3-D porous hydrogen-
bonded network remains intact upon exchange of the guest molecules.  
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Scheme 1.14: Molecular structure of a compound forming a hydrogen-bonded framework. 
  
1.5.8.2. Tunnel type inclusion complexes with van der Waals bonded hosts  
There are many examples of channel type inclusion complexes formed by cleft and tweezer 
shaped molecules. Deoxycholic acid (DCA) is an example of a cleft molecule. 2,6-
Dimethylbicyclo[3.3.1]nonane-exo-2,exo-6-diol and Trogers base (Scheme 1.15) are 
examples of tweezer shaped molecules which form inclusion complexes with different guest 
molecules.  
26 
 
HO
H3C
OH
CH3
H3C
O
HO
CH3
CH3
OH
HO H
2,6-dimethylbicyclo[3.3.1]nonane-2,6-diol deoxycholic acid
N
N
Trogers base
 
Scheme 1.15: Molecular structures of 2,6-dimethylbicyclo[3.3.1]nonane-2,6-diol (a), 
deoxycholic acid (b), Trogers base (c). 
 
DCA forms orthorhombic, tetragonal and hexagonal inclusion complexes with a variety of 
guests which include organic acids, aliphatic and aromatic hydrocarbons, alcohols, alkaloids, 
and methyl orange. The host network in these complexes is stabilised through van der Waals 
interactions. In addition to the DCA molecules, some substituted bicyclo[3.3.1]nonane 
compounds form host networks which are stabilised through van der Waals interactions. The 
molecular shape of the substituted bicylco[3,3,1] compounds is suitable for the molecules to 
form supramolecular inclusion channels type structures.
62
 Based on these biclyclic molecules, 
analogous compounds like Trogers base have emerged as a valuable building block for the 
construction of a number of chiral host systems for molecular recognition studies.
63
 
 
1.5.8.3. Tunnel type two-component host network  
Robust tunnel type inclusion complexes resulting from two-component host-networks are 
rare. The 1:1 co-crystal of caffeine and succinic acid forms a host network in which different 
guest molecules occupy the void space to form a host-guest assembly as shown in Figure 1.7. 
The structure determined by single crystal X-ray diffraction shows that the caffeine and 
succinic acid molecules form layers held together though O-H···O, O-H···N and pairs of C-
H···O hydrogen bonds. The channels are occupied by the different guest molecules existing in 
stoichiometric or non-stoichiometric ratios.
64
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Figure 1.7: Host-guest arrangement in a caffeine–succinic acid co-crystal.62 
 
1.5.8.4. Clathrate inclusion compounds  
The term clathrate was coined by H. M. Powell in 1948.
65
 Clathrates are molecular complexes 
formed by host molecules which pack in crystal structures such that they leave cavities 
between them. The cavities produced by the host molecules are occupied by guest molecules. 
In clathrate structures the guest is entirely enclosed in a framework formed by the host 
molecules. These molecular complexes can be divided into three types depending on the type 
of interaction observed between the host molecules.  
1. Directionally hydrogen-bonded hosts: The complexes formed by hydroquinone 
(quinol) belong to this category of clathrate complexes. There are three known 
polymorphs of quinol (α, β, γ). Among the three polymorphs only the β-polymorphic 
arrangement is known to form clathrate type complexes. The β-quinol clathrates are 
structurally isomorphous but are known to crystallise in three space groups depending 
on the guest molecules and the interactions between them. The guest molecules 
enclosed by the β-quinol clathrates include Ar, Kr, Xe, HCOOH, CO2, HBr, C2H2, 
CH4, SO2, etc. 
2. Host networks formed by a combination of van der Waals interactions and hydrogen 
bonds: Host networks formed by phenol and related compounds belong to this class of 
clathrates. The crystals formed by the phenol clathrate networks crystallise  in the 
rhombohedral space group 𝑅3̅, containing small guest molecules like HCl, HBr, HI, 
H2S, SO2, CO2, etc. In addition to the phenol molecules, Dianin’s compound is known 
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to form clathrate complexes with many organic compounds Scheme 1.16. 
X
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Scheme 1.16: Molecular structure of Dianin’s compound. (R2, R2’, R6, R7, R8 are CH3 
or H. While X and Y can be O or S). 
 
3. Van der Waals linked hosts: Tetraphenylene (Scheme 1.17) is known to form clathrate 
complexes with dioxane, pyridine, CCl4, benzene, CHCl3 and acetone as guests. 
tetrabenzo[a,c,e,g] cyclooctatetraene  
Scheme 1.17: Molecular structure of tetraphenylene. 
 
1.6. Co-crystals or molecular complexes in the context of the pharmaceutical industry  
Co-crystals represent a well-known class of compounds termed addition compounds,
66
 
organic molecular compounds,
67
 mixed binary molecular crystals,
68
 molecular complexes
69
 or 
solid-state complexes.
70
 Prototypical examples of co-crystals in the literature were reported as 
early as 1844 and 1893.
71,72
 While co-crystals have been known for some time, to date there is 
no consensus between various research groups on the definition of what constitutes a co-
crystal (Table 1.3). One agreed commonality is that all co-crystals are crystalline materials 
comprised of at-least two different chemical components, i.e. co-crystals are analogous to 
multi-component crystals. However, there is no consensus on what constitutes a component 
and this can be drastically different, ranging from neutral to ionic species involving solids, 
liquids and gases states. 
In this thesis, the term co-crystal will imply the following criteria: 
1. A multi-component crystalline material existing in a definite stoichiometry. 
2. The components in the crystal are held together through neutral hydrogen bonding or other 
non-covalent interactions. 
3. To differentiate a co-crystal from solvates or pseudo polymorphs, we use the concepts of 
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crystal engineering, i.e. if the molecular complex containing the solvent molecule or 
molecules is assembled through known or conceivable molecular recognition events then 
we consider it to be a co-crystal rather than a solvate. In cases where the molecular 
complex containing the solvent molecule is one isolated case obtained as a serendipitous 
result of crystallisation, in such cases we consider the crystal as a solvate rather than a co-
crystal. 
 
Table 1.3: Various definitions of a co-crystal reported in the literature: 
Author Definition of a co-crystal Ref. 
Bond, A. “synonym for multi-component molecular crystal” 73 
Aakeroy, C. B. 
“compounds constructed from discrete neutral molecular species, 
made from reactants that are solids at ambient conditions and are 
present in definite stoichiometric amounts” 
74
 
Nangia, A. 
“multi-component solid-state assemblies of two or more compounds 
held together through by any type or combination of intermolecular 
interactions” 
75
 
Stahly, G. P. 
“ a molecular complex that contains two or more different 
molecules in the same crystal lattice” 
76
 
Childs, S. L. 
“ crystalline materials made up of two or more components, usually 
in a stoichiometric ratio, each component being an atom, ionic 
compound, or molecule” 
77
 
Jones, W. 
“ a crystalline complex of two or more neutral molecular 
constituents bound together in the crystal lattice through 
noncovalent interactions, often including hydrogen bonding” 
78
 
Zaworotko, M. 
J. 
“are formed between molecular or ionic active pharmaceutical 
ingredient (API) and a co-crystal former that is solid under ambient 
conditions” 
79
 
 
1.6.1. Pharmaceutical co-crystals  
It is well-known that properties of materials (crystalline or amorphous) are fundamentally 
dependent on the molecular arrangement within the solid. Altering the molecular arrangement 
or intermolecular interactions within a solid, with or without introducing new molecular 
species/component can and usually does affect the properties of that particular solid material. 
30 
 
Hence co-crystals or multi-component crystals represent one strategy to alter the physical and 
chemical properties of pharmaceutical compounds. Given the importance of active 
pharmaceutical ingredients (APIs) and new chemical entities (NCEs), in terms of their 
intellectual property it is perhaps surprising that only in recent years have crystal engineering 
strategies been implemented in the pharmaceutical industry. In addition, co-crystallisation 
represents an alternative to drug product formulation.  
 
Pharmaceutical co-crystals are multi-component crystals containing at least one component 
which is an API or NCE. Generally a pharmaceutical co-crystal consists of an API and a co-
crystal former (CCF). Analogous to the salts and polymorphs, co-crystals also alter the 
properties of the active ingredient. Properties of APIs that are of importance in the 
pharmaceutical industry include melting point, solubility, chemical stability, dissolution 
profile, hygroscopicity, bioavailability, and mechanical properties. Current strategies to alter 
the chemical and physical properties of pharmaceutical compounds are based on co-
crystallisation, salt formation, hydrate/solvate formation, screening and identification of 
different polymorphic forms and co-crystallisation of the API. While the strategies may be 
successful, no particular one offers a complete solution for property enhancement applicable 
to all APIs. Each API must be examined on a case by case basis based on the desired final 
property. The number of publications and reviews detailing the use of crystal engineering and 
supramolecular concepts applied to APIs is extensive and are continuing to increase.
80
 Most 
commonly the publications are based on targeting a particular supramolecular synthon while 
using solid-state synthesis strategies to address the desired property enhancement of the API. 
In the beginning, examination of the API  in terms of the number of hydrogen bond donor and 
acceptor groups,
81
 the salt forming capability,
82
 and the conformational flexibility is carried 
out. Based on the targeted property and the API, suitable co-crystal formers are selected while 
considering the toxicology profiles of the CCFs. However, to date, predicting the outcome of 
a particular co-crystal reaction is not possible until tested experimentally.
83
 Examples of using 
co-crystals to enhance the properties of APIs are discussed here.  
 
1.6.1.1. Hydrate formation 
Co-crystals are supramolecular assemblies synthesised by targeting the hydrogen bonding 
ability of the functional groups in the API. Solvate or hydrate formation of an API also relies 
on the ability of the API to form hydrogen-bonding interactions. Therefore, when compared to 
a free API, a pharmaceutical co-crystal will have a reduced propensity for the formation of a 
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hydrate or solvate, thus stabilising the API. This however depends on the strength of the 
intermolecular interactions formed between the API and co-crystal former (CCF) when 
compared to the strength of the intermolecular interactions between the API and solvent 
molecule. An example of co-crystals stable to hydration is the co-crystal of carbamazepine 
with nicotinamide and saccharin. A purely anhydrous form of carbamazepine transforms into 
a dihydrate while the co-crystals of carbamazepine with isonicotinamide or saccharin do not 
form a dihydrate even after exposure to high levels of relative humidity.
84
 
A similar study on caffeine-oxalic acid co-crystals shows that they do not transform to the 
hydrate form under high relative humidity.
85
 An analogous study conducted on co-crystals of 
S-oxiracetam showed an improved hygroscopic stability compared to S-oxiracetam (ox). 
Oxiracetam is a nootropic drug used in the treatment of cognition disfunction. It is a racemic 
compound comprised of S-ox and R-ox enantiomers. It is noticed that the S-ox enantiomer is 
highly hygroscopic and transforms into a liquid when exposed to 85% relative humidity (RH) 
at 25 
o
C in three days. The co-crystals of S-ox with gallic acid and 3,4-dihydroxybenzoic acid 
are found to be stable at all RHs.
86
  
Generally anhydrate forms of any drugs are more soluble in water when compared to the 
hydrate forms. In this context, norfloxacin is an exception, since its hydrate is more water 
soluble than the anhydrate.
87
  In all the known hydrate forms of norfloxacin (NFLX),
88
 it 
exists in a zwitterionic state when compared to the anhydrate form. The formation of a 
zwitterionic state in hydrated forms is responsible for the increased water solubility of NFLX 
hydrates when compared to the anhydrate form. 
 
1.6.1.2. Chemical Stability 
Co-crystals of pharmaceutical compounds are known to improve the stability of the active 
pharmaceutical ingredient. It has been noticed that, in the solid state, a single component 
carbamazepine polymorph undergoes photodegradation to form a cyclobutyl dimer as the 
main product. 
89,90
 It has been noticed that the degradation is possible only when the azepine 
rings of carbamazepine are within a distance of 4.1Å. This was confirmed by the synthesis of 
carbamazepine co-crystals in which the azepine rings are separated by more than 4.1Å, which 
prevented the photodegredation and thereby stabilises the API. 
 
1.6.1.3. Dissolution rate 
Dissolution rates of various pharmaceutical co-crystals have been reported. One of particular 
importance is itraconazole (an antifungal agent). Itraconazole has a very low water solubility 
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and is marketed in its amorphous form to increase bioavailability. Remenar et al. 
91
 
synthesised and structurally characterised co-crystals of itraconazole. They demonstrate that 
the dissolution profiles of itraconazole co-crystals are comparable to the amorphous form and 
20-fold higher when compared to the crystalline form of itraconazole. 
 
1.6.1.4. Bioavailability 
If co-crystals of any API are to be a viable alternative for a solid form of a drug, it is 
mandatory to study bioavailability.  Two recently published articles have reported 
bioavailability studies conducted on co-crystals. McNamara et al. reported that a 1:1 co-
crystal of 2-[4-(4-chloro-2-fluorophenoxy)phenyl]pyrimidine-4-carboxamide with glutaric 
acid had a dissolution rate 18 times higher than the pure API. Bioavailability studies revealed 
that the co-crystal attained approximately three times higher plasma concentrations for the 
same dose in dogs.
92
 Another such example is the co-crystal of Amgen compound (AMG 517) 
with sorbic acid. The co-crystal is isolated by co-slurrying of AMG 517 with sorbic acid.  The 
co-crystal exhibited better dissolution and bioavailability than the free API. Pharmacokinetic 
studies of the co-crystal revealed that only 30 mg/kg of the co-crystal were necessary to 
achieve similar plasma levels in rats, when compared to the 500 mg/kg dose needed for the 
free API.
93
 
 
1.6.1.5. Co-crystals with improved solubility profiles 
It is estimated that around 40% of the drugs on the market and around 70% of the new 
chemical entities are poorly water soluble. An improvement in the solubility of the drugs can 
enhance their bioavailability. Pharmaceutical co-crystals represent a strategy to enhance the 
solubility of the API. In this perspective, some recent examples of co-crystals with enhanced 
solubility compared to the APIs are discussed here. One such example is niclosamide.
94
 
Niclosamide is an anthelmintic drug used for the treatment of worm infection in humans and 
animals. It is practically insoluble in water and is usually formulated as a suspension. 
Pharmaceutical co-crystals of niclosamide with caffeine, urea, p-aminobenzoic acid, 
theophylline, nicotinamide and isonicotinamide were synthesised and structurally 
characterised. It was observed that among all the crystalline forms of niclosamide the 
molecular complex containing niclosamide-theophylline and acetonitrile showed the highest 
solubility, improved by six times when compared to that of the API. 
The pharmaceutical industry at the moment is facing a crisis due to the combined effects of 
increased research and development (R&D) costs and a decreasing number of new chemical 
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entities being identified. In addition to this, a very high proportion of NCEs cannot be 
advanced to the next stage of the development process due to poor aqueous solubility. While 
co-crystals represent one possible strategy, new approaches are required to overcome the 
solubility issue. In cases where no acceptable co-crystal or salt form can be generated, the 
pharmaceutical industry is left with no option but to deliberately generate an amorphous form 
of a drug. Amorphous or partially crystalline forms of the drug candidates are known to have 
high aqueous solubility.
95
 However, formulations containing amorphous forms are less stable 
when compared to the crystalline forms. Amorphous materials are less stable and often more 
reactive to process related techniques, which include milling, drying, compression and 
thermal stress.
96
 In addition, there is always a significant risk that the amorphous form 
crystallises at a later stage.   
 
1.7. Salts 
Salt formation is used as the traditional approach in the pharmaceutical industry to alter the 
physical and chemical properties of APIs. It is estimated that more than half of the marketed 
drugs are administered as salts.
97
 One major limitation for salt formation is that the API must 
possess a suitable ionisable site. In comparison, the co-crystallisation is targeted at the very 
nature of a compound being an API, i.e. the presence of external functional groups, regardless 
of possessing acidic, basic or ionisable functional groups. Examples in the literature are 
extensive where the salt forms of a drug are known to possess better solubility profiles 
compared to the API. One interesting example is lamotrigine,
98
 which is an anticonvulsant 
drug and has low water solubility. A series of lamotrigine salts with dicarboxylic acids were 
generated and their aqueous solubility has been investigated. Since all the synthesised salts 
were isostructural, it could be concluded that the solubility was directly related to that of the 
precursor dicarboxylic acid. 
 
1.8. Undesirable forms of APIs  
While crystalline forms of any drug candidates may be potentially important, process related 
serendipitous isolation of polymorphs, solvates, amorphous forms and solid solutions are 
undesirable. In the subsequent sections, the potentially unstable forms of pharmaceutical 
crystals, and the transformations they undergo to enhance their stability, are highlighted. An 
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excellent review of potentially unstable pharmaceutical compounds and their effects on drug 
formulation is given by Shekunov and York.
99
  
 
1.8.1. Polymorphism 
An active pharmaceutical ingredient can exist in various solid forms and often show 
polymorphism.
100
 Polymorphism is defined as the ability of a substance to exist in more than 
one crystalline form, with different arrangements and or conformations of the molecule in the 
crystal lattice.
101
 Different polymorphs have divergent physical properties. In the context of 
the pharmaceutical industry, polymorphs can significantly alter the pharmacokinetic factors, 
such as rates of absorption, drug availability, and the resulting physiological 
concentrations.
102
 In the context of polymorphism, McCrone noted that the number of forms 
known for each compound is proportional to the time and money spent in research of that 
compound.
103
  
 
Polymorphs of a compound may be isolated under the same set of conditions; these are called 
concomitant polymorphs. In certain cases, specific crystallisation conditions including 
temperature and concentration may lead to the isolation of polymorphs. For example, two 
polymorphs of the drug sulphathiazole (II and III) can be crystallised from water, two other 
polymorphs (I and IV) are obtained from acetone, and only one (I) can be recrystallised from 
n-propanol.
104
 In some cases, when the isolated polymorphic form is metastable, solid-state 
transformation from one polymorph to another may take place.
105
 The time duration of these 
transformations can range from seconds to years. Hence the occurrence of a metastable form 
is particularly worrying for the pharmaceutical industry.  
 
One such example is the serendipitous isolation of a polymorph of norvir, an HIV protease 
inhibitor. There was a serious shortage of the supply of norvir capsules due to the discovery of 
a new polymorph.
106
 It is therefore necessary to understand the kinetic process of 
crystallisation for any drug candidate.  
 
1.8.2. Solvates  
The solvate form of a drug candidate provides another opportunity to modify the 
physicochemical properties due to their inherent capacity to alter the crystal structure.
107
 
However, a solvate or hydrate form may transform into anhydrous forms or into a solid form 
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containing non-stoichiometric amounts of solvent molecules, which affects the stability and 
crystallinity of the compound.
94
 Therefore in the case of solvates it is therefore necessary to 
completely understand the stability of the form.   
 
1.8.3. Chiral drugs 
More than half of all marketed drugs are chiral.
108
 In these cases the problems are associated 
with the enantiomeric purity of the drug. A chiral impurity incorporated into the crystal will 
alter the physicochemical properties of the crystalline material. In most cases the chiral 
compounds exists as a racemic mixture. However, the presence of a metastable racemic 
mixture must be avoided.
76
  
 
1.8.4. Solid-state transformations 
In some cases, during the shelf-life of a drug compound, it may undergo a solid-state 
transformation to a more stable form. The transformations may be photochemically-induced, 
thermally-induced, or the result of mechanical stress during compression.
109
 Solid-state 
transformations of the compound alter the structure and hence the properties of the material. It 
is proposed that molecules undergo solid-state transformations if there are defects in the 
crystal structure or in cases involving intergrowths of two polymorphic compounds.
110
 In such 
cases a thorough investigation must be conducted to understand the stability and 
transformation of the compound.  
 
1.8.5. Solvent-mediated transformations  
While solid state transformations are rare, solvent-mediated transformations of the drug 
compounds are common in the pharmaceutical industry. At almost every stage of the 
developmental process, pharmaceutical compounds come into contact with solvent molecules. 
The appearance and disappearance of a solvated form can and does hamper the development 
process. Therefore, a complete understanding of the kinetics and the mechanisms of solvent-
mediated transformations is of practical importance.
111
 
All of the above mentioned examples illustrate the instability and the transformations of 
pharmaceutical compounds under certain conditions. Different crystalline modifications can 
have a dramatic effect on the properties of the drug substance, in particular the toxicity, 
dissolution rate, and bioavailability. It is therefore imperative that the kinetic factors affecting 
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the crystallisation process are well understood in order to confer the polymorphic form of a 
pharmaceutical material. 
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Chapter 2: Experimental methods 
2. Co-crystal synthesis  
2.1. Mechano-chemical methods of co-crystallisation 
The co-crystals presented in the thesis are initially synthesised through mechano-chemical 
process of co-crystallisation. Mechano-chemical reactions are solid–state reactions activated 
by grinding or milling. Mechano-chemical methods have in recent years gained importance 
for the synthesis of molecular complexes. The synthesis of molecular complexes requires the 
breaking and formation of intermolecular interactions stabilised through hydrogen bonds, 
halogen bonds, π–π interactions, and van der Waals interactions. Early investigations of solid 
state intermolecular reactions were carried by Etter
112,113
 and Rastogi.
114
 Etter investigated the 
reactions between solids stabilised through hydrogen bonding interactions. She demonstrated 
that co-crystals of molecular systems can be prepared not only by evaporation through 
solution but also by grinding together stoichiometric amounts of the components. Rastogi 
studied reactions between picric acid and naphthalene, phenanthrene, anthracene and 
naphthols in the solid state.
12
 Molecular complex synthesis through mechanochemical routes 
has gained wide importance in recent years.
115
 The process of grinding two or more molecular 
species and be done in two different ways,  
1. Grinding in the presence of the solvent. 
2. Grinding in the absence of solvent. 
Mechanochemical synthesis of co-crystals requires simple equipment, often a mortar and 
pestle can suffice. Stoichiometric amounts of the APIs and the CCFs are ground using a 
mortar and pestle with or without the presence of a solvent component. In the thesis presented 
here, the solvent drop grinding method of co-crystallisation was followed. The polycrystalline 
materials obtained from the solvent drop grinding were then analysed by powder X-ray 
diffraction (PXRD). 
 
2.2. Crystallisation from solution 
In order to study the intermolecular interactions existing in a crystalline material it is essential 
to obtain diffraction quality crystals of the material. The crystals of the molecular complexes 
presented in the thesis were prepared by crystallisation from solution. The chemical purity 
and stability of the components is taken into consideration before crystallisation. A suitable 
concentration range of ≈ 5 wt % ≤ Xcrystalline material ≤ 30 wt% with respect to the solvent of 
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crystallisation was used to obtain diffraction quality crystals. The material for crystallisation 
is dissolved in a suitable solvent and allowed to crystallise isothermally by slow evaporation 
of the solvent. The crystals obtained were then analysed by X-ray diffraction techniques. 
Initially, all the molecular complexes were analysis by PXRD. Powder X-ray diffraction was 
performed to identify crystalline phase’s different form the starting materials. The crystals for 
which the characteristic diffraction patterns of the starting materials were not present were 
then analysed by single crystal X-ray diffraction to confirm the co-crystal formation. 
2.3. Powder X-ray diffraction  
Generally, many materials with interesting properties can only be prepared as polycrystalline 
materials. In such a case powder X-ray diffraction is the only option to extract structure-
related information for the material. A powder diffraction pattern is as a measure of the 
scattered intensity as a function of the Bragg angle. The powder diffraction pattern is a 
fingerprint of that particular material and is dependent on the structural features of the 
material. The structural features of crystalline materials or phases are manifested in powder 
diffraction pattern as Bragg reflections with each possessing specific intensity, peak shape 
and location. 
 
The equation representing the interplanar distance as function of the unit cell parameters and 
miller indices, h, k, l for the triclinic system may be expressed as: 
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Expressions for other crystal systems can be derived from the above equation while 
considering the restrictions imposed on the unit cell parameters. 
The experimental data obtained in a powder diffraction pattern is a one dimensional 
projection of the three dimensional reciprocal lattice, recorded as a function of the Bragg 
angle. Thus, in a powder diffraction pattern the directions are lost and only the lengths of the 
reciprocal lattice vectors are measured. While in a single crystal X-ray diffraction experiment, 
both the length and the direction of the reciprocal space are preserved. The loss of direction in 
a two-dimensional case is shown in the Figure 2.1. 
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Figure 2.1: Illustration showing the projection of a 1-D reciprocal lattice (top) onto a 1-D 
(1/d) axis (bottom). 
 
Reliability of indexing powder patterns: The reliability of indexing the peaks in a powder 
diffraction pattern is based on obtaining the minimum discrepancy between the observed 2θ 
positions and the calculated 2θ positions (obtained by assigned index triplets from the unit 
cell parameters). For N observed reflections, the reliability of indexing (𝜀) is given by he 
formula; 
𝜀 = ∑ (2𝜃ℎ𝑖𝑘𝑖𝑙𝑖
𝑜𝑏𝑠 −  2𝜃ℎ𝑖𝑘𝑖𝑙𝑖
𝑐𝑎𝑙𝑐 )𝑁𝑖=1
2 
where, h, k, l and i are integers. 
 
Powder X-ray diffractometer 
The powder X-ray diffraction data for polycrystalline materials presented in the thesis were 
obtained using the Bruker D8 Discover and Bruker D8 Advance diffractometers. The Bruker 
D8 diffractometer was used for phase identification of polycrystalline materials. The Bruker 
D8 Discover diffractometer, operates in transmission geometry with Cu Kα radiation (λ = 
1.5418 Å) and fitted with a Göbel X-ray focusing mirror and a LynxEye linear detector. 
Finely ground samples of each of the products from co-crystal screening experiments were 
d*(32) 
b*
* 
(00) a* 
0 1/d32 
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contained in a 96-well plate. Data for each sample were collected over the angular range 4 ≤ 
2θ/° ≤ 50, counting for 0.25 s at each 0.02019 increment of the detector position. The 
diffractometers used in the analysed are shown in Figure 2.2. 
 
 
Figure 2.2: Bruker D8 Advance (left) and D8 Discover diffractometers used in this work. 
 
Bruker D8 Advance diffractometer operates in Bragg-Brentano geometry and is fitted with a 
germanium crystal to allow only the Cu Kα1 (=1.54056 Å) radiation and possess a Lynxeye 
linear detector. The D8 Advance diffractometer is used when high resolution data were 
required for indexing the polycrystalline phases. Data were collected on finely ground 
samples over the angular range 5≤ 2𝜃/𝑜 ≤ 60 at an increment of 0.01o of the detector 
position with a counting time of 0.4 sec. Data collection was done using the zero background 
sample holders, which are made of single crystal silicon cut in such a way that the peaks 
corresponding to the silicon do not interfere with the sample over the 2θ range scanned. 
The powder diffraction patterns of the polycrystalline materials were evaluated using the 
EVA
116
 software package. Indexing of diffraction patterns and refinements of unit cell 
parameters against the powder diffraction pattern is done using the TOPAS software.
117
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2.4. X-ray diffraction  
2.4.1. Background 
X-ray diffraction is used to analyse the spatial distribution of electron density in crystalline 
compounds.  An X-ray diffraction experiment is analogous to viewing an object at higher 
magnification using an optical microscope. In a typical optical microscope, the radiation 
scattered by an object is recombined using a lens allowing it to be viewed at higher 
magnification. In order to view the atomic arrangement one would need a radiation that is of 
the order of around 0.1nm. X-rays belong to that part of the electromagnetic spectra, which 
possess wavelengths of the order of 1Å. However, there is no known material that could focus 
the X-rays scattered by crystalline compounds, thus making it impossible to view atomic 
arrangement. The alternative method to study crystalline compounds is by the use of the 
phenomena of diffraction. 
 The interaction between X-rays and crystalline material is the interaction between an 
oscillating electric field of X-rays with the point charges in atoms and molecules. The 
oscillating electric field component of the electromagnetic radiation forces the electrons and 
protons to oscillate about their equilibrium positions. The oscillating point charges, according 
to theory of electromagnetic radiation, emit energy in the form of radiation with a frequency 
similar to that of incident wave. 
 
 
 
 
 
 
 
 
 
Figure 2.3: Scattering of point charges for the derivation of Laue diffraction conditions. 
 
The X-rays being a part of the electromagnetic radiation can be represented in terms of plane 
waves with appropriate wave vectors. A crystal is assumed to be a periodic arrangement of 
atoms and molecules possessing a three-dimensional translational symmetry. In order to 
ruvw 
D 
Ro 
Ro 
A 
B C 
R 
R 
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explain the scattering from a crystal, it will be sufficient to consider two point charges A and 
C in three-dimensional lattice. The point charges A and C are assumed to be separated by a 
translational vector ruvw, which is related to the non-collinear basis vectors a, b, c as ruvw = ua 
+ vb + wc; where u, v, w are integers. Considering, Ro and R to be the incident and scattered 
wave vectors from point charges A and C respectively (Figure 2.3). Considering constant 
wavelengths, the magnitudes of incident and scattered wave vectors will be identical. 
 |𝐑| = |𝐑𝐨| = 
1
𝜆
  eq.− (2.1) 
The waves scattered from point charges A and C interfere with one another. The interference 
is constructive if the optical path difference is an integral multiple of the wavelength λ. From 
Fig. 2.3 the optical path difference (Δ) is given by  
Δ = AD – BC 
= ruvw . 
𝐑
|𝐑|
 − ruvw . 
𝐑𝐨
|𝐑𝐨|
 
= λ ruvw . (S − So) 
the condition for constructive interference therefore is 
ruvw .  k = integer,   
Where, k = (R – Ro) is called the diffraction vector in reciprocal lattice. 
The eq. 2.1 can be written as  
 (ua + vb + wc) . k = integer  
the above equation is equivalent to, 
 a . k = h, b . k = k, c . k = l  eq.− (2.2) 
The interference between the scattered waves to be constructive, the above three conditions 
have to be satisfied, where h, k, l are integers. These three conditions were discovered by Max 
von Laue and are named after him and are called Laue conditions.
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Figure 2.4: Geometrical interpretation of Laue’s equations. 
The Laue equations are represented geometrically by considering a plane with intercepts a/h, 
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b/k, and c/l along the three co-ordinate axis (figure 2.4). The interplanar distance (dhkl) i.e. the 
distance from the origin to the plane in is the projection of the vector 
a
ℎ
 on the direction of 
plane normal to it, if 
𝐤
|𝐤|
 is a unit vector normal to 
a
ℎ
, then the projection of the vector  
a
ℎ
 on 
𝐤
|𝐤|
 
is simply the scalar product of the two vectors and is given by, 
dhkl = 
a
ℎ
 .
𝐤
|𝐤|
 = 
1
|𝐤|
  (following from eq.(2.2))  eq. – (2.3). 
If we consider 2θ to be the angle between the incident and scattered waves, for |𝐤| we have  
|𝐤| = |R| sinθ + |RO| sinθ = 
2𝑠𝑖𝑛𝜃
𝜆
   
From eq’s (2.1) & (2.3), we have 
𝜆 = 2dhklsinθ 
For a family of lattice planes having common factor n, the above equation can be written as  
n𝜆 = 2dh’k’l’sinθ. 
The above equation is called Bragg equation.
119
 It is a simplest representation of Laue 
equations, in terms of known wavelength, a measurable scattering angle and the interplanar 
spacing of the (hkl) family of planes. 
2.4.2. Structure factor and electron density  
 For a crystal containing N atoms, the equation for X-ray scattering is obtained as a Fourier 
transform of the electron density and is given by  
F(k) = ∫ 𝜌(𝑟)exp (2𝜋𝑖 𝐤  .  𝑟).   eq.− (2.4)                 
Where, F(k) is called the structure factor corresponding to diffraction vector k,  
k is related to the diffraction angle θ by |𝐤| = 2 sin (𝜃) 𝜆⁄ , 
and 𝜌(𝑟)is the electron density at position 𝑟. 
One of the principal aims for applying X-ray diffraction is to elucidate the internal structure 
of a material. In the above equation we have expressed the structure factor as a Fourier 
transform of electron density, while the inverse is also true it is not straightforward to 
calculate the electron density. The main reason is that in a X-ray diffraction experiment we 
measure a quantity proportional to the amplitude of the structure factor, I(hkl). 
I(hkl) ∝ |𝐹(ℎ𝑘𝑙)|2 
To compute the arrangement of electron density in a unit cell given by the formula, 
ρ(𝑥𝑦𝑧) = 
1
𝑉
∑ ∑ ∑ 𝐹(ℎ𝑘𝑙)∞𝑙=−∞
∞
𝑘=−∞
∞
ℎ=−∞  exp[−2𝜋𝑖(ℎ𝑥 + 𝑘𝑦 + 𝑙𝑧)] 
the crystallographer must somehow deduce the values of F(hkl) from the intensities.   
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2.4.3. The phase problem  
In order to determine the electron density (𝜌(𝑥𝑦𝑧)) within a unit cell, we must obatin the 
values of F(hkl). In a diffraction experiment we measure a quantity proportional to the 
amplitude of structure factor. The relation between the available |𝐹(𝐤)| and the desired 𝐹(𝐤) 
can be explained as follows and is termed the phase problem in crystallography. 
The structure factor is a complex number and can be written in a general form as, 
 F(k) = A(k) + iB(k) 
Where, A(k) and B(k) are the real and imaginary parts of the complex number F(k). If F(k) is 
considered as a vector in a complex plane, the square of its length is given by   
     |𝐹(𝐤)|2 = F(k) F*(k) 
where F*(k) is the complex conjugate of F(k). 
The phase of F(k), denoted as φ(k), is the angle between the vector F(k) and the real axis 
A(k), as shown in the Argand diagram 
(Figure 2.5). 
 
A(k), B(k) and F(k) form a right angled 
triangle, in which  
A(k) = |𝐹(𝐤)| cos  (𝜑(𝐤)) and  
B(k) = |𝐹(𝐤)| sin (𝜑(𝐤)). 
 
Consequently,  
  I(k) = |𝐹(ℎ𝑘𝑙)|2.  
 
Therefore, in a diffraction experiment by 
measuring the intensities, we are losing 
information on the phases.  
 
2.4.4. Solutions to the phase problem  
Initial methods for crystal structure analysis of simple structures included extensive use of 
space-group symmetry and trial-and-error methods. The first systematic approach for 
structure determination was put forward by Patterson. 
F(k)= A(k)+iB(k) 
F*(k)=A(k)-iB(k) 
0 
F*(k) 
x 
y 
φ(k) 
φ(k) 
F(k) 
IM 
Re 
 
Figure 2.5: Argand diagram 
representing the structure factor F(k) 
as a complex number. 
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2.4.4.1. Patterson Method  
The Patterson method
120,121,122
 is an indirect method of solution to the crystallographic phase 
problem. The principle of Patterson methods is demonstrated easily by considering the 
diffracted intensities, 
 I(k) ∝ |𝐹(𝐤)|2 
= F(k) F*(k) 
= (∑ 𝑓𝑗 exp  (2𝜋𝑖 𝐤 . 𝑟𝑗)
𝑁
𝑗=1 ) (∑ 𝑓𝑘 exp  (−2𝜋𝑖 𝐤 . 𝑟𝑘)
𝑁
𝑘=1 ) 
= ∑ ∑ 𝑓𝑗𝑓𝑘 exp  (2𝜋𝑖 𝐤 . (𝑟𝑗 − 𝑟𝑘)
𝑁
𝑘=1
𝑁
𝑗=1 ) 
Where, 
 N= total number of atoms in the unit cell, 
 fj and fk are the scattering factors of atoms j and k , 
 rj and rk are the respective position vectors of atoms j and k and k is the diffraction 
vector. 
The equation for electron density at a point 𝑟 in crystal space can be written as 
𝜌(𝑟) = 
1
𝑉
∑ 𝐹(𝐤)𝐤 exp(−2𝜋𝑖 𝐤 . 𝑟) 
The Patterson function P(𝑢) is the resultant function obtained from the Fourier synthesis of  
the above equation when F(k) is replaced by |𝐹(𝐤)|2 and is written as  
P(𝑢) = 
1
𝑉
∑ |𝐹(𝐤)|2𝐤 exp(−2𝜋𝑖 𝐤 . 𝑢) 
Where, 𝑢 corresponds to the inter-atomic vectors (𝑟𝑗 − 𝑟𝑘). The above equation is the same 
form of the electron density equation but without the term phase angle in the expression. The 
Patterson function can be calculated by the Fourier synthesis of |𝐹(𝐤)|2. 
2.4.4.2. Direct methods of estimating relative phases  
These are based on the statistical methods for estimating the relative phases while considering 
that the electron density is never negative, and consists of isolated sharp peaks at atomic 
positions. The electron density map is calculated with the derived phases of the structure 
factors, without any prior structural knowledge. The structure factor equation can be written 
as, 
F(k) = ∑ 𝑓𝑗
𝑁
𝑗=1 (𝐤) exp (2𝜋𝑖 𝐤 . 𝑟𝑗) = |𝐹(𝐤)| exp[𝑖𝜑(𝐤)], 
Where, 𝑟𝑗 is the position vector of the j
th
 atom, 𝜑(𝐤) is the phase of the structure factor 
corresponding to diffraction vector k. From the above equation it can be seen that by shifting 
the origin by a vector 𝑝, there will be a change in the phase by an amount of 2πk . 𝑝. The new 
phase is given by 𝜑′(𝐤) and is equal to 𝜑(𝐤) −  2𝜋𝐤 . 𝑝. 
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Structure invariants: 
𝜑′(𝐤) = 𝜑(𝐤) −  2𝜋𝐤 . 𝑝 
Considering linear combinations on both sides with integer coefficients Zk,  
∑ Z𝐤
𝐤
 𝜑′(𝐤) =  ∑ 𝑍𝐤
𝐤
𝜑(𝐤) −  2𝜋 (∑ 𝑍𝐤𝐤) . 𝑝
𝐤
 
For a set of k vectors that are linearly dependent  
∑ 𝑍𝐤𝐤
𝐤
= 0 
   Then we have, 
∑ Z𝐤
𝐤
 𝜑′(𝐤) =  ∑ 𝑍𝐤
𝐤
𝜑(𝐤). 
The above equation shows that no matter by what vector the origin is shifted; there exists a set 
of phases whose linear combination is independent of the choice of origin. These phases are 
called structure invariants. 
If we consider this in terms of single structure factor F(k), one can deduce that the structure 
factor F(k) is independent of the choice of origin when the vector k=0. 
When the product of two structure factors F(k) and F(l) is considered, the combined structure 
factor will be phase invariant when the vectors are arranged such that k = −l.   
Similarly, when the product of three structure factors F(k), F(l) and F(h) are considered, we 
can deduce that the product of the three structure factors F(k), F(l) and F(h) will be 
independent of the choice of the origin, when the conditions k + l + h = 0, or k = − (l + h), 
are satisfied. 
 
Structure seminvariants: 
In structure invariants, the choice of the origin was completely unrestricted. However, in 
crystal structures, the origin of the unit cell is usually chosen at some symmetry element or 
intersection of symmetry elements, except for the space group P1. Therefore, depending on 
the space group, there exist certain linear combinations of phases whose values remain 
unchanged provided the changes are subject to space-group symmetry constraints. These 
phases are called structure seminvariants. 
 𝜑′(𝐤) = 𝜑(𝐤) −  2𝜋𝐤 . 𝑝 
From, the above equation, when 𝑝 is an allowed translation vector for a particular space 
group, then the dot product k . 𝑝 is an integer, in this case the phase is altered by a factor 2π, 
which is effectively unchanged. Such phases are called structure seminvariants. 
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The first attempts for determining phases of structure factor amplitudes were made by Harker 
and Kasper
123,124
 and was based on Schwarz and Cauchy inequalities, which was later 
developed by Karle and Hauptman
125,126
 considering the probability theory. Karle and 
Hauptman showed that the determinant of unitary structure factors is non-negative only if the 
electron density is non-negative at every point in the unit cell.  A complete list of phase 
invariants and seminvariants for the 230 space groups were listed by Hauptman and Karle and 
are in a general form now listed in the International Tables for Crystallography Volume B.  
 
Sayre equation: The Sayre formalisation
127
 of phase determination for the structure factor 
amplitudes is based on two assumptions, 
1. The crystal is composed of isolated identical atoms possessing identical displacement 
parameters and spherical symmetry, 
2. A hypothetical crystal structure is considered for which the electron density is squared 
at each point. 
Sayre’s first relationship for diffraction vectors H, K and H-K holding the triplet relationship 
is given by  
𝐹𝐇 = 
𝑓
𝑉𝑓2
 ∑ 𝐹𝐊𝐹𝐇−𝐊𝐊  
From the above equation, it can be deduced that the phase of 𝐹𝐇 is the equal to the phase of 
the summation on the right hand side, since the term 
𝑓
𝑓2
 called the shape factor term is a real 
and positive quantity. 
2.5. Least-squares refinement 
The structure obtained from Patterson method, direct methods or from any other structure 
solution method is an approximate structure and is not very precise in terms of the structural 
parameters. A more precise structure is required in order to understand the underlying 
chemistry of the compound. The more precise a given crystal structure, the better the values 
of the computed bond lengths and bond angles. The process of obtaining precise atomic 
coordinates from those obtained from an initial structure solution model is called refinement 
of the crystal structure.
 128
 The atomic positions x, y, z and the atomic displacement 
parameters of each atom are adjusted in a iterative process until a convergence is reached 
between the calculated |𝐹(ℎ𝑘𝑙)|c and observed structure amplitudes |𝐹(ℎ𝑘𝑙)|o.  
The best values of the atomic positions and displacement parameters are obtained when the 
difference (D) between the observed and calculated structure factor amplitudes is minimum.  
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D = ∑ 𝑤ℎ𝑘𝑙[𝐹(ℎ𝑘𝑙)𝑜 −  𝐹(ℎ𝑘𝑙)𝑐]ℎ𝑘𝑙
2 
where, 𝑤ℎ𝑘𝑙 is the weight factor for each hkl reflections. 
The refinement of the structure is considered to be complete when the changes in the 
individual parameters are no longer significant. The progress of refinement or the 
improvement in the agreement between |𝐹(ℎ𝑘𝑙)|o and |𝐹(ℎ𝑘𝑙)|c crystal structure is monitored 
by a term known as the residual index, R value, which is defined as 
R = ∑  ||𝐹(ℎ𝑘𝑙)𝑜| −  |𝐹(ℎ𝑘𝑙)𝑐||ℎ𝑘𝑙  / ∑ |𝐹(ℎ𝑘𝑙)𝑜|ℎ𝑘𝑙    
The R value measures the precession of the results. A high value of R suggests that the 
structure is not likely to be the correct structure in terms of the assigned atoms.  
 
2.6. Single crystal X-ray diffraction (SXRD) 
In an X-ray diffraction experiment, diffraction quality crystal is selected by careful 
examination of the crystals under a polarising microscope. The selected crystal is mounted on 
the goniometer head (Figure 2.6(a)) whilst holding to a cryoloop fibre and is centered to a 
position on the diffractometer, at which all the axes of rotation (θ, χ, φ, ω) intersect. The X-
rays generated from the X-ray source interact with the crystal and are measured by the 
detector as diffracted intensity.  
A standard setting of single crystal X-ray diffractometer consists of (a) an X-ray generator 
fitted with a beam collimator and a monochromator, (b) a goniometer head, upon which the 
crystal to be analysed is mounted, (c) diffractometer circles (θ, χ, φ, ω), which allow the 
crystal to be rotated in different orientations, (d) a beam stopper, used to stop the direct beam 
that passes through the crystal, and (e) a detector, used to measure the diffraction peaks. 
X-ray Sources:  
The most common sources of X-rays available in a laboratory are conventional sealed X-ray 
tubes. Conventional sealed X-ray sources can be of two types, (a) sealed tubes and (b) 
rotating anode tubes. The X-rays used in the study were generated from a sealed X-ray tube.  
A sealed X-ray tube consists of a stationary anode coupled with a cathode, with both placed in 
a ceramic container sealed under high vacuum (Figure 2.6). Sealed X-ray tubes have very low 
efficiency (1%) since much of the energy of the accelerated electrons is converted into heat; 
hence the anode of the X-ray tube is continuously cooled by circulating cold water. A typical 
X-ray emission spectrum generated from a laboratory sealed tube is shown in Figure 2.6.  
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Figure 2.6: Schematic (left) and photographic (right) representation of a sealed X-ray tube 
 
Figure 2.7: The X-ray emission spectrum generated from a typical sealed X-ray tube 
containing a copper anode. 
 
Single crystal data collection for all the complexes reported here were performed using a 
Bruker Nonius X8-Apex2
129
 CCD diffractometer, equipped with a graphite monochromatised 
Mo Kα X-ray source (λ = 0.710173 Å). An Oxford Cryosystems Cryostream was used to cool 
the crystals to 100 K prior to data collection. The data collection for most of the crystals 
presented here is done at 100 K to reduce the thermal vibrations.  
e
-
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Indexing, Data collection and structure solution: 
Indexing of the reflections and the data collection was achieved using the automated software 
SMART. The indexing process involves recording at least 20 reflections at known values of 
θ, χ, φ, ω angles.  These 20 or more reflections are arranged in an increasing order of 
magnitude of the diffraction vector. The three shortest non co-planar vectors are chosen as 
basis vectors of the reciprocal lattice and are arbitrarily assigned indices of 100, 010 and 001. 
By the method of approximation, the orientation matrix and the corresponding unit cell 
dimensions are obtained.  The initial values of cell parameters are refined through least-
squares refinement to obtain better values with standard deviations. 
Based on the range of indices hkl observed in the indexing process and the wavelength of the 
radiation used, the intensity data collection is planned and executed automatically by the 
computer. The entire data set is then reduced by integration using the SAINT package. 
Lorentz and polarization corrections are applied to all the data, followed by correction for 
absorption using SADABS
130
 programme. The space group symmetry of the crystals is 
determined by sorting the systematic absences using the XPREP programme. Crystal 
structures of the compounds were solved by direct methods using SHELXS
131
 and are refined 
on full matrix by least-squares refinement process using values of F or F
2
 in CRYSTALS.
132
 
All non-hydrogen atoms were refined with anisotropic displacement parameters.  
 
  
 
Figure 2.8: (a) Goniometer head (b) centering the single crystal on the diffractometer. 
 
All non-hydrogen bonding hydrogen atoms were placed geometrically and refined with the 
isotropic displacement parameter fixed at 1.5 times Ueq of the atoms to which they are 
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attached. Hydrogens involved in hydrogen-bonding interactions were located via the 
difference Fourier map inspection and were refined isotropically. 
 
2.7. Spectroscopic methods  
2.7.1. Nuclear Magnetic Resonance (NMR)  
The basic principle of NMR spectroscopy is based on the property of nuclei possessing spin. 
Any spinning nucleus will have an intrinsic nuclear spin quantum number, I. The most 
common nucleus for NMR studies, the proton, has a spin of 1/2. This spin half nucleus 
interacts with the external magnetic field by giving rise two energy levels, characterised by 
the quantum number ‘m’. In the case of spin half nuclei the two values of m are −
1
2
 and + 
1
2
. 
The energy level with m =+ 
1
2
 is denoted by α and is termed “spin up”. The energy level with 
m= −
1
2
 is denoted by β and is termed “spin down”. 
In any spectroscopic technique there are selection rules, in the case of NMR, the selection rule 
is that only the transitions that have a change in m value corresponding to ±1 are allowed.  
Figure 2.9: Process of recording a typical NMR experiment. 
The typical NMR experiment is shown in Figure 2.9. On applying a radio frequency pulse, the 
bulk magnetisation vector under the influence of the external magnetic field precesses at a 
constant angle β to form a cone and is called Larmor precession. 
If the external magnetic field strength is Bo, the frequency of the Larmor precession (ω0) is 
given by  
 ω0 = − γB0, 
in terms of frequency (νo) in Hertz, 
 ν0 = −
1
2𝜋
 γB0 
Where, γ is the gyromagnetic ratio. 
B0 z 
x y y x 
z 
B
o0 
RF pulse 
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In a typical 
1
H-NMR experiment, the sample under investigation is placed under the external 
magnetic field and allowed to equilibrate for a fixed amount of time, after which the 
radiofrequency (RF) power is switched on and a 90
o
 RF pulse is applied to the sample to 
rotate the bulk magnetization by 90
o
. After the RF pulse is switched off, the induced current 
from the sample is recorded as a signal by the same RF coil wound around the sample in the 
xy-plane. 
1
H-NMR spectra for all the molecular complexes studied here were recorded using a Bruker 
300 MHz spectrometer after dissolving the compounds in DMSO-d6. 
1
H chemical shift values 
are reported on the δ scale. 
2.7.2. Infrared spectroscopy  
The infrared (IR) range falls in the region between the microwave and visible regions of the 
electromagnetic spectrum. It is divided into three regions; the near-, the mid- and the far- 
infrared regions. The mid-infrared region, possessing wavelengths approximately 4000–400 
cm
-1
 is of importance to study the molecular vibrations in organic solids. For a given 
vibrational mode to be infrared active it must be associated with a change in dipole moment. 
Of the many vibrational modes in a molecule, only a few atoms have large displacements 
while the rest of the molecule is almost stationary. The frequency of such vibrations is 
characteristic for that particular functional group. The infrared spectrum of a compound is 
unique (except for enantiomers) to that particular compound and is used to identify that 
particular compound. 
 
 
Infrared spectroscopic data for all the molecular complexes presented in the thesis were 
recorded using a Perkin–Elmer 100 attenuated total reflectance (ATR) spectrometer operating 
under diffuse reflectance geometry. ATR is a technique where the sample to be analysed is 
Figure 2.10: A multiple reflection ATR system. 
Sample in contact with 
evanescent wave 
Infrared 
beam 
ATR crystal 
To Detector 
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placed in contact with the internal reflection element or ATR crystal (Germanium crystal), 
acting as a sensing element allowing to record the spectrum of the sample. A typical ATR 
setup is shown in Figure 2.10. Prior to recording an IR spectra, the crystal is cleaned and 
background spectrum collected. The sample was then analysed by placing a pinch of the 
compound on the crystal area fitted with a pressure arm positioned exactly over the 
sample/crystal area. Force is then applied through the pressure arm on to the sample by 
pushing it into close contact with the crystal. The spectrum is recorded based on the total 
internal reflection property of the crystal resulting in the formation of an evanescent wave. 
The incident wave is passed through the crystal such that it reflects at least once from the 
internal surface of the crystal, in contact with the sample. The evanescent wave formed by the 
reflected beam extends into the sample which is recorded by the detector as spectrum of the 
sample in absorption bands. 
2.8. Thermo analytical methods  
2.8.1. Differential Scanning Calorimetry (DSC)  
Working principle: During a typical DSC analysis, a test sample and the reference material 
are subjected to a programmed temperature change. Thermal energy is altered to the sample 
or the reference containers in order to maintain the sample and reference at the same 
temperature. The amount of thermal energy added is monitored in terms of thermal 
transitions. 
 
The DSC data for all the compounds reported here were performed using a Seiko model DSC-
6200 instrument. The samples were weighed into DSC aluminium pans, crimped with a 
pinhole in the lid and analysed over the temperature range 25–280 oC using a constant heating 
rate of 10
 o
C/min. The data were processed using Muse Measurement v.5.4 (Build 263) 
software. 
 
2.8.2. Thermogravimetric Analysis 
Thermogravimetric (TG) analysis provides a quantitative measurement of any weight changes 
associated with thermally induced transitions. It records directly the loss in weight as a 
function of temperature or time for transitions that involve dehydration or decomposition. 
Thermogravimetric curves are characteristic of a given compound or material due to the 
unique sequence of physical transitions that occur over definite temperature ranges. The rates 
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of these chemically induced transformations are often a function of the molecular structure. 
The changes in weights may involve physical or chemical bonds forming and breaking at 
elevated temperatures. These processes may involve volatile products or form reaction 
products that result in a change in weight of the sample. 
 
For TG/DTA analysis, approximately 5 mg of material into an open aluminium pan and 
loaded into a simultaneous thermogravimetric/differential thermal analyser (TG/DTA) and 
held at room temperature.  The sample was then heated at a rate of 10°C/min from 25°C to 
300°C during which time the change in sample weight was recorded along with any 
differential thermal events (DTA) compared to the reference.  Nitrogen was used as the purge 
gas, at a flow rate of 100 cm
3
/min. 
2.9. Cambridge Structural Database in crystal engineering  
A large number of organic and organo-metallic crystal structures are organised and contained 
within the Cambridge Structural Database (CSD).
133
 While there are other crystallographic 
databases,
134
 CSD is suitably organised for crystal engineering studies. There are at present 
577,833 structures in CSD
135
 consisting of different classes of compounds, which include 
organic and organometallic compounds. The availability of large numbers of structural data in 
the form of crystallographic information files (CIFs) provides an effective way to extract 
information of how chemical compounds are arranged within in a crystal. The development of 
new tools for harnessing crystallographic information available in the CSD has allowed for 
effective crystal engineering. 
The utilisation of CSD for crystal engineering studies focuses on features of crystal structures 
that are not immediately apparent for individual crystal structures. For example searches 
based on molecular symmetry, molecular connectivity, molecular geometry, supramolecular 
geometries and connectivity or any other supramolecular feature can be performed. A range 
of possible search options are available through the graphical interface ConQuest
136
 software. 
The CSD analysis is performed using CSD v 5.23 (2012 release with Nov 2011 updates). 
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Chapter 3: Crystal engineering methods for the synthesis of paracetamol 
co-crystals 
3.1. Introduction 
Paracetamol (PAC), also known as acetaminophen is a widely used analgesic and antipyretic 
drug used in the treatment of fever, headaches, and other major aches and pains. It belongs to 
a class of drugs known as aniline analgesics. In its molecular structure (Scheme 3.1) 
paracetamol contains two conventional hydrogen bond donors, a phenolic O-H and the amidic 
N-H, and three acceptor groups, an amide oxygen, phenolic oxygen and amidic nitrogen. In 
the crystalline form, these hydrogen bond donor and acceptor groups arrange differently 
relative to the carbon backbone to form three known polymorphs of paracetamol. The first 
polymorph of paracetamol (form-I) crystallises in monoclinic system, the second (form-II) 
and the third (form–III) forms crystallise in orthorhombic system. Apart from the three known 
crystalline forms, paracetamol is also known to exist in an amorphous form. Amongst the 
three known crystalline forms, the monoclinic form-I (Figure 3.1) is the thermodynamically 
stable form and is the active ingredient in all the tablets containing paracetamol. In the crystal 
structure of paracetamol form-I, molecules are arranged in a herringbone pattern to form 
puckered hydrogen-bonded sheets (Figure 3.2). Due to the arrangement of the molecules in 
puckered hydrogen-bonded sheets, the molecules in form-I do not slip over one another upon 
compression. Therefore, paracetamol form-I requires a wet granulation step or addition of 
other binding agents called plasticisers prior to the tabletting process, adding significant cost 
to the production.
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 Considering the higher costs involved in the production of paracetamol, 
much of the research on paracetamol is focussed on (a) identifying facile methods for the 
crystallisation of form-II
138
 and (b) identifying new crystalline polymorphic forms of 
paracetamol and (c) obtaining new co-crystal forms of paracetamol with better compression 
properties.  
Paracetamol form-II crystallises in an orthorhombic crystal system with Pbca as the space 
group. It is a metastable form and is known to convert to form-I over time.
139
 In its crystal 
structure the molecules arrange to form flat hydrogen-bonded sheets
140
 (Figure 3.3) and it is 
therefore amenable to direct compression. While there are serious problems in isolating 
paracetamol form-II on an industrial scale
141
, several research groups have recently reported 
specific methods for the selective crystallisation of paracetamol form-II. In this context, the 
article published by Thomas et al.,
142
 is of particular importance. It is reported that in the 
presence of some co-formers (co-crystal forming agents) like substituted benzoic acids, 
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paracetamol form-II can be produced in 100% yield. In addition, it is also observed that 
altering the API:coformer ratio can have a significant effect on the yield of paracetamol form-
II produced. Crystallisation of paracetamol with 4-aminobenzoic acid in a 4:1 mole ratio 
resulted in the isolation of a mixture of form-I and form-II, while crystallisation of 
paracetamol with 4-aminobenzoic acid in 1:1, 2:1 molar ratios resulted in a 100% yield of 
form-II. Interestingly, the form-II obtained by the above method in quantitative yield is stable 
up to one year. Earlier reports of obtaining paracetamol form-II were based on slow cooling 
of melts and via crystallisation from ethanolic solution when seeding technique is applied. 
While the melt crystallisation technique is not reproducible, the yield of form-II through 
crystallisation from ethanolic solution was reported to be very low (less than 30%) at 
optimised conditions of crystallisation.  
The third polymorph of paracetamol (form-III), known for a decade,
143
 is the most unstable 
form of paracetamol. While the structural information from single crystal X-ray diffraction 
still remains elusive, Marc-Antoine et.al. recently reported the crystal structure of this 
polymorph determined from powder X-ray diffraction methods.
144
 The molecule crystallises 
in orthorhombic crystal system with Pbca as the space group. The authors also noticed a close 
relationship between the cell parameters of form-II and form-III. The cell dimensions of form-
II and form-III are related in the following way: form-III a = form-II b, 2 ∗ form-III b = form-
II c, and form-III c = 2 ∗ form-II a. The close relationship in the cell parameters of form-II 
and form-III is attributed to the fact that paracetamol molecules in both form-II and form-III 
arrange to form a two-dimensional hydrogen-bonded network (Figure 3.4). The difference in 
the two orthorhombic forms is due to the different orientations of the benzene rings with 
respect to the plane formed by the two-dimensional hydrogen bonding network. 
OHN
H3C
O
H
 
Scheme 3.1: Molecular structure of paracetamol, indicating rotational bonds. 
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Figure 3.1: Packing arrangement of paracetamol form-I, viewed along ‘b’. Solid red lines 
represent intermolecular hydrogen bonds. Key: nitrogen, blue circles; oxygen, red circles; 
carbon, black circles; hydrogen, small white circles.  
 
Figure 3.2: Packing arrangement of paracetamol form-I, viewed along ‘a’. 
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Figure 3.3: Packing arrangement in paracetamol form-II, viewed along ‘c’. 
 
Figure 3.4: Packing arrangement in paracetamol form-III, viewed along ‘c’. 
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In-order to identify developable forms of paracetamol with better compression properties, 
several research groups have synthesised and structurally characterised multi-component 
crystalline forms of paracetamol involving N,N’-dimethylpiperazine, 4,4’-bipyridine, N-
methylmorpholine, morpholine, 1,4,8,11-tetraazacyclotetradecane, 1,4-
diazabicylco[2,2,2]octane, ethanol, water, piperazine and 1,4-dioxane as co-crystal formers 
(CCFs) or solvates.
145
 In this context, the co-crystals of paracetamol published by Karki et.al. 
is of importance. Four new co-crystals of paracetamol with theophylline, oxalic acid, 
naphthalene and phenazine as co-crystal formers were synthesised and structurally 
characterised. These co-crystals are reported to have better compression properties when 
compared to that of paracetamol form-II.
146
  
In the chapter presented here a crystal engineering-based method for the synthesis of new co-
crystal forms of paracetamol is presented. Initially, the Cambridge Structural Database (CSD) 
was used as a means to identify potential CCFs; this was followed by co-crystal screening by 
mechanochemical crystallisation techniques to identify new co-crystals of paracetamol. 
The crystal structures of both the paracetamol forms (form-I and form-II) possess identical 
hydrogen bonds between the pac molecules. In both form-I and form-II the phenolic O-H 
group of paracetamol acts both as a hydrogen bond donor and acceptor, thereby acting as a 
bridge between two other paracetamol molecules through N-H···O and O-H···O interactions.  
While the hydrogen bonds formed in the two polymorphic forms are identical, the two 
crystalline forms of paracetamol differ in the manner in which the paracetamol molecules are 
arranged within the crystal lattice. Taking the hydrogen bond distance as the criterion,  the 
strongest hydrogen bonds (Table 3.1) in both form-I and form-II are observed between the 
phenolic O-H group and the amide oxygen (d(H···O) = 1.77Å) resulting in the O-H···O 
hydrogen bonds. In addition to the O-H···O interactions, the N-H donors of paracetamol 
participate in N-H···O hydrogen bonds, where the phenolic oxygen acts as an acceptor. These 
interactions are weaker (d(H···O) = 2.00Å) compared to the O-H···O hydrogen bonds. In 
order to synthesise co-crystals of paracetamol, it is necessary to rearrange or replace the 
existing hydrogen bonds in the paracetamol with interactions from the CCFs. The CSD 
database search serves as a starting point to identify suitable co-crystal former molecules. 
Targeting the phenolic-OH group of paracetamol, the CSD search is conducted to identify a 
series of functional groups which form complementary hydrogen bonds with the phenolic-OH 
groups. Based on the functional groups identified from the CSD search, a series of molecules 
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possessing functional groups which can form complementary hydrogen bonds with 
paracetamol were selected for co-crystal screening (Scheme 3.2). 
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Scheme 3.2: Chemical structures of explored co-crystal formers and paracetamol. 
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Table 3.1: Geometric parameters of hydrogen bonds in crystalline paracetamol form-I. 
 
hydrogen 
bond 
d(H···A) (Å) d(D···A) (Å) 
θ (o) 
(D-H···A) 
(H···A) vdW 
cutoff 
contraction 
(%) 
Paracetamol O-H···O=C 1.77 2.66(3) 166.1 36 
Paracetamol N-H···O 2.00 2.91(2) 163.8 26 
 
 
3.2. CSD analysis 
Potential co-crystal formers were identified by the CSD analysis using the CSD version 5.33 
(November 2011) + 2 updates. In the CSD analysis, the following criteria were applied: 1. 
The search is restricted only to organic crystal structures for which the three-dimensional co-
ordinates have been determined. 2. Crystal structures with R ≤ 7.5% were only retained in the 
search. 3. Disordered structures, structures known to have errors and polymeric species were 
excluded from the search. The summary of the results from the CSD search are presented in 
Table 3.2. The database search was conducted by targeting the phenolic OH group of 
paracetamol. The results of the CSD search are divided into two categories: raw and refined. 
The raw search results represent the occurrence of particular functional groups in the presence 
of other functional groups. The refined search results represent the occurrence of that 
particular functional group with no additional functional groups in the immediate vicinity. 
From the search it is identified that there are 8009 crystal structures in the CSD database 
which contain at least one phenolic O-H moiety. These 8009 crystal structures could be 
stabilised through combination of supramolecular homosynthons and supramolecular 
heterosynthons depending on the functional groups present in the molecules. 
Of the identified 8009 crystal structures 13% of them possess the O-H···O-H supramolecular 
homosynthon synthon while in the remaining crystal structures the phenolic O-H group 
participates in other supramolecular heterosynthons. The raw data of the CSD search reveals 
that the percentage occurrence of the O-H···N supramolecular heterosynthon in molecules 
containing phenolic O-H, aromatic nitrogen or amines is between 42-52%. In the absence of 
other functional groups the percentage occurrence of the O-H···N supramolecular 
heterosynthon increases to 54% and 64% respectively for pyridyl and amines functional 
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groups. In the case of structures containing the phenol and amide functional groups, the raw 
data indicates that the percentage occurrence of the amide···amide supramolecular 
homosynthon is predominant when compared to the occurrence of phenolic O-H···amide 
heterosynthon. However, the phenolic O-H···amide interactions are predominant in the 
refined data. In the crystal structures containing phenolic O-H and carboxylic acid groups, in 
both the raw and refined data the supramolecular heterosynthons formed between the phenolic 
O-H and carboxylic acid groups prevail over the acid-acid and OH···OH supramolecular 
homosynthons. The CSD data of crystal structures containing the phenol and amine functional 
groups indicate that the phenol-amine interactions formed through O-H···NH2 supramolecular 
heterosynthons are more common when compared to the O-H···OH supramolecular 
homosynthons. In summary, the CSD data on crystal structures suggest that molecules 
containing phenol OH groups have a marked preference for the formation of supramolecular 
heterosynthons over supramolecular homosynthons. 
Taking into consideration the percentage of occurrence of the supramolecular heterosynthons 
observed in refined searches, molecules containing at least one of the functional groups 
involving aromatic nitrogen, amides, carbonyl groups, carboxylic acids, and amines were 
selected as potential co-crystal formers (Scheme 3.2). Following the selection of potential co-
crystal formers, experimental co-crystal screening was conducted using a solvent drop 
grinding technique of co-crystallisation. 
In the solvent drop grinding screening process, stoichiometric amounts of the API 
(paracetamol) and each potential co-crystal former were ground together for ca. 5 min with a 
mortar and pestle in the presence of a solvent component (15 μl of solvent per 50 mg of 
starting materials). The grinding experiments were conducted in seven different solvent 
systems which included methanol, ethanol, acetonitrile, chloroform, n-propanol, 
tetrahydrofuran, and acetone.  The solvents were chosen to contain at least one representative 
from each of the polar protic, polar aprotic, and nonpolar solvent categories. In addition, care 
was taken to include a wide range of dielectric constants, ranging from 4.8 to 37.5. The 
polycrystalline materials obtained from the solvent drop screening experiments were analysed 
by PXRD using a Bruker D8 Discover instrument. The details of the instrument are given in 
Section 2.3. Analysis by powder X-ray diffraction revealed that for critical PAC/CCF ratios, 
the reflections arising from the starting materials were absent when trans-1,4-
diaminocylcohexane, 1,2-bis(4-pyridyl)ethane (BPEA), 1,2-di(4-pyridyl)ethylene (BPEE) and 
1,4,8,11-tetraazacyclotetradecane (cyclam) were used as co-crystal formers. This indicates the 
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formation of a new phase in each of the cases. In order to study the intermolecular interactions 
and the arrangement of molecules in the material, suitable single crystals were obtained by the 
slow evaporation method and the crystal structure determined by SXRD. The instrument 
details of instrument used for determining crystal structures are given in Section 2.6.  
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Table 3.2: Summary of the results from the search of Cambridge Structural Database (CSD). 
functional 
groups 
present
b
 
raw data
c
 refined data
d
 
Range/Å 
Mean 
distance/Å 
 
No. Of 
structures 
homosynthons Heterosynthons 
No. of 
structures 
homosynthons heterosynthons 
OH 8009 1023 (13%) - 3490 316 (9%) - 
2.41-
3.04 
2.805(2) 
OH and 
Narom 
580 62 (11%) 302 (52%) 160 11 (7%) 86 (54%) 
2.51-
3.07 
2.735(3) 
OH and 
CONH2 
119 
66 (55%) 
CONH2···O=CNH2 
38 (32%) 
OH···O=CNH2 
44 
11 (32%) 
CONH2···O=CNH2 
26 (76%) 
OH···O=CNH2 
2.54-
3.03 
2.707(3) 
7 (6%) OH···OH 
31 (24%) 
OH···NH2CO 
2 (9%) OH···OH 
24 (70%) 
OH···NH2CO 
2.62-
3.09 
2.812(4) 
OH and 
O=C 
2592 
269 (10%) 
OH···OH 
1136 (44%) 
OH···O=C 
396 26 (7%) OH···OH 
166 (42%) 
OH···O=C 
2.42-
3.04 
2.745(2) 
OH and 
COOH 
683 
230 (33%) 
COOH···O=C(OH) 
387 (56%) 
OH···O=C(OH) 
86 
35 (41%) 
COOH···O=C(OH) 
58 (67%) 
OH···O=C(OH) 
2.38-
3.02 
2.672(3) 
23 (4%)OH···OH 
362 (53%) 
OH···OHC=O 
6 (7%) OH···OH 
55 (64%) 
OH···OHC=O 
2.61-
3.08 
2.812(2) 
OH and 
NH2 
427 28 (7%) OH···OH 
179 (42%) 
OH···NH2 
225 13 (6%) OH···OH 
101 (64%) 
OH···NH2 
2.56-
3.07 
2.848(4) 
a- The following parameters were used as search criteria: 3D-coordinates determined, only organic crystal structures with R≤7.5% were included in the search 
while structures with disorder and errors, and polymeric species were excluded. The search was performed on CSD Version 5.33 (November2011) + 2-
updates. 
b- A search for molecules containing the specified functional group(s) either exclusively or in conjunction with other groups. 
c- The raw search results refer to the specified functional group(s) including occurrences where other groups may be present.  
d-The refined search results refer to the specified functional group(s) in the absence of other groups in the immediate vicinity.  
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Figure 3.5: ORTEP plot of co-crystal (1) (The displacement ellipsoids are drawn at the 50% 
probability level and atoms in the asymmetric unit are labelled). Key: nitrogen, blue circles; 
oxygen, red circles; carbon, grey circles; hydrogen, small white circles. 
3.3. Results and discussion 
3.3.1. Co-crystal (1) [(paracetamol)1-(trans-1,4-diaminocylcohexane)0.5] 
Synthesis of co-crystal (1)  
Single crystals of co-crystal (1) were obtained by dissolving paracetamol (302 mg, 2.00 
mmol) and trans-1,4-diaminocyclohexane (114 mg, 1.00 mmol) in 3 mL of methanol. 
Colourless crystals of (1) were obtained after four days when the solution containing 
PAC/CCF was allowed to stand at room temperature.  
The 
1
H-NMR spectrum on isolated single crystals of co-crystal (1) was recorded in DMSO-d6 
to confirm the PAC/CCF ratio. 
1H chemical shift values are reported on the δ scale. 1H-NMR 
(300 MHz, DMSO-d6) of the co-crystal (1): δ 9.64 (s, 2H), 7.32 and 6.66 (AA′XX′, 2 × 4H), 
3.97 (br. s, 6H), 2.45 (m, 2H), 1.97 (s, 6H), 1.68 (m, 4H), 1.00 (m, 4H). The integral values in 
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the 
1
H-NMR data suggests that the API and the CCF exists in 2:1 molar ratio. (Appendix 
A.1.1) 
 
Figure 3.6: The crystal packing arrangement in co-crystal (1) viewed along [001]. 
Crystal structure description of co-crystal (1) 
Structural analysis by SXRD revealed the structural features in co-crystal (1). Figure 3.5 
represents the local co-ordination and atom numbering scheme in (1). The asymmetric unit of 
(1) consists of one molecule of paracetamol and half molecule of trans-1,4-
diaminocyclohexane (Figure 3.5). The crystal structure of (1) suggests that the CCF, trans-
1,4-diaminocylcohexane occupies the inversion centre. (1) crystallises in the triclinic crystal 
system with ?̅?1 as the space group. The full details of the crystallographic information of (1) 
are presented in Table 3.5.  
In (1), the paracetamol molecules are hydrogen-bonded through N(2)-H(2)···O(2) 
interactions. These interactions lead to the formation of chains, denoted as C(4), extending 
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infinitely along the a crystallographic axis. Two adjacent paracetamol molecules are cross 
linked by the co-crystal former through O(1)-H(1)···N(1)  and N(1)-H(16)···O(1) hydrogen 
bonding interactions (Figure 3.6). The two adjacent paracetamol molecules and the co-crystal 
former arrange to form an asymmetric two-dimensional hydrogen-bonded network as shown 
in Figure 3.6. This asymmetric two dimensional hydrogen-bonded network extends infinitely 
on both ends of the CCF to form hydrogen-bonded layers of paracetamol and CCF (Figure 
3.7). In addition to these hydrogen bonds, several weak and N(1)-H(15)···O(2) interactions 
between the two-dimensional networks extend the structure into the third dimension.  
 
Figure 3.7: Packing arrangement showing hydrogen-bonded layers in co-crystal (1). 
Table 3.3: Geometric parameters for the hydrogen bonds in co-crystal (1) 
Hydrogen bond 
d 
(H···A)/Å 
d 
(D···A)/Å 
 
(D-H···A)/
o
 
(H···A) vdW 
cutoff 
contraction / % 
N(2)-H(2)···O(2) 2.06 2.96(2) 174.1 23 
O(1)-H(1)···N(1) 1.81 2.68(2) 169.9 33 
N(1)-H(16)···O(1) 2.26 3.15(4) 169.9 17 
N(1)-H(15)···O(2) 2.32 3.16(5) 158.0 15 
 
A comparison (Figure 3.8) of the simulated powder pattern generated from the single crystal 
data with the powder pattern of the material obtained from solvent drop grinding experiment 
indicates that the single crystal is representative of the bulk material.  
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Figure 3.8: Comparison plot of powder X-ray data (blue pattern) vs single crystal simulated 
powder X-ray patter (red) of co-crystal (1). 
 
The DSC thermogram of co-crystal (1) shows a sharp endotherm with an onset temp of 154.0 
°
C, corresponding to the melting of the co-crystal (1) (Figure 3.9). The thermal events 
following this could be due to the decomposition of the material. The melting temperature of 
co-crystal (1) is significantly lower than the melting temperature of paracetamol form-I (
 Figure 3.10), which melts at 172.1 
o
C possessing an onset temperature of 168.8 
o
C. 
This suggests that the cohesive energy in co-crystals (1) are significantly lower when 
compared to that of paracetamol form-I. This is manifested in terms of comparatively weak 
hydrogen bonding interactions when compared to paracetamol form-I (Table 3.1and Table 
3.3). 
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Figure 3.9: DSC of co-crystal (1). 
 
 Figure 3.10: DSC of paracetamol form-I.  
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3.3.2. Co-crystal (2) [(paracetamol)2.0-(1,2-di(4-pyridyl)ethylene)1.0-(MeOH)1.0] 
Synthesis of co-crystal (2) 
Diffraction quality crystals of co-crystal (2) were obtained from a methanol solution 
containing 2 mmol (302 mg) of paracetamol and 1 mmol of 1,2-di(4-pyridyl)ethylene (182 
mg). Pale yellow coloured crystals of co-crystal (2) were isolated after five days when the 
solution was allowed to stand at room temperature for crystallisation.  
The 
1
H NMR spectrum of co-crystal (2) indicates the presence of 1 molecule of methanol 
while the API-CCF ratio is 2:1. δ 1H NMR (300 MHz, DMSO-d6) of the co-crystal (2): 9.65 
(s, 2H), 9.16 (br. s, 2H), 8.60 and 7.60  (AA’XX’, 2 × 4H), 7.53 (s, 2H), 7.34 and 6.68 
(AA’XX’, 2 × 4H), 4.13 (s, 1H), 3.17 (s, 3H), 1.97 (s, 6H). (Appendix A.1.2) 
 
Crystal structure description of co-crystal (2) 
The asymmetric unit of co-crystal (2) contains two molecules of paracetamol, one molecule 
of 1,2-di(4-pyridyl)ethylene (BPEE) and one molecule of methanol (Figure 3.11). The three 
components crystallise in a triclinic system with ?̅?1 as the space group. The full 
crystallographic details are given in Table 3.5. 
 
Figure 3.11: ORTEP diagram of co-crystal (2). 
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Figure 3.12: Packing arrangement in co-crystal (2). 
The crystal packing arrangement of co-crystal (2) demonstrates that two crystallographically 
independent paracetamol molecules are linked through N(4)-H(4)···O(2) hydrogen bonding 
interactions (Figure 3.12). These dimeric paracetamol units are connected by the methanol 
molecules, the solvent of crystallisation. The methanol molecules act as a bridge between the 
neighbouring dimeric pairs of paracetamol molecules through N(3)-H(2)···O(5) and O(5)-
H(5)···O(4) hydrogen bonding interactions (Figure 3.12). The paracetamol and methanol 
molecules arrange to form chains propagating infinitely, directed approximately along [1̅10] 
(Figure 3.12). These paracetamol-methanol chains are crosslinked by the co-crystal former 
1,2-di(4-pyridyl)ethylene through O(1)-H(1)···N(1) and O(1)-H(3)···N(3) hydrogen bonds 
(Figure 3.12 and Table 3.4). In addition to the hydrogen bonding interactions, there are strong 
π-π interactions between the neighbouring aromatic rings of BPEE. These π-π interactions are 
arranged in a face to face/centre to edge stacking arrangement with a slip angle of 18.2
o
, 
possessing a centroid to centroid distance of 3.32 Å. The three components arrange to form a 
two-dimensional network. Several weak interactions between the 2D networks stabilise the 
co-crystal to extend the structure into the third dimension. Comparison of the single crystal 
simulated powder pattern with the powder pattern generated from solvent drop grinding 
experiment suggests that the crystal analysed is representative of the bulk material (Figure 
3.13). 
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Table 3.4: Geometric Parameters for the hydrogen bonds in co-crystals (2) 
Hydrogen bond 
d 
(H···A)/Å 
d 
(D···A)/Å 
 
(D-H···A)/
o
 
(H···A) vdW 
cutoff 
contraction / % 
O(1)-H(1)···N(1) 1.85 2.78(6) 177.9 33 
N(3)-H(2)···O(5) 1.93 2.83(3) 162.9 29 
O(3)-H(3)···N(2) 1.85 2.71(4) 169.8 33 
N(4)-H(4)···O(2) 1.99 2.90(7) 173.8 27 
O(5)-H(5)···O(4) 1.76 2.72(4) 173.8 35 
 
 
Figure 3.13: Comparison plot of powder X-ray data vs single crystal simulated pattern of co-
crystal (2). 
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DTA/TGA of co-crystal (2) 
The DTA/TG data (Figure 3.14) of co-crystal (2) shows a broad endotherm with an onset of 
110.9
 °
C, with a corresponding weight loss of 6.1% in the TG curve. The weight loss in the 
TG thermogram corresponding to the loss of 1 mole of methanol molecules from the crystal 
lattice. The endothermic transition in the DTA consists of two peaks at 115.9 
°
C and 118.0 
°
C. The first peak at 115.9 
°
C could be due to the loss of methanol molecules from the crystal 
lattice; this is immediately followed by the melting of the material at 118.0 
°
C. The melting at 
118.0 
°
C correlates with the melting of the co-crystal (2) as observed in capillary melting 
experiments. The transitions in the DTA curve following the melting of the material could be 
due to the decomposition of the material, seen as abrupt weight loss in the TGA curve (Figure 
3.14). 
 
Figure 3.14: DTA/TG data of co-crystal (2). 
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Table 3.5: Crystallographic data of co-crystals (1)-(4). 
 (1) (2) (3) (4) 
Chemical 
formula 
C11H16N2O2 C29H32N4O5 C40H42N6O4 C43H62N8O11 
Formula 
weight 
208.26 516.59 670.8 867.01 
Crystal 
system 
Triclinic triclinic Triclinic triclinic 
a / Å 5.0174(5) 9.0546(2) 8.9707(4) 9.888(2) 
b / Å 8.8907(9) 10.6241(2) 12.8633(6) 14.169(3) 
c / Å 12.7562(1) 14.3162(3) 16.8305(2) 16.272(4) 
α / o 106.21(4) 82.97(3) 106.06(2) 79.15(2) 
β / o 91.40(5) 89.69(3) 95.27(2) 79.09(2) 
γ / o 90.15(5) 73.85(3) 95.13(3) 88.40(3) 
Space group P1̅ P1̅ P1̅ P1̅ 
V / Å
3
 546.2 (1) 1312.3 (5) 1844.8 (1) 2198.5 (8) 
Z 2 2 2 2 
N reflection/ 
Nparameter 
4141 / 136 4904 / 343 4389 / 469 10747 / 550 
ρcalc / g cm
-3
 1.266 1.307 1.208 1.310 
Radiation 
type 
Mo Kα (λ 
=0.710173 Å) 
Mo Kα (λ 
=0.710173 Å) 
Mo Kα (λ 
=0.710173 Å) 
Mo Kα (λ 
=0.710173 Å) 
T / K 100 100 293 100 
 range/° 2-40 1 – 27 2 – 27 1 – 28 
Range of h -8 to 8 -9 to 11 -11 to 11 -12 to 13 
Range of k -15 to 15 -17 to 18 -16 to 16 -18 to 18 
Range of l -18 to 21 -13 to 11 -16 to 21 -0 to 21 
Rmerge 0.019 0.023 0.028 0.097 
R1 / % 3.75 4.18 5.44 4.08 
WR2 / % 4.24 4.34 5.67 4.84 
Goodness-
of-fit 
1.072 1.117 1.102 0.965 
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3.3.3. Co-crystal (3) [(paracetamol)2.0-(1,2-di(4-pyridyl)ethane)2.0] 
Synthesis of co-crystal (3) 
Single crystals of co-crystal (3) were isolated after 5 days from a DMSO solution containing 
a 1:1 molar ratio of paracetamol (151 mg, 1.00 mmol) and 1,2-di(4-pyridyl)ethane (BPEA) 
(184 mg, 1.00 mmol).  
The 
1
H-NMR data of isolated single crystals of co-crystal (3) suggests that the paracetamol 
and 1,2-di(4-pyridyl)ethane are in a 1:1 mole ratio. 
1
H-NMR (DMSO-d6) of co-crystal (3): δ 
9.66 (s, 2H), 9.15 (s, 2H), 8.44 and 7.25 (AA’XX’, 2 × 4H), 7.33 and 7.25 (AA’XX’, 2 × 
4H), 2.94 (s, 8H), 1.97 (s, 6H). (Appendix A.1.3) 
The DSC data (Figure 3.15) of co-crystal (3) reveals a sharp endotherm with an onset 
temperature of 113.7 °C and peak at 116.6 °C, which corresponds to the melting of the 
compound. The endotherm occurs at a significantly different temperature when compared to 
the melting temperatures of PAC (168-172 °C) and BPEA (110-112 °C). 
 
Figure 3.15: DSC of co-crystal (3). 
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Crystal structure description of co-crystal (3) 
The co-crystal (3) crystallises in triclinic crystal system with four independent molecules in 
the asymmetric unit, two each of paracetamol and the co-crystal former 1,2-di(4-
pyridyl)ethane (Figure 3.16). The CH2 groups of one of the crystallographically independent 
BPEA molecules are found to be disordered over two sites and were refined anisotropically 
with occupancies of 0.47 and 0.53. Analogous to co-crystals (1) and (2), the phenolic O-H 
groups of both the paracetamol molecules participate in hydrogen bonding interactions with 
the co-crystal former through O(1)-H(1)···N(4) and O(3)-H(44)···N(2) interactions. While in 
co-crystals (1) and (2) it is only the phenolic O-H group that participates in hydrogen bonding 
interactions with the CCF, here in co-crystal (3), the amidic N-H groups of both the 
paracetamol molecules also participates in hydrogen bonding interaction with the CCF 
through N(6)-H(6)···N(3) and N(5)-H(45)···N(1) interactions (Figure 3.17 and Table 3.6). 
From the crystal packing arrangement it can be noticed that none of the carbonyl groups 
participate in conventional hydrogen bonding interactions. However, they participate in weak 
C-H···O interactions with inversion related molecules. The two components in co-crystal (3) 
arrange to produce crystallographically distinct stepped chains of molecules as presented in 
Figure 3.17. In addition to the conventional hydrogen bonding interactions there are several 
weak interactions between the one dimensional chains extending the structure into a third 
dimensional structure. 
A comparison (Figure 3.18) of single crystal simulated powder pattern with the experimental 
powder pattern suggests that the crystal analysed is representative of the bulk sample, as 
evident from the 
1
H-NMR data. 
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Figure 3.16: ORTEP diagram of co-crystal (3). 
 
Figure 3.17: Packing arrangement in co-crystal (3). 
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Table 3.6: Geometric Parameters for the hydrogen bonds in co-crystals (3) 
Hydrogen bond 
d 
(H···A)/Å 
d 
(D···A)/Å 
 
(D-H···A)/
o
 
(H···A) vdW 
cutoff 
contraction / % 
O(1)-H(1)···N(4) 1.75 2.71(2) 166.6 36 
N(6)-H(6)···N(3) 2.02 2.99(6) 166.4 26 
O(3)-H(44)···N(2) 1.77 2.75(3) 175.8 35 
N(5)-H(45)···N(1) 1.98 2.96(4) 175.5 28 
 
 
Figure 3.18: Comparison of powder X-ray data (blue pattern) vs single crystal simulated 
patter of co-crystal (3) (red pattern). 
  
79 
 
3.3.4. Co-crystal (4) [(paracetamol)4.0-(1,4,8,11-tetraazacyclotetradecane)1.0] 
Synthesis of co-crystal (4) 
Single crystals of co-crystal (4) were isolated after three days from a methanolic solution 
containing 4:1 molar ratio of paracetamol (151 mg, 1.00 mmol) and 1,4,8,11-
tetraazacyclotetradecane  (50 mg, 0.25 mmol).  
The DSC thermogram of co-crystal (4) (Figure 3.20) shows an endothermic transition with an 
onset temp of 124.1 
°
C, corresponding to the melting of the compound. 
Crystal structure description of co-crystal (4) 
The asymmetric unit of co-crystal (4) consists of four crystallographically independent 
paracetamol molecules, two cations of 1,4,8,11-tetraazacyclotetradecane (cyclam) occupying 
inversion centres and a carbonate dianion (Figure 3.20). 
 
Figure 3.19: DSC of co-crystal (4). 
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Figure 3.20: ORTEP diagram of co-crystal (4). 
Two crystallographically independent paracetamol molecules hydrogen bond through N(1)-
H(9)···O(4), N(2)-H(17)···O(2) and N(3)-H(25)···O(8), N(4)-H(62)···O(6) hydrogen 
bonding interactions to form two independent C(9) chains of paracetamol molecules. These 
chains propagate along [1̅00] direction (Figure 3.21).  
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Figure 3.21: Hydrogen binding interactions between paracetamol molecules in co-crystal (4). 
In addition to the hydrogen bonding interactions, there are π···π interactions acting between 
each independent paracetamol chains. These interactions are arranged in a perpendicular (T-
Shaped) configuration with bonding distances of around 3.693Å-4.204Å. The carbonate 
dianion is central to the arrangement of the molecules in co-crystal (4). Each oxygen atom, 
while acting as acceptors participates in two hydrogen bonding interactions to cross link the 
paracetamol chains through O(1)-H(1)···O(11), O(3)-H(35)···O(10) and O(5)-H(34)···O(9), 
O(7)-H(33)···O(10) hydrogen bonding interactions to form a two-dimensional network as 
shown in Figure 3.21. In addition, the carbonate dianion also participates in hydrogen 
bonding interactions with two cyclam cation molecules through N(7)
+
-H(48)···
-
O(11) and 
N(5)
+
-H(50)···
-
O(9) to form a three dimensional structure. The full crystallographic details 
and geometric parameters of all the hydrogen bonding interactions of (4) are given in Table 
3.5 and Table 3.7 respectively. The cyclam molecules do not participate in hydrogen bonding 
interactions with the paracetamol molecules. The cyclam molecules while hydrogen bonding 
with the carbonate dianions lie in the spaces created by the two-dimensional network formed 
between the paracetamol and carbonate dianion molecules (Figure 3.22). Whilst the work on 
(4) was in progress, a crystal structure similar to (4) was reported by Vania et.al.,
147
 
However, the reported crystal structure is different form co-crystal (4) and is a hydrate form 
of (4). Due to the presence of water molecules in the crystal structure there are additional 
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hydrogen bonding interactions in the reported structure which is significantly different to (4) 
presented here. 
 
Figure 3.22: Hydrogen bonding interactions between paracetamol and co-crystal former 
(1,4,8,11-tetraazacyclotetradecan) in co-crystal (4). 
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Table 3.7: Geometric parameters for the hydrogen bonds in co-crystal (4) 
Hydrogen bond 
d 
(H···A)/Å 
d 
(D···A)/Å 
 
(D-H···A)/
o
 
(H···A) vdW 
cutoff 
contraction / % 
O(1)-H(1)···O(11) 1.53 2.57(7) 172.7 43 
N(1)-H(9)···O(4) 1.95 2.81(5) 168.0 28 
N(2)-H(17)···O(2) 2.04 2.91(6) 166.8 25 
N(3)-H(25)···O(8) 1.97 2.83(7) 173.5 28 
O(7)-H(33)···O(10) 1.67 2.60(2) 169.3 39 
O(5)-H(34)···O(9) 1.68 2.60(4) 172.3 38 
O(3)-H(35)···O(10) 1.67 2.62(5) 166.7 39 
N(7)-H(47)···N(8) 
(intra) 
2.13 2.87(7) 124.7 22 
N(7)
+
-H(48)···
-
O(11) 
1.88 2.64(8) 146.4 31 
N(5)-H(49)···N(6) 
(intra) 
2.22 2.87(4) 132.3 18 
N(5)
+
-H(50)···
-
O(9) 1.59 2.65(6) 164.6 42 
N(4)-H(62) ···O(6) 2.15 3.02(3) 167.8 21 
 
3.4. Discussion 
The molecular structure of paracetamol contains two hydrogen bond donors; the phenolic O-
H and the amidic N-H groups and three acceptor groups; the amidic nitrogen, oxygen and 
phenolic oxygen atoms as shown in Scheme 3.1. During the co-crystal formation these 
hydrogen bond donor and acceptor groups of paracetamol are in competition with the donor 
and acceptor groups of different CCF molecules. The resulting structure in most cases is the 
one that optimizes the donor-acceptor interactions between the paracetamol and the CCF 
molecules. Considering the hydrogen bonding interactions in paracetamol form-I) it can be 
noticed that the strong hydrogen bonds in paracetamol form-I are formed between the 
phenolic O-H and amidic carbonyl groups. These interactions are absent in all the co-crystals 
(1)-(4) and are replaced by the O-H···N supramolecular synthon in co-crystals (1)-(3) and O-
H···O interactions in co-crystal (4). These interactions between the paracetamol and CCF 
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molecules operate over similar distances compared to the O-H···O interactions in the 
paracetamol form-I, suggesting that they are of comparable strength. The argument of 
comparable strength is supported by the percentage contraction in the H···A van der Waals 
cut-off and red shift of the ν(D-H) stretching frequencies, measured by infrared spectroscopy 
(Table 3.8).  The IR spectra of paracetamol form-I and co-crystals (1)–(4) are given in 
(Appendix A.2.2 to A.2.5)   
Table 3.8: Bond stretching frequencies in paracetamol and the four co-crystals, determined 
by infra-red spectroscopy. 
Assignment 
pac in gas-
phase
148
 
pac 
Form I 
(1) (2) (3) (4) 
ν(O-H) / cm
-1
 3653 3160 3326 3070 3195 3163 
ν(N-H) / cm-1 3465 3324 3326, 3273 3290 3246 3276 
ν(C-H)aromatic / cm
-1
 3034 2895 3049 2870 2950 2980 
ν(C=O) / cm-1 1721 1651 1636 1653 1673 1653 
 
According to the empirical rules of hydrogen bonding interactions proposed by Etter,
149
 the 
best hydrogen bonding interactions are observed between the best donor and acceptor groups 
in the system. The geometric and spectroscopic data of hydrogen bonding interactions in co-
crystals (1) – (4) are consistent with the best donor – best acceptor rule. In co-crystals (1) – 
(4) the best donor, phenolic O-H is hydrogen-bonded to the best acceptor, resulting in the 
formation of O−H···N interactions, while in co-crystal (4) it results in the formation of 
O−H···O interactions. Consistent with the other suggestions of Etter et. al. all of the 
remaining proton donors and acceptors also participate in hydrogen bond formation, as 
evidenced in all the four co-crystals by the N−H···O=C interactions between paracetamol 
molecules, which are of similar strength to those observed in paracetamol itself. Co-crystal 
(2) has additional hydrogen bonds N−H···O and O−H···O=C due to the incorporation of 
solvent molecules in the crystal lattice. The hydrogen bonding interactions in co-crystals (1) – 
(4) are in accord with the empirical rules proposed by Etter. 
Complexes with hydrogen bonds are stabilised by a combination of electrostatic, polarization, 
induction, and dispersion energy terms. From an electrostatic viewpoint, any hydrogen 
bonding interaction may be considered to have contributions from interactions between 
monopoles, dipoles, quadrupoles, etc., each of which has a different characteristic cut-off in 
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terms of distance. One common means of assigning the character of the hydrogen bond is the 
contraction, with respect to the sum of the van der Waals radii, of the H···A distance. Proton-
centered hydrogen bonds typically exhibit a contraction of between 40 and 55% of the sum of 
the van der Waals radii.
150
 In co-crystals (1)−(4)the van der Waals cut-off contraction lies for 
most hydrogen bonds between 20 and 40% (Table 3.3, Table 3.4, Table 3.6, Table 3.7) which 
suggests these hydrogen bonds may be classed as being of moderate strength in which the 
electrostatic interaction terms are dominant. In co-crystal (4), due to presence of charged 
species, the van der Waals contraction exceeds 40% in the O−H···O interaction, suggesting 
that the interaction is strong when compared to other interactions. It has been empirically 
established that hydrogen bonds become increasingly linear with increasing strength, as 
linearity optimizes the electrostatic component (dipole−monopole, dipole−dipole) of the 
interaction. The electrostatic contribution to the intermolecular interaction tends to dominate 
and imparts directionality on hydrogen bonds. This is particularly significant in short and 
proton-centered hydrogen-bonds, whose typical angular range is 160 ≤θ/°≤ 180, but also 
applies to longer bonds of electrostatic nature. According to Reed et al.,
151
 charge transfer 
between donor and acceptor groups has a strong influence on the geometrical and spectral 
properties of the co-crystals. In particular, in a D−H···A hydrogen bond there is charge 
transfer from lone pairs or π-molecular orbitals of the electron donor (proton acceptor) to the 
anti-bonding orbitals of the D−H bond of the electron acceptor (proton donor). An increase of 
electron density in the anti-bonding orbitals elongates the D−H bond, which causes the red-
shift of the D-H stretching frequency. Therefore charge transfer and hence hydrogen bond 
formation may be inferred from comparison of characteristic vibrational frequencies of a free 
R-D-H group with that of the same group in the presence of a hydrogen bond acceptor. The 
characteristic vibrational frequencies of the four co-crystals (1)−(4) and of crystalline 
paracetamol form I may be compared with those observed in the gas phase infrared spectrum 
of paracetamol (Table 3.8). The frequencies of the ν(O−H), ν(N−H), and ν(C=O) stretching 
vibrations in co-crystals (1)−(4) and in paracetamol form I are red-shifted by up to 16% 
relative to the equivalent vibrations in the gas-phase spectrum of paracetamol. From the 
crystal structure determination, it can be deduced that the lone pair of the nitrogen atom of 
each of the co-crystal formers (1)−(3) and the lone pair of the oxygen atom in co-crystal 
former (4) is aligned along the axis of the O−H bond of the hydroxyl group of paracetamol, 
thereby facilitating charge transfer between the donor and acceptor pair. Therefore, we 
conclude that both electrostatic and charge transfer terms influence the directional behaviour 
of the hydrogen bonds in co-crystals (1)−(4). 
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In all four co-crystals presented here, the structural and spectroscopic data indicate that the 
hydrogen bonds formed between the PAC and the CCF are of comparable strength to those 
originally present in the API. Co-crystals (1)−(3) studied here have the same, i.e. O−H···N 
supramolecular heterosynthon between the PAC and CCF, while in co-crystal (4) there is no 
direct interaction between the co-former and paracetamol instead the paracetamol  molecules 
are hydrogen-bonded to the carbonate anion through O−H···O synthon. In structure (3) in 
addition to the O−H···N there is a N−H···N supramolecular interaction observed between the 
PAC and CCF. Our investigations show that difunctional CCFs, able to form chain-like 
structural motifs through distinct hydrogen bonds, are necessary for co-crystal formation with 
paracetamol. This is in accordance with previously reported CCFs in multi- component 
crystalline forms of paracetamol. Although CSD analysis suggests carboxylic acids and 
amides as potential co-crystal formers, our experiments demonstrate that they are not 
effective for paracetamol. This may be due to the self-complementary hydrogen bonding 
nature of these functional groups, which favours homosynthon formation rather than 
heterosynthon with phenolic O-H group. A hierarchical arrangement between the best donor 
of paracetamol to the best acceptor in CCF is observed in all the co-crystals presented here 
and is indeed observed in almost all of the previously reported co-crystal forms of 
paracetamol. Of the reported co- crystals of paracetamol, only those involving theophylline 
and bipyridine
152
 do not follow the hierarchical arrangement of hydrogen bonding. In the case 
of the paracetamol-bipyridine co-crystal, strong π−π interactions (at a distance of ca. 3.4 Å) 
between the pyridine moieties of bipyridine stabilize the crystal structure in co-operation with 
the hydrogen bonds. In the case of the paracetamol-theophylline co-crystal,
152
 the best 
acceptor of theophylline, the imidazole nitrogen atom, does not participate in conventional 
hydrogen bonds. The two molecules are arranged such that they form flat hydrogen-bonded 
sheets. 
The DSC data of the co-crystals reveal single sharp endotherms at 157.9, 113.1, 116.6, and 
124.3 °C for products (1)−(4) respectively. These endotherms, which correspond to the 
melting point of the solids, occur at significantly different temperatures to those of 
paracetamol (168−172 °C) or the co-crystal former (trans-1,4-diaminocyclohexane, 68−72 
°C; trans- 1,2-di-(4-pyridyl)-ethylene, 148−152 °C; 1,2-bis(4-pyridyl)-ethane, 110−112 °C; 
1,4,8,11-tetraazacyclotetradecane, 185-188 °C), indicating the formation of co-crystals and 
not simple physical mixtures. All the four co-crystals described here have melting 
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temperatures reduced from that of paracetamol, suggesting that the cohesive energy of co-
crystals (1)−(4) is reduced from that of pure paracetamol form I. 
 
3.5. Conclusion  
Analysis of structural data in the CSD resulted in the identification of a range of potential co-
crystal formers which form complementary hydrogen bonding interactions with paracetamol. 
Subsequent co-crystal screening by solvent-drop grinding in conjunction with high-
throughput PXRD led to the discovery of four new co-crystals of paracetamol. The co-
crystals (1)−(3) presented here utilize the O−H···N supramolecular heterosynthon, while co-
crystal (4) utilises the O−H···O synthon. The ability of phenols to form these hetero and 
homo synthons is consistent with the results of the analysis of the structural database, 
suggesting the approach may be applicable to a wider range of phenol derivatives. 
Comparison of the geometric and spectroscopic parameters of the hydrogen-bonds in co-
crystals (1)−(4) with those for paracetamol reveals that they are of similar strength, 
irrespective of the chemical identity of the synthon. The study shows that a balance between 
the retrosynthetic approach (synthon method) and database screening of supramolecular 
synthons provides a useful approach to the targeted synthesis.  
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Chapter 4: Hydrogen-Bonded Host-Guest Complexes of Furosemide 
4.1. Introduction  
Molecular host–guest complexes are those that are composed of two or more molecules or 
ions that are held together through non-covalent interactions and are arranged in a unique 
structural relationship. A necessary requirement for a complex to be classified as host-guest 
complex is that the host and the guest molecules are distinguishable from one another. In the 
host–guest complexes, the host component is generally the larger molecule and it 
encompasses or forms an array to include the smaller guest molecules. Based on the 
arrangement of guest molecules, there are two principal types of host – guest complexes: the 
tunnel inclusion complexes
153
 and the clathrates
154
. In the first type the guests are included in 
the tunnels between the host molecules and can be in mutual contact with one other, arranged 
in a head-to-head or head-to-tail orientation. In the second category the guests are in the 
cages separated from one another by the intervening host molecules. The host molecules are 
also broadly classified into two main types: (i) those that form complexes by fitting convex 
guests into the concave cavity of hosts and (ii) those that form lattice inclusion compounds by 
packing in such a manner as to leave cavities, channels or layers in the crystal structure so as 
to accommodate various guest molecules. In a host-guest arrangement, the host molecules 
can interact through directional bonds of various types, of which hydrogen bonding is 
undoubtedly the most important one. However, host arrangements formed through non-
directional forces such as the ubiquitous dispersion forces or van der Waals forces are also 
known.
155
  
The design and synthesis of crystalline molecular complexes that assemble into a host-guest 
arrangement in the solid-state is an area of intense current interest. A key to controlling the 
packing arrangement in a crystal lies in controlling the type and orientation of the non-
covalent interactions between the components. The strong and directional nature of hydrogen 
bonds has led to their widespread use in self-assembling systems. In the solid state, rules have 
been delineated to allow the reasonable prediction of hydrogen-bonding packing patterns in 
crystals. However, the synthesis of host-guest molecules in the crystalline state based on 
empirical rules is often frustrating due to the absence of reliable structural paradigms. In the 
absence of reliable structural parameters, chemists are left with no option but to search for 
molecular components that persistently form host-guest arrangements in the presence of a 
variety of guests.  
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The host-guest complexes discussed in this chapter are the binary molecular complexes of 
furosemide. The host-guest arrangement of the complexes studied here are derived by 
analysing their crystal structures. The complexes presented here belong to the class of 
compounds called crystalline clathrates. According to IUPAC, clathrates are “inclusion 
compounds in which the guest molecule is in a cage formed by the host molecule or by a 
lattice of host molecules”.156  
Furosemide (FUR) is a loop diuretic drug, which is widely used in the treatment of 
congestive heart failure and oedemas arising from cardiac, renal, and hepatic failure.
157
 It is a 
class IV drug according to the biopharmaceutics classification system (BCS) and suffers from 
both low permeability and low solubility.
158
 The low permeability and delivery-related issues 
have been addressed by a number of approaches, the most recent ones being emulsification 
and the use of mesoporous materials as carriers.
159
 Goud et al.
160
 used co-crystallisation as 
their strategy to improve the solubility of furosemide. The formation of co-crystals between 
furosemide and eight different co-crystal formers (caffeine, urea, p-aminobenzoic acid, 
acetamide, nicotinamide, isonicotinamide, adenine, and cytosine) was reported, with 
enhanced solubility and dissolution profiles of these materials relative to pure furosemide. 
However, only two of the compositions (caffeine and cytosine co-crystals) were obtained as 
single crystals, whereas the crystal structures of the other six co-crystals remained unknown. 
The molecular structure of furosemide is shown in Scheme 4.1. The molecular structure gives 
an indication of the molecule’s ability to exhibit conformational polymorphism161 about its 
various flexible bonds. The rigid portion of the molecule is the anthranilic acid moiety, and 
the conformationally flexible portions are the sulfonamide group and the furan ring. The 
intramolecular N-H···O hydrogen bond renders rigidity to the anthranilic acid moiety; 
consequently, rotation about the phenyl-carboxylic acid C-C bond is difficult. Sulfonamide 
and furan ring torsions can result in different conformers in solution, thereby increasing the 
likelihood of polymorphism in the solid state. 
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Scheme 4.1: Molecular structure of furosemide. The arrows indicate the conformational 
flexibility of the molecule along these bonds. 
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Scheme 4.2: Hydrogen bonding interactions observed in known polymorphic forms of 
furosemide. 
The first crystal structure of furosemide was published in 1978 by Lamotte et  al.
162
 Two 
other polymorphic crystalline forms of furosemide were reported by Babu et al.
163
 Matsuda
164
 
and Ge et al.
165
 attempted to crystallise  several crystalline forms of furosemide. Whilst they 
were unsuccessful in obtaining the crystal structures of the new crystalline forms, they 
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characterised three polymorphic forms and two solvates of furosemide by FTIR, terahertz 
spectroscopy, PXRD and thermal analysis. There are three known forms of furosemide for 
which crystal structures have been determined. All the three known forms of furosemide 
contain the acid-acid supramolecular synthon and differ by the hydrogen bonding network 
formed by the sulphonamide groups (Scheme 4.2). The commonly available crystalline form 
of furosemide is labelled as form-I and is the thermodynamic stable form. The other two 
forms of furosemide are metastable and convert to form-I by grinding. 
The synthesis of a series of host-guest complexes formed by furosemide. While the host-
guest arrangement of the complexes presented is a serendipitous outcome of the synthesis, the 
design strategy is based on the empirical rules proposed by Margaret Etter.
166
 Etter 
formulated that, in neutral organic compounds, the crystal packing is dependent on the 
interaction between the best hydrogen bond donor and acceptor groups present in a system in 
which other possible intermolecular interactions are weak and non-directional. The design 
strategy is based on what follows from the above rule but on a higher level. It is proposed that 
that the crystal packing in a system will depend on the charge assisted hydrogen bonding 
interaction whilst containing other directional hydrogen bonding interactions.  
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Scheme 4.3: Molecular diagram of the guest molecules and the supramolecular synthons 
studied here. 
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Based on the above proposed strategy the six co-crystal formers (Scheme 4.3) were selected 
for the investigation of the molecular complex formation. Based on the predicted pKa
15
 
values of the co-formers and furosemide it was anticipated that furosemide will form salts 
with imidazole (IM), piperazine (PIP) and 1,4,8,11-tetraazacyclotetradecane (cyclam) and co-
crystals with 1,2-bis(4-pyridyl)ethane (BPEA), 1,2-di(4-pyridyl)ethylene (BPEE) and 4,4’-
bipyridyl (BIPY) molecules. Whilst some of the results presented here are in agreement with 
this prediction, others do not show proton transfer between the FUR and CCF. The molecular 
complexes presented here were initially synthesised though solvent drop grinding followed 
by crystallisation from appropriate solvents through slow solvent evaporation. In the chapter, 
the term molecular complex is synonymously used to represent salts and co-crystals.  
 
4.2. Results and discussion  
4.2.1. Crystal structure description of molecular complex (5) [(furosemide)1-
(imidazole)1] 
Single crystals of molecular complex (5) were obtained by dissolving furosemide and 
imidazole (1:1) in 2 mL of methanol. Light yellow coloured crystals of (5) were isolated 
within 2 hours. The single crystal structure reveals that (5) crystallises in a centrosymmetric 
space group, P21/C. The full crystallographic details of (5) are presented in Table 4.2.  
 
Figure 4.1: ORTEP plot of co-crystal (5) (The displacement ellipsoids are drawn at the 50% 
probability level and atoms in the asymmetric unit are labelled). Key: chlorine, green circles; 
sulphur, yellow circles; nitrogen, blue circles; oxygen, red circles;  carbon, grey circles; 
hydrogen, small white circles. 
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Figure 4.2: Hydrogen bonding interactions between furosemide and imidazole molecules in 
molecular complex (5). Solid red lines represent intermolecular hydrogen bonds. Key: 
chlorine, green circles; sulphur, yellow circles; nitrogen, blue circles;oxygen, red circles; 
carbon, grey circles; hydrogen, small white circles. 
 
Figure 4.3: Hydrogen bonding interactions between furosemide molecules in molecular 
complex (5). 
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Figure 4.4: Host molecules forming channels in molecular complex (5), without the 
imidazole guest molecules. 
 
 
Figure 4.5: Host-guest arrangement in molecular complex (5). The imidazole molecules are 
shown in space fill settings. 
The asymmetric unit consists of one molecule each of furosemide and imidazole (5) (Figure 
4.1). Each furosemide molecule is hydrogen-bonded to two adjacent imidazole molecules 
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through N
+
(3)-H(6)···O–(1) and N(4)-H(16)···O(4) hydrogen bonding interactions (Table 
4.1) (Figure 4.2). In addition, each furosemide molecule is hydrogen-bonded to two other 
furosemide molecules through N(1)-H(1)···O(2) and N(1)-H(2)···O(2) hydrogen bonding 
interactions (Table 4.1) to form a cyclic motif of the type R2
2
(4), as shown in Figure 4.3. 
Apart from these hydrogen bonding interactions, one C-H group of the furan ring hydrogen 
bonds to the carbonyl group of carboxylate anion through C(12)-H(12)···O(2) interactions 
(Table 4.1). The furosemide molecules assemble to form a host network possessing channels 
as shown in Figure 4.4. The channels propagate infinitely along the a crystallographic axis. 
These host channels in complex (5) are occupied by the imidazole guest molecules. A space-
filling representation of the guest molecules occupying the host furosemide channels is 
shown in Figure 4.5. 
The DSC thermogram of complex (5) shows a sharp endothermic transition with an onset 
temp of 201.5 
o
C, corresponding to the melting of the compound the molecular complex 
(Figure 4.6). The transitions following this could be due to the decomposition of the material. 
 
Figure 4.6: DSC of molecular complex (5). 
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4.2.2. Crystal structure description of molecular complex (6) [(furosemide)1-
(piperazine)1] 
The crystals of molecular complex (6) were obtained by slow evaporation from an ethanolic 
solution containing furosemide and piperazine in a 1:1 mole ratio. Colourless crystals of (6) 
appeared after 2 days. The single crystal structure shows that the asymmetric unit of (6) 
consists of one molecule each of furosemide and piperazine (Figure 4.7). 
 
Figure 4.7:  ORTEP plot of furosemide – piperazine molecular complex (6). 
 
Figure 4.8: Hydrogen bonding interactions between furosemide and piperazine in molecular 
complex (6). 
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Figure 4.9: Hydrogen bonding interactions between furosemide molecules in molecular 
complex (6). 
 
 
Figure 4.10: Hydrogen bonding interaction between piperazine molecules in molecular 
complex (6). 
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Figure 4.11: Furosemide channels in molecular complex (6). 
The compound crystallises in the monoclinic crystal system with P21/n as the space group. 
Analogous to the molecular complex (6), each furosemide molecule is hydrogen-bonded to 
two other furosemide molecules through N(1)-H(1)···O(2) and N(1)-H(2)···O(2) hydrogen 
bonding interactions (Table 4.1) to form a ring motif of the type R2
2
(4) (Figure 4.9). In 
addition, similar to complex (5), one of the C-H groups of furan also participates in hydrogen 
bonding interactions with the carbonyl group of the carboxylate anion to form a C(12)-
H(12)···O(2) interaction (Table 4.1). The furosemide molecules arrange to form a host 
network of molecules resulting in channels as shown in Figure 4.11. These channels extend 
infinitely along the ‘b’ crystallographic axis.  The channels formed by the furosemide 
molecules are occupied by the piperazine molecules (Figure 4.12). The piperazine molecules, 
whilst hydrogen bonding with the furosemide molecules, also hydrogen bond among 
themselves through N(3)-H(6)···N(1) interactions to form an infinite network of hydrogen-
bonded piperazine molecules (Figure 4.10). These interactions extend infinitely along the b 
crystallographic axis. Each piperazine molecule is hydrogen-bonded to the furosemide 
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molecules through N
+
(3)-H(6)···O
-
(1) charge assisted hydrogen bonding interactions (Figure 
4.8). The crystal packing arrangement of molecular complex (6) is shown in Figure 4.12. The 
full crystallographic details of (6) are given in Table 4.2. 
 
Figure 4.12: Host-guest assembly in molecular complex (6). The guest piperazine molecules 
are shown in space fill representation. 
The DSC thermogram of (6) indicates an endothermic transition with an onset temp of 214.5 
o
C, corresponding to the melting of the compound (Figure 4.13). Complex (6) possesses a 
significantly different melting temperature compared to the starting materials FUR (220-222 
o
C) and PIP (109-110 
o
C). 
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Figure 4.13: DSC of molecular complex (6). 
4.2.3. Crystal structure description of molecular complex (7) [(furosemide)1-(1,4,8,11-
tetraazacyclotetradecane)0.5] 
Single crystals of molecular complex (7) were obtained by slow evaporation from an acetone 
solution containing furosemide and 1,4,8,11-tetraazacyclotetradecane in a 1:0.5 mole ratio. 
The crystal structure shows that the molecule crystallises in the P1̅ space group. The full 
crystallographic details of (7) are given in Table 4.2. The crystal structure of (7) shows that 
the asymmetric unit consists of one molecule of furosemide and half a molecule of 1,4,8,11-
tetraazacyclotetradecane, with 1,4,8,11-tetraazacyclotetradecane molecules possessing an 
inversion centre (Figure 4.14). Two furosemide and one 1,4,8,11-tetraazacyclotetradecane 
molecules generate a three component supermolecule stabilised through N
+
(3)-H(6)···O
-
(1) 
charge assisted hydrogen bonding interactions (Table 4.1)  (Figure 4.15). The crystal 
structure shows that proton transfer occurs between the furosemide O-H groups to the basic 
amine nitrogen of cyclam resulting in the formation of a salt (Figure 4.15). Analogous to 
molecular complexes (5) and (6), similar hydrogen bonding interactions N(1)-H(1)···O(2) 
and N(1)-H(2)···O(2)  (Table 4.1) are observed between the furosemide molecules resulting 
in the formation of a ring motif, R2
2
(4) (Figure 4.16). Whilst all other molecular complexes 
(5) and (6) contained hydrogen bonding interactions formed between the C-H of furan and 
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the carbonyl of furosemide, these interactions are not observed in molecular complex (7). 
However, several weak interactions exist between the furosemide molecules which lead to 
channels as shown in Figure 4.17. These channels are occupied by the co-former cyclam 
(Figure 4.18).  
 
Figure 4.14: ORTEP plot of molecular complex (7). 
 
Figure 4.15: Hydrogen bonding interactions between furosemide and 1,4,8,11-
tetraazacyclotetradecane in molecular complex (7). 
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Figure 4.16: Interactions between furosemide molecules in molecular complex (7). 
 
Figure 4.17: Channels formed by furosemide host network in molecular complex (7). 
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Figure 4.18: Host-guest arrangement in molecular complex (7). 
The DSC data of the molecular complex (7) (Figure 4.19) shows a sharp endothermic 
transition with an onset temperature of 177.0 
o
C, corresponding to the melting of the 
compound. The transitions following this could probably be due to the decomposition of the 
material. The melting endotherm of the complex (7) is different to the melting points of the 
starting materials FUR (218-220 
o
C) and cyclam (182-186 
o
C).  
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Figure 4.19: DSC of molecular complex (7). 
4.2.4. Crystal structure description of molecular complex (8) [(furosemide)1-(1,2-bis(4-
pyridyl)ethane)0.5] 
Diffraction quality crystals of molecular complex (8) were obtained from a 2-propanol 
solution containing furosemide and 1,2-bis(4-pyridyl)ethane in 1:0.5 mole ratio. The 
asymmetric unit of (8) consists of one molecule of furosemide and half a molecule of 1,2-
bis(4-pyridyl)ethane, with 1,2-bis(4-pyridyl)ethane molecules occupying inversion centre 
(Figure 4.20). The complex crystallises in a monoclinic crystal system with P21/c as the space 
group. The full crystallographic details of (8) are given in Table 4.2. The 1,2-bis(4-
pyridyl)ethane molecules and the furosemide molecules are hydrogen-bonded through N
+
(3)-
H(6)···O
-
(1) charge assisted hydrogen bonding interactions (Table 4.1) (Figure 4.22). 
Analogous to molecular complexes (5) and (6), the furosemide molecules hydrogen bond 
through N(1)-H(1)···O(2) and N(1)-H(2)···O(2)  interactions (Table 4.1)  to form the ring 
motif, R2
2
(4) (Figure 4.21). In addition, one of the C-H groups of furosemide also participates 
in hydrogen bonding interactions with the carbonyl group though C(12)-H(12)···O(2) 
interactions (Table 4.1). The furosemide molecules arrange to form a network of host 
molecules containing channels, extending infinitely along the a crystallographic axis as show 
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in Figure 4.23. These channels are occupied by the 1,2-bis(4-pyridyl)ethane molecules 
resulting in the formation of host-guest assembly as shown in Figure 4.24.   
 
Figure 4.20: ORTEP plot of molecular complex (8). 
 
Figure 4.21: Hydrogen bonding interactions between furosemide molecules in molecular 
complex (8). 
 
Figure 4.22: Hydrogen bonding interactions between furosemide and 1,2-bis(4-
pyridyl)ethane in molecular complex (8). 
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Figure 4.23: Furosemide channels in molecular complex (8). 
 
Figure 4.24: Host-guest arrangement in molecular complex (8). 
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The DSC thermogram of the molecular complex (8) (Figure 4.25) shows a sharp endothermic 
transition with an onset temperature of 237.9 
o
C and a peak at 242.3 
o
C. The endothermic 
transition matches with the melting of the complex as analysed by a capillary melting 
experiment. The melting transition is immediately followed by an exothermic transition, 
which could be due to the decomposition of the material. 
 
Figure 4.25: DSC of molecular complex (8). 
Table 4.1: Geometric parameters for the hydrogen bonds in molecular complexes (5) – (10) 
Compound Hydrogen bond 
d 
(H···A)/Å 
d 
(D···A)/Å 
 
(D-H···A)/
o 
(5) N
+
(3)-H(6)···O
−
(1) 1.70 2.61(2) 164.3 
(5) N(1)-H(1)···O(2) 2.32 2.99(4) 132.6 
(5) N(1)-H(2)···O(2) 1.89 2.83(5) 162.2 
(5) 
N(2)-H(4)···O(1) 
(intra) 
1.96 2.64(2) 127.9 
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(5) C(12)-H(12)···O(2) 2.36 3.3(2) 169.7 
(5) N(4)-H(16)···O(4) 1.97 2.83(6) 164.7 
(6) N
+
(3)-H(6)···O
−
(1) 1.67 2.65(3) 165.7 
(6) N(1)-H(1)···O(2) 1.89 2.79(4) 174.9 
(6) N(1)-H(2)···O(2) 2.16 2.88(6) 133.6 
(6) 
N(2)-H(4)···O(1) 
(intra) 
1.95 2.63(7) 135.6 
(6) C(12)-H(12)···O(2) 2.41 3.33(5) 169.1 
(6) N(3)-H(7)···N(4) 1.93 2.79(3) 158.3 
(7) N
+
(3)-H(6)···O
−
(1) 1.86 2.33(3) 148.3 
(7) N(1)-H(1)···O(2) 2.02 2.86(5) 150.8 
(7) N(1)-H(2)···O(2) 1.91 2.84(6) 173.3 
(7) 
N(2)-H(4)···O(1) 
(intra) 
1.98 2.67(4) 138.6 
(7) 
N(3)-H(7)···N(4) 
(intra) 
2.22 2.89(2) 140.7 
(8) N
+
(3)-H(6)···O
−
(1) 1.67 2.58(2) 167.1 
(8) N(1)-H(1)···O(2) 2.05 2.87(2) 173.8 
(8) N(1)-H(2)···O(2) 2.3 
3.0(4) 
138.1 
(8) 
N(2)-H(4)···O(1) 
(intra) 
1.93 2.65(6) 140.7 
(8) C(12)-H(12)···O(2) 2.56 3.49(5) 163.5 
(9) N
+
(3)-H(6)···O
−
(1) 1.63 2.54(4) 161.4 
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(9) N(1)-H(1)···O(2) 2.06 2.84(7) 175.2 
(9) N(1)-H(2)···O(2) 2.24 2.97(4) 136.7 
(9) 
N(2)-H(4)···O(1) 
(intra) 
1.94 2.64(4) 137.5 
(9) C(12)-H(12)···O(2) 2.56 3.35(7) 173.7 
(10) N(1)-H(2)···O(3) 2.19 3.0(4) 146.0 
(10) 
N(2)-H(4)···O(2) 
(intra) 
1.99 2.68(3) 136.7 
(10) O(1)-H(6)···N(3) 1.76 2.60(5) 164.8 
(10) C(13)-H(13)···O(2) 2.44 3.18(6) 130.8 
(10) N(1)-H(1)···O(1) 2.60 3.06(5) 120.6 
 
4.2.5. Crystal structure description of molecular complex (9) [(furosemide)1-(1,2-di(4-
pyridyl)ethylene)0.5] 
 The single crystals of molecular complex (9) were obtained by slow evaporation from an 
ethanolic solution containing furosemide and 1,2-di(4-pyridyl)ethylene in a 1:0.5 molar ratio. 
The crystal structure of (9) is isostructural to the molecular complex (8). The molecule 
crystallises in a monoclinic crystal system with P21/c as the space group. The asymmetric 
unit of the molecule consists of one molecule of furosemide and half a molecule of 1,2-di(4-
pyridyl)ethylene, with the 1,2-di(4-pyridyl)ethylene occupying the inversion centre (Figure 
4.26). The full crystallographic details are given in Table 4.2. The crystal structure shows that 
there is complete transfer of the furosemide O-H protons to the basic pyridyl nitrogens of 1,2-
di(4-pyridyl)ethylene. The N
+
-H hydrogen on the 1,2-di(4-pyridinum)ethylene cation was 
located from difference density map. Two furosemide and one 1,2-di(4-pyridyl)ethylene 
molecules generate a three component super molecule stabilised through N
+
(3)-H(6)···O
-
(1) 
charge assisted hydrogen bonding interactions (Table 4.1)  (Figure 4.27). Similar to the 
molecular complex (8), the two components furosemide and 1,2-di(4-pyridyl)ethylene 
arrange to form a host-guest assembly as shown in Figure 4.28 and Figure 4.29, with the 
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furosemide molecules forming the host network and the 1,2-di(4-pyridyl)ethylene molecules 
occupying the guest positions.  
 
Figure 4.26: ORTEP plot of molecular complex (9). 
 
Figure 4.27: Hydrogen bonding interactions between furosemide and 1,2-di(4-
pyridyl)ethylene in molecular complex (9). 
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Figure 4.28: Host-guest assembly in molecular complex (9). 
 
Figure 4.29: Host-guest assembly in molecular complex (9). 
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The molecular complex (9) has a higher melting point (DSC endotherm at 246.5 
o
C) 
compared to that of the two starting materials (Figure 4.29). 
 
Figure 4.29: DSC of molecular complex (9). 
 
4.2.6. Crystal structure description of molecular complex (10) [(furosemide)1-(4,4’-
bipyridyl)0.5] 
The single crystals of co-crystal (10) were obtained from a 2-propanol solution containing 
furosemide and 4,4’-bipyridyl in 1 to 0.5 mole ratio. Pale yellow coloured crystals of co-
crystal (10) were obtained after 2 days of crystallisation. (10) crystallises in monoclinic 
crystal system with C2/c as the space group. The asymmetric unit of (10) consists of one 
molecule of furosemide and half a molecule of 4,4’-bipyridyl (Figure 4.30). The co-crystal 
former, 4,4’-bipyridyl, holds a crystallographic inversion centre. The two components 
furosemide and 4,4’-bipyridyl are stabilised through the acid-pyridine supramolecular 
synthon, while forming the O(1)-H(6)···N(3) and C(13)-H(13)···O(2) hydrogen bonding 
interactions (Table 4.1) (Figure 4.31). The N-H groups of furosemide hydrogen bond with 
one of the sulphoxide SO2 oxygen atoms in the sulphonamide and the oxygen of the O-H 
groups of acid through N(1)-H(2)···O(3) and N(1)-H(1)···O(1) interactions (Table 4.1) as 
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shown in Figure 4.32. The furosemide molecules arrange to a network of molecules forming 
channels extending infinitely along the b crystallographic axis as shown in Figure 4.33. The 
channels formed by the furosemide molecules are occupied by the guest molecules 4,4’-
bipydiyl to form a host-guest assembly as shown in 
 
Figure 4.34. The full crystallographic details of the molecular complex are presented in Table 
4.2. 
 
Figure 4.30: ORTEP diagram of co-crystal (10). 
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Figure 4.31: Hydrogen bonding interactions between furosemide and 4,4’-bipyridyl. The 
4,4’-bipyridyl occupies inversion centre.  
. 
 
Figure 4.32: Hydrogen bonding interactions between furosemide molecules. 
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Figure 4.33: Host network: Channels formed by the furosemide molecules. 
 
Figure 4.34: Host-guest assembly in co-crystal (10). 
 
The DSC thermogram of the co-crystals of molecular complex (10) (Figure 4.35) shows a 
sharp endothermic transition with an onset temperature of 223.4 
o
C. The endothermic 
transition corresponds to the melting of the compound as examined by the capillary melting 
experiment. The transitions following the melting could be due to the decomposition of the 
material. 
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Figure 4.35: DSC thermogram of molecular complex (10). 
 
Table 4.2: Crystallographic data of co-crystals (5)-(10). 
 (5) (6) (7) (8) (9) (10) 
Chemical 
formula 
C15H15Cl1
N4O5S1 
C16H21Cl1 
N4O5S1 
C17H23Cl1 
N4O5S1 
C18H17Cl1 
N3O5S1 
C18H16Cl1 
N3O5S1 
C17H15Cl1 
N3O5S1 
Formula 
weight 
398.8 416.8 430.9 422.9 421.9 408.8 
Crystal 
system 
monoclinic monoclinic triclinic monoclinic monoclinic monoclinic 
a / Å 8.759(8) 13.19(3) 8.864(9) 9.011(9) 9.0086(6) 26.35(5) 
b / Å 21.264(19) 8.764(18) 9.562(10) 20.70(3) 19.7597(12) 6.648(13) 
c / Å 9.205(9) 16.08(3) 11.930(15) 9.974(10) 10.0500(7) 21.29(5) 
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α / o 90 90 93.97(3) 90 90 90 
β / o 95.110(17) 98.87(4) 101.61(4) 93.644(17) 94.150(4) 107.61(7) 
γ / o 90 90 90.49(2) 90 90 90 
Space 
group 
P21/c P21/n P1̅ P21/c P21/c C2/c 
V / Å
3
 1708.5(3) 1837.4(7) 987.9(2) 1856.2(4) 1784.3(3) 3555.0(13) 
Z 4 4 2 4 4 8 
N reflection/ 
Nparameter 
2958/235 2914/244 4890/253 4837/253 3303/253 3144/244 
ρcalc / g 
cm
-3 
1.55 1.51 1.45 1.51 1.57 1.53 
Radiation 
type 
Mo Kα (λ 
=0.710173 
Å) 
Mo Kα (λ 
=0.710173 
Å) 
Mo Kα (λ 
=0.710173 
Å) 
Mo Kα (λ 
=0.710173 
Å) 
Mo Kα (λ 
=0.710173 
Å) 
Mo Kα (λ 
=0.710173 
Å) 
T / K 100 100 100 100 100 100 
 range/° 2.9 to 30.1 1.8 to 29.7 1.7 to 33.9 2.2 to 32.1 2.2 to 29.9 2.9 to 30.4 
Range of 
h 
-12 to 12 -18 to 18 -13 to 13 -13 to 13 -12 to 12 -37 to 35 
Range of 
k 
0 to 30 0 to 12 -14 to 14 0 to 30 0 to 27 0 to 9 
Range of 
l 
0 to 12 0 to 22 0 to 18 0 to 14 0 to 14 0 to 25 
R1 / % 4.4 4.1 4.3 3.5 4.7 3.7 
WR2 / % 4.8 4.3 5.5 3.6 5.4 3.9 
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Goodness
-of-fit 
1.031 1.113 0.9123 1.102 0.9447 1.123 
 
4.3. Discussion  
The molecular structure of furosemide (Scheme 4.1) indicates that the molecule contains four 
conventional hydrogen bond donor and six conventional hydrogen bond acceptor groups, 
after taking into consideration that the halogen atom (chlorine) can also act as hydrogen bond 
acceptor. In addition, furosemide is confomationally flexible along the furanylmethylamino 
(−NH−CH2−C4H3O) and sulfamoyl (−SO2−NH2) fragments. At the same time, some 
molecular fragments seem to be very rigid, i.e. the benzene ring, secondary amino group, the 
carboxylic acid group, the chlorine, as well as the sulphur atoms lie practically in one plane. 
The conformation of the sulfamoyl and furanylmethylamino fragments can be described by 
three torsion angles: C2−C1−S1−N1 (τ1), C6−N2−C8−C9 (τ2), and N2−C8−C9−O5 (τ3) (Figure 
4.36 for atom numbering). The latter two torsion angles characterize the rotation of the 
furanylmethylamino fragment along the N2−C8 bond and of the furanyl ring along the C8−C9 
bond. The other important structural feature in the furosemide is the orientation of the NH2 in 
relation to the SO2 in the sulphonamide group. In all the molecular complexes studied here 
the NH2 is oriented anti to the SO2 in the sulphonamide group. The results of the 
conformational analysis of the furosemide molecule in the crystal structure are summarized in 
Table 4.3.  
Table 4.3: Several torsion angles: τ1 (C2−C1−S1−N1), τ2 (C6−N2−C8−C9), τ3 
(N2−C8−C9−O5), and orientation of NH2 group in the sulfamoyl group characterizing the 
conformation of the furosemide molecule in different molecular complexes. 
Crystal structure τ1 τ2 τ3 
Orientation 
of NH2 conformation 
Furosemide form-I 163.2(4) -61.4(6) -57.6(6) trans TG
−
G
−
anti 
Molecular complex (5) -66.0(6) -172.6(9) -65.6(2) trans G−TG−anti 
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Molecular complex (6) -64.6 (3) 164.6(1) -81.2(5) trans G
−
TG
−anti
 
Molecular complex (7) 68.2(4) -69.6(9) -47.8(8) trans G+G−G−anti 
Molecular complex (8) -65.4(9) 166.2(4) -107.4(1) trans G
−
TT
anti
 
Molecular complex (9) -65.1(5) 176.2(4) -124.3(6) trans G
−
TT
anti
 
Molecular complex (10) 64.7(8) -70.7(8) -60.1(8) trans G
+
G
−
G
−anti
 
 
 
Figure 4.36: ORTEP of furosemide with numbering. 
In the molecular complexes presented here the sulfamoyl group adopts either gauche+ or 
gauche− conformation, with no intermediate trans conformation. The furanylmethylamino 
fragment, when compared to the furosemide form-I adopts trans conformation in molecular 
complexes (5), (6), (8) and (9), while being gauche− in (7) and (10) molecular complexes. All 
the overlayed conformations of furosemide are shown in Figure 4.37. While the carboxylic 
acid group in furosemide form-I and in molecular complex (10) lie in the plane of the 
benzene ring, in other molecular complexes presented here the carboxylate anion is slightly 
twisted with respect to the benzene plane.  
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Figure 4.37: Overlaid conformations of furosemide molecules in all the molecular 
complexes. 
 
A generally accepted guideline
167
 for salt formation is that the proton transfer will occur from 
an acid to a base when the difference in pKa (ΔpKa being the difference between the pKa 
value of a protonated base and that of the acid) is >3.5, and a neutral co-crystal will form 
when the ΔpKa < 0. A co-crystal to salt continuum exists between 0 ≤ΔpKa ≤ 3.5. The 
molecular complexes formed by piperazine, imidazole, 1,4,8,11-tetraazacyclotetradecane are 
in agreement with the calculated pKa values.
168
 Whilst the calculated pKa of values for 1,2-
bis(4-pyridyl)ethane, 1,2-di(4-pyridyl)ethylene and 4,4’-bipyridyl fall in the 0 ≤ΔpKa ≤ 3.5 
range, salt formation is observed in the single crystal structure when 1,2-bis(4-pyridyl)ethane 
and 1,2-di(4-pyridyl)ethylene are used as co-formers. However, a neutral molecular complex 
resulted when 4,4’-bipyridyl is used as the co-crystal former. This suggests that the prediction 
of the degree of proton transfer in the solid-state form based on the pKa difference remains 
imprecise and may also show variations with the solvent of crystallisation. The 
1
H-NMR 
spectra of the molecular complexes (6)-(10) are given in Appendices A.1.4 to A.1.8. The 
1
H-
NMR data suggests that the crystal analysed is a representative of the bulk material. 
The molecular complexes (5) - (9) are stabilised through charge transfer hydrogen bonding 
interactions. The charge separation resulting from the proton transfer leads to the dominance 
of electrostatic interactions over other noncovalent interactions. The molecular complexes (5) 
to (9) exhibit the charge assisted hydrogen bonding interactions. These interactions drive the 
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molecular complex formation whilst forming other hydrogen bonds between furosemide 
molecules. The hydrogen bonding interactions observed between the furosemide molecules 
are different in co-crystal (10) when compared to the interactions in molecular complexes (5) 
–(9). In molecular complex (10), the two components are stabilised through a neutral acid-
pyridine heterosynthon. In summary, the molecular complexes (5) – (10) studied here suggest 
that the charge transfer hydrogen bonding interactions can be used to control the auxiliary 
hydrogen bonding interactions. These auxiliary hydrogen bonds between furosemide 
molecules arrange to form a network of host molecules exhibiting 1D channels. These 
channels are occupied by the guest (co-crystal former) molecules in all the molecular 
complexes. The guests molecules studied here vary in size and shape.  
4.4. Conclusion 
In conclusion, six new host-guest molecular complexes of furosemide with various 
heterocyclic bases have been synthesised and structurally characterised. It has been 
demonstrated that the crystal packing arrangement of the molecules is dependent on the 
dominant intermolecular interaction in the complex. The charge assisted hydrogen bonding 
interaction is the dominant interaction in the molecular complexes (5) to (9). This interaction 
drives the crystal packing arrangement in the complexes to form persistent hydrogen bonding 
interactions between furosemide molecules. Such persistent hydrogen bonding interactions 
between furosemide molecules are not observed in molecular complex (10), where the two 
components are stabilised through an acid-pyridine supramolecular synthon. In all the 
complexes, the two components arrange to form host-guest supramolecular complexes. A 
detailed conformational analysis of furosemide shows that the molecule can exist in different 
conformational orientations. This allows the host network formed by the furosemide 
molecules to accommodate different guests of varying size.  
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Chapter 5: A Robust Two-Dimensional Hydrogen-Bonded Network for the 
Predictable Assembly of Ternary Co-crystals. 
5.1. Introduction 
One of the primary goals of molecular crystal engineering is, given the molecular structure of 
the constituent components, one should be able to predict the crystal structure.
169
 In this 
context, John Maddox
170
 noted that “inability to predict crystal structures from the molecular 
structures is one of the continuing scandals of modern science”. The prediction of crystal 
structure is of importance since the crystal structure of any material is most arguably the 
important piece of information that could be obtained about the material, which directly or 
indirectly determines/influences the properties of the material.
171
 A crystal is considered as a 
supermolecule
172
 and, when compared to the molecular structure, represents a higher level of 
complexity with crystallisation considered as the supramolecular reaction. In order to predict 
crystal structures on a routine basis, a complete understanding of the synthetic step, the 
crystallisation process, is required. In the absence of a complete understanding of the 
crystallisation process, crystal engineers are left with no option but to empirically develop 
new strategies leading to the prediction of related crystal structures. At present the prediction 
of crystal structures is done by two methods: (a) computational methods and (b) crystal 
engineering based methods. Computational methods of crystal structure prediction are precise 
and deal primarily with known molecular compositions. It usually involves the analysis of 
molecular recognition features of the constituent molecules in the context of how they 
generate symmetry operations when optimized to form a close packing structure, thus 
resulting in the prediction of crystal structure. Usually, by this method a number of possible 
crystal structures are obtained, with the experimental structure being hidden amongst the 
other possible structures. The computational method of structure prediction is often 
inadequate or extremely difficult when (i) the experimental structure is not the 
thermodynamically stable structure but a higher-energy (metastable) kinetically stabilised 
structure and (ii) in systems containing flexible molecules with the number of symmetry-
independent non-hydrogen atoms >20 and (iii) in systems with Z’>1. 
Crystal engineering methods of crystal structure prediction are generally less precise 
compared to ab-initio or force-field methods and are typically restricted to predicting 
networks of entirely new phases containing known molecules. Crystal engineering based 
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structure prediction can be done in two ways (i) based on a blueprint obtained rationally or 
serendipitously
173
 and (ii) retro-synthesis based structure prediction. By the first process, the 
crystal structure of a known compound serves as a blueprint for rational selection and 
prediction of the packing arrangements in related compounds. The retro-synthesis based 
strategy involves the identification of a robust combination of supramolecular synthons from 
CSD analysis that are specific to functional groups. A crystal engineer then seeks to 
reproduce these supramolecular synthons in a series of related molecules. Both processes 
involve complete understanding of the delicate intermolecular interactions existing between 
the component or components. However, the ability to reproduce a set of supramolecular 
synthons or to synthesise a material based on a blueprint structure occurs only in an ideal 
situations. Often serious problems arise due to the following reasons:  
1. The number of possible supramolecular synthons can increase steeply upon little 
increase in the molecular functionality.  
2. Since the hydrogen bonding/ intermolecular interactions existing between the 
molecular components are weak the presence of polymorphism
174
 cannot be avoided. 
3. The most serious problem is the interference from the hydrocarbon residue, which is 
considered to be a supramolecular functionality and participates in molecular 
recognition units.  
Structure prediction by retro-synthesis based strategies has been limited to the prediction of a 
supramolecular synthon, with little or no control over the packing arrangements of other 
functional groups. Prediction of crystal packing arrangements by these methods occurs only 
in ideal or rare situations. Strategies that overcome the above problems and allow the 
prediction of space group symmetry, gross structural features, and the prediction of lattice 
parameters and atomic co-ordinates are of importance in crystal engineering.  
In this chapter, the prediction of the space group and crystal packing arrangements in co-
crystals uses the crystal engineering method and is based on identifying an n-dimensional 
network and utilising the n-dimensional network to predict the space groups and packing 
arrangements in other co-crystals. The approach in the chapter for the synthesis of n-
dimensional networks is based on selection of components based on the geometry of the 
functional groups. The geometry of the functional groups plays important role in the 
molecule’s ability to participate in hydrogen bonding interactions. The identification of a 
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robust n-dimensional network reduces the structure prediction problem of crystal engineering 
to the 3-n dimensions thereby improving the predictability. Whilst robust supramolecular 
synthons
175
 are common between functional groups, robust networks based on combinations 
of supramolecular synthons are extremely rare: a notable exception being the publications 
from Ward group,
176
 where the robust two-dimensional network utilized ionic interactions. 
In addition to crystal structure prediction, one of the challenges of organic crystal engineering 
is the ability to synthesise higher order crystals. In order to synthesise ternary or higher order 
co-crystals, a better understanding of the molecular recognition processes is required. 
Synthesizing higher order co-crystals and understanding molecular recognition processes is 
absolutely essential if we are to understand the enormously complex and efficient molecular 
recognition processes in enzyme–coenzyme–substrate complexes.177 While the number of 
binary co-crystals are increasing every day, synthesis of ternary or higher order crystals is 
still challenging and frustrating, with few exceptions.
178
 This is largely due to the absence of 
reliable structural paradigms. Synthesis of ternary or higher order co-crystals is also 
hampered by the number of possible cross-over reactions and by the solubility of the 
components. A mixture of several components with quite different solubility profiles could 
form a co-crystal, but more often than not will only result in the precipitation of the 
individual component with the lowest solubility. One alternative for this is to select the 
solvent of crystallisation as one of the components, which has been followed in the work 
presented here. While there is no agreement between different research groups on what 
constitutes a component, it is accepted that if there is a crystal engineering aspect attached to 
how the solvent molecules arrange within the crystal then the solvent molecule can be 
regarded as a component and the molecular complex termed as ternary or binary co-crystal 
rather than a co-crystal solvate or solvate.  
With the target of identifying a robust two-dimensional network and to synthesise ternary co-
crystals, whilst working with furosemide. Furosemide is a conformationally flexible molecule 
which contains carboxylic acid and sulphonamide in addition to other functional groups. The 
pseudo-tetrahedral sulphonamide group, unlike the planar carboxylic acid group, provides 
additional dimensionality for hydrogen bonding interactions.
179
 The ability of carboxylic acid 
groups to form molecular complexes with pyridine functional groups is well known and has 
been used in many cases.
180
 Considering the known ability of carboxylic acids to readily form 
the acid-pyridine supramolecular heterosynthon, 4,4’-bipyridyl was selected as one of the co-
crystal formers (CCF). The strategy for the identification of a robust two-dimensional 
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network and co-crystal synthesis is based on utilising the geometry of the functional groups 
present in furosemide, 4,4’-bipyridyl and other ternary components. The results which 
resulted in positive outcome of mechano-chemical synthesis or co-crystallisation are 
presented here. All the co-crystals presented here were initially synthesised through 
mechano-chemical methods and then through crystallisation from solvent. 
5.2. Co-crystal (11) [(furosemide)1- (4,4’-bipyridyl)0.5]  
5.2.1. Synthesis of co-crystal (11)  
Considering the molecular symmetry of 4,4’-bipyridyl (Scheme 5.2). Furosemide (33.0 mg, 1 
mmol) and 4,4’-bipyridyl (7.8 mg, 0.5 mmol) were ground together with a mortar and pestle 
in the presence of 20 μL of acetonitrile for 5 minutes. The solvent drop grinding method 
indicated the formation of a phase different to the starting materials, as analysed by XRPD. 
Identical amounts of furosemide and 4,4’-bipyridyl were then dissolved in 2 ml of acetonitrile 
and allowed to crystallise  through slow evaporation of solvent. Single crystals of diffraction 
quality were obtained after 2 days.  
 
Figure 5.1: ORTEP plot of co-crystal (11) showing the atom numbering. (The displacement 
ellipsoids are drawn at the 50% probability level and atoms in the asymmetric unit are 
labelled). Key: chlorine, green circle; sulphur, yellow circles; oxygen, red circles; nitrogen, 
blue circles; carbon, grey circles; hydrogen, small white circles. 
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5.2.2. Crystal structure of co-crystal (11)  
Single crystal data collection followed by structural analysis revealed the structural features 
in co-crystal (11). The asymmetric unit of (11) consists of one molecule of furosemide and 
half molecule of 4,4’-bipyrdiyl (bipy) (Figure 5.1). The compound crystallises in a 
monoclinic crystal system with P21/n as the space group. The full crystallographic details are 
given in Table 5.1. 
 
Figure 5.2: Packing arrangement in co-crystal (11), viewed along the [010] direction. Solid 
red lines represent intermolecular hydrogen bonds. Key: chlorine, green circles; sulphur, 
yellow circles; oxygen, red circles; nitrogen, blue circles; carbon, black circles; hydrogen, 
small white circles. 
The two components in co-crystal (11) are held together through O(1)-H(1)···N(3) 
interactions between the O-H donor group of the carboxylic acid and the pyridyl nitrogen of 
bipyridyl (Table 5.3). In addition to the O-H···N interactions, the sulphonamide donors of 
furosemide are hydrogen-bonded to the carboxylic acid acceptors through N(2)-H(2)···O(1) 
and N(2)-H(3)···O(2) hydrogen bonding interactions (Table 5.3). Two inversion related 
furosemide molecules, stabilised through N(2)-H(2)···O(1) interactions propagate along the 
screw axis to generate a host network of furosemide molecules, with the bipy molecules 
occupying the guest positions (Figure 5.2). The two components arrange to form a three 
dimensional structure through host-guest as shown in Figure 5.2. The co-crystal (11) is a 
polymorphic form of co-crystal (10) presented in section 4.6.2. 
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Differential Scanning Calorimetry (DSC) of co-crystal (11) 
The DSC thermogram of co-crystal (11) was obtained by weighing around 5.0 mg of the 
sample in an aluminium pan and crimping with a pinhole in the lid. The weighed sample was 
analysed over the temperature range between 25 and 280 °C at a constant heat rate of 10 
o
C/min. The thermogram of (11) reveals a sharp endotherm at 225.4 
o
C with an onset at 222.9 
o
C, which corresponds to the melting of (11). The melting is followed by decomposition 
(Figure 5.3).  
 
Figure 5.3: DSC thermogram of co-crystal (11). 
Considering the ditopic acceptor nature of bipyridyl and the ability of the donor groups in 
furosemide to form a multiple hydrogen bonding interactions, the co-crystal formation was 
anticipated at a 1:1 molar composition of fus-bipy molecules. However, this was not the case; 
the two components remained as a physical mixture of the two components at this 
composition (Figure 5.4).   
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Figure 5.4: Powder X-ray diffraction data illustrating the formation of physical mixture 
when the composition of fus-bipy was altered to 1:1 molar composition. 
This is the starting point for the investigation of ternary co-crystals. Considering the 
geometry of the functional groups in furosemide and the ability of bipyridyl, to act as ditopic 
acceptor, by systematically introducing a third component to the fus–bipy (1:1) mixture, it 
was possible to isolate crystalline phases different from the starting materials. The third 
component introduced, was altered in terms of the number of hydrogen bond donor and 
acceptor groups present. Initially dimethyl sulphoxide and methanol were used as the ternary 
components. 
 5.3. Co-crystal (12) [(furosemide – bipyridyl – DMSO (1-1-1)] 
5.3.1. Crystal structure of co-crystal (12) 
Diffraction quality crystals of co-crystal (12) were obtained after 5 days when equimolar 
amounts of furosemide and bipyridyl dissolved in DMSO were allowed to crystallise  by slow 
solvent evaporation. (12) crystallises in the space group P1̅ (Table 5.1). The asymmetric unit 
of (12) consists of one molecule each of furosemide, bipyridyl and DMSO (Figure 5.5). The 
DMSO molecule acts as a conventional hydrogen bond acceptor and is hydrogen-bonded to 
one of the N-H donors of furosemide through N(1)-H(7)···O(6) hydrogen bonding 
interactions (Figure 5.6), while the other N-H group of furosemide is hydrogen-bonded to one 
of the pyridyl groups of 4,4’-bipyridyl through N(1)-H(6)···N(3) interactions (Table 5.3). 
One end of the bipyridyl molecule is hydrogen-bonded to the N-H donor of the sulphonamide 
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while the other end of bipyridyl participates in the well-known acid-pyridine supramolecular 
heterosynthon through O(1)-H(1)···N(4) and C(21)-H(21)···O(2) interactions (Table 5.3) 
(Figure 5.6).  
 
 Figure 5.5: ORTEP plot of co-crystal (12). 
 
 
Figure 5.6: Hydrogen bonding interactions in co-crystal (12). 
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Thermal analysis of co-crystal (12) 
Single crystals of co-crystal (12) were subjected to a combined TGA/DTA (Figure 5.7) 
analysis. The thermogram indicates an endothermic transition at 117.2 
o
C with a weight loss 
of around 15.2%, which is due to the loss of 1 mole of DMSO molecule in (12). This 
transition is followed by a broad exothermic transition which could be due to the loss of half 
molecule of 4,4’-bipyridyl. This transition is followed by an endothermic transition, 
corresponding to the melting of the compound at 217.7 
o
C. 
 
Figure 5.7: DTA/TGA of co-crystal (12). 
Discussion:  
In addition to the conventional hydrogen bonding interactions, the C-H groups of DMSO 
participate in weak C(24)-H(28)···O(4) interactions with the sulphoxide acceptor groups of 
furosemide to form a two-dimensional network involving three components. The hydrogen 
bonds observed between furosemide and other components are in accordance with the 
principle of hierarchy as proposed by Etter.
181
 In addition to the hydrogen bonding 
interactions, there are π–π interactions between the aromatic moiety of furosemide and one of 
the pyridyl rings of 4,4’–bipyridyl (Figure 5.8). The two-dimensional network formed by co-
crystal (12) is shown in Figure 5.9. The interactions between furosemide and the ternary 
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component propagate along a crystallographic axis, while the interactions between 
furosemide and bipyridyl propagate diagonally in the ac plane.  
 
Figure 5.8: π–π interactions between the aromatic moieties of furosemide and 
bipyridyl in co-crystal (12). 
 
Figure 5.9: The two-dimensional network in co-crystal (12) viewed along the [010] 
direction. 
b 
c a 
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The co-crystal (12) crystallises in the P1̅ space group while stabilised through an asymmetric 
two dimensional network. Therefore, upon reproducing the asymmetric two–dimensional 
network like the one observed in (12) one can expect the space group to be unaltered (P1̅). 
The crystal packing arrangement and space group of (12) serves as a blueprint for the 
selection and rational synthesis of other ternary co-crystals presented here. Taking the weak 
C-H···O interactions between the furosemide and ternary component into consideration, co-
crystal formation was anticipated by introducing a ternary component containing functional 
groups which could act both as a donor and acceptor simultaneously. Alcohols serve as good 
targets for this purpose. Since the hydrogen bonding interactions between DMSO and 
furosemide molecules are along a crystallographic axis in (12), by introducing molecules 
containing alcohol functional groups as ternary components, co-crystal formation can be 
anticipated through similar hydrogen binding interactions with a reduced a crystallographic 
axis. 
5.4. Co-crystal (13) [(furosemide – bipyridyl – MeOH (1-1-1)] 
5.4.1. Synthesis of co-crystal (13) 
Furosemide (33.0 mg, 1.0 mmol) and 4,4’-bipyrrdyl (15.6 mg, 1 mmol) were ground together 
in the presence of 20 μl of methanol using a mortar and pestle. The product obtained from the 
solvent drop grinding method was dissolved in 2 ml of methanol and allowed to crystallise  
via slow evaporation of methanol. Single crystals of diffraction quality were isolated from the 
crystallisation flask after one day and were analysed by single crystal X-ray diffraction.  
 
Figure 5.10: ORTEP plot of co-crystal (13). 
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Figure 5.11: Hydrogen bonding interactions between furosemide and bipyridyl in co-crystal 
(13), viewed along the [100] direction. 
5.4.2. Crystal structure of co-crystal (13)  
Co-crystal (13) consists of one molecule each of furosemide, 4,4’-bipyridyl and methanol in 
the asymmetric unit (Figure 5.10). As expected, based on the blueprint structure (12), the 
three components crystallise  in space group P1̅ through similar combinations of hydrogen 
bonding interactions to form an asymmetric two-dimensional network. The full 
crystallographic details are given in Table 5.1. Analogous to co-crystal (12), the syn N-H (syn 
with respect to chlorine) and the carboxylic O-H of furosemide are hydrogen-bonded to the 
pyridyl nitrogen of bipyridyl through N(1)-H(6)···N(3) and O(1)-H(1)···N(4) hydrogen 
bonding interactions (Table 5.3), these interactions extend diagonally in the [100] direction 
(Figure 5.11). These furosemide – bipyridyl aggregates are linked by the methanol molecule 
through N(1)-H(7)···O(6) and O(6)-H(25)···O(3) hydrogen bonding interactions (Table 5.3), 
extending infinitely along the a crystallographic axis (Figure 5.12). In addition to the 
hydrogen bonding interactions, there are strong π-π interactions between the aromatic rings of 
furosemide and bipyridyl as shown in Figure 5.13.  These arene–arene interactions are not 
completely parallel but, as is usual for such systems, are arranged in a slipped face-to-face/ 
center-to-edge stacking arrangement, with a slip angle of 13.4
o
 (Figure 5.13). The arene – 
arene interactions of the kind observed here are known to serve as robust supramolecular 
synthons
182
 and are abundant in chemical and biological systems.
183
 The π–π interactions 
interact cooperatively while extending infinitely along the crystallographic a axis.
184
 In 
addition to these interactions, the C-H groups of one of the pyridyl moieties of bipyridyl is 
involved in weak interactions with the furan ring to form perpendicular C-H···π interactions, 
extending infinitely through the crystallographic b axis. These interactions, measured from 
the center of the furan ring to the C(14) and C(13) carbon atoms, have a distance of 
3.332(3)Å and 4.027(2)Å.  
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Figure 5.12: Hydrogen bonding interactions in co-crystal (13) between the furosemide and 
ternary component (methanol) extending infinitely along the crystallographic a axis. 
 
Figure 5.13: π–π interactions between the furosemide and pyridyl moieties in co-crystal (13), 
viewed through crystallographic a axis (the dotted black lines represent the hydrogen bonding 
interactions). 
Thermal analysis of co-crystal (13)  
The TGA/ DTA of co-crystal (13) is shown in Figure 5.14. The thermogram indicates a 
crystal–crystal phase transition at 103.2 oC, accompanied by a weight loss of 7.2%, which 
corresponds to the loss of one mole of methanol. In addition to this, there is a transition at 
220.2 
o
C with an onset of 219.5 
o
C corresponding to the melting of the compound, which is 
followed by decomposition of the material. 
b 
c a 
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Figure 5.14: TG/ DTA of co-crystal (13). 
Based on the blue print structure of co-crystal (12), it was anticipated that will be a decrease 
in the a crystallographic axis going from (12) to (13) (Table 5.1), while the interactions 
between furosemide and ternary component (methanol) are along the crystallographic a axis 
as observed in (13). In both ternary co-crystals (12) and (13), the ternary components DMSO 
and MeOH have an identical role, acting as a bridge between the furosemide–bipyridyl 
aggregates. The three components in the two ternary co-crystals (12) and (13) are stabilised 
through an asymmetric two-dimensional hydrogen bonding network. The two dimensional 
network formed by co-crystals (12) and (13) is shown in Figure 5.9 and Figure 5.15 
respectively. 
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Table 5.1: Crystallographic data of co-crystals (11), (12), and (13). 
 
 (11) (12) (13) 
Chemical formula C17H15Cl1N3O5S C24H25Cl1N4O6S2 C24H25Cl1N4O6S2 
Formula weight 408.8 565.1 519.0 
Crystal system monoclinic triclinic triclinic 
a / Å 11.4883(6) 9.7483(4) 7.3552(9) 
b / Å 9.6632(5) 10.4805(4) 9.3457(11) 
c / Å 16.1106(8) 14.1432(5) 18.124(2) 
α / o 90.00 96.253(2) 80.525(6) 
β / o 101.252(2) 93.883(2) 82.376(6) 
γ / o 90.00 114.448(2) 75.758(6) 
Space group P21/n P1̅ P1̅ 
V / Å
3
 1754.12(16) 1297.39(9) 1185.5(2) 
Z 4 2 2 
N reflection/ Nparameter 8688/244 7440 / 334 9112/316 
ρcalc / g cm
-3
 1.548 1.446 1.454 
Radiation type 
Mo Kα (λ 
=0.710173 Å) 
Mo Kα (λ 
=0.710173 Å) 
Mo Kα (λ 
=0.710173 Å) 
T / K 100 100 100 
 range/° 3 – 44 4 – 34 1 – 40 
Range of h -22 – 22 -15 – 15 -12 – 12 
Range of k -16 – 18 -16 – 16 -14 – 15 
Range of l -31 – 31 -21 – 21 -31 – 31 
Rmerge 0.0455 0.0263 0.0305 
R1 / % 4.26516 4.46 4.17 
WR2 / % 4.64728 4.5 4.47 
Goodness-of-fit 1.076 1.118 1.077 
 
In co-crystals (12) and (13), the lattice metrics along the a and c axis and the angle β between 
them are dependent on the two-dimensional network. The two dimensional network depends 
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on the hydrogen bonding interactions and the conformational flexibility of the sulphonamide 
group.  
 
Figure 5.15: Two-dimensional network in co-crystal (4). 
A careful examination of crystal structures (12) and (13) suggests that the length of the b 
lattice parameter is determined on the long axis of the furosemide molecules, which is 
determined by the conformational flexibility of the furosemide molecules. It is important to 
mention that the dependence of the angles α and γ could not be rationalized based on the 
structural features observed in ternary co-crystals (12) and (13). Considering the two-
dimensional network observed in co-crystal (13), and noticing that the methyl groups of 
methanol in crystal structure (13) are involved only in van der Waals interactions, other 
alcohol functional group containing compounds (ethanol, 2-propanol, 1-butanol) were used as 
ternary components. 
5.5. Co-crystals (14) [(furosemide – bipyridyl – ethanol (1-1-1)]; (15) [(furosemide – 
bipyridyl – 2-propanol (1-1-1)]; and (16) [(furosemide – bipyridyl – 1-butanol (1-1-1)] 
5.5.1. Mechanochemical synthesis of ternary co-crystals (14), (15), and (16) 
Co-crystals (14), (15) and (16) were synthesised mechano-chemically by grinding furosemide 
(1.00 mmol, 33.0mg) and 4,4’-bipyridyl (1.00 mmol, 15.6mg) separately in the presence of 
20 μl of ethanol, 2-propanol, 1-butanol for 2 minutes using a mortar and pestle.  
In each case, new polycrystalline materials resulted. Their powder diffraction patterns differ 
from those of either the starting materials or any known binary phases. It was not possible to 
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isolate single crystals of co-crystals (14), (15) and (16). Several crystallisation attempts using 
a 1:1 molar ratio of furosemide and bipyridyl in presence of ethanol, 2-propanol, 1-butanol 
resulted in the concomitant formation of co-crystals (10) (furosemide – bipyridyl (1-0.5)) and 
(11) furosemide – bipyridyl (1-0.5). The two co-crystals (10) and (11) are co-crystal 
polymorphs; in this section (11) is discussed while (10) was discussed in section 4.2.6. 
While, it has not been possible to isolate single crystals of ternary co-crystals (14), (15) and 
(16), evidence for the formation of a ternary co-crystal is obtained by the analysis of powder 
X-ray diffraction patterns of polycrystalline materials obtained by solvent drop grinding. 
Figures 5.16, 5.17 and 5.18 present the powder diffraction patterns of co-crystals (14), (15) 
and (16) indexed using TOPAS.
185
 The unit cell parameters obtained by indexing reflections 
in co-crystals (14), (15) and (16) and the residual profile fitting parameters obtained by fitting 
each of the powder patterns are given in Table 5.2.   
 
Figure 5.16: Powder X-ray diffraction pattern of co-crystal (14) (Furosemide – bipyridyl 
– ethanol). The blue pattern represents the observed powder profile; the red pattern 
represents the profile calculated by using the cell parameters obtained by indexing the 
reflections of co-crystals (14); the bottom profile in each of the figures represents the 
difference between the observed and calculated powder patterns. 
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Figure 5.17: Powder X-ray diffraction pattern of co-crystal (6) (Furosemide – bipyridyl – 2-
propanol). The reflections marked in blue represent the reflection of co-crystal (15) while the 
reflections marked in black represent the reflections of furosemide form-I. 
 
 
Figure 5.18: Powder X-ray diffraction pattern of co-crystal (6) (Furosemide–bipyridyl–1-
butanol) 
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Table 5.2: Unit cell parameters of co-crystals (14), (15) and (16) from powder diffraction 
pattern. 
 (14) (15) (16) 
Chemical formula C24H25Cl1N4O6S C25H27Cl1N4O6S C26H29Cl1N4O6S 
Formula weight 533.0 547.0 561.0 
Crystal system triclinic triclinic triclinic 
a / Å 7.193(8) 7.860(5) 7.537(4) 
b / Å 9.780(6) 10.001(2) 9.374(3) 
c / Å 18.694(2) 18.402(4) 18.282(2) 
α / o 89.88(5) 76.13(1) 81.67(7) 
β / o 75.50(3) 76.56(5) 80.54(5) 
γ / o 73.17(1) 70.94(2) 75.6(3) 
Space group P1̅ P1̅ P1̅ 
V / Å
3
 1208.96(5) 1257.41(2) 1226.57(8) 
FOM 7.8 5.5 7.2 
Rwp / % 8.64 5.62 4.95 
 
Discussion: 
The powder diffraction pattern analysis of co-crystals (14), (15) and (16) suggests that the 
ternary components ethanol, 2-propanol, 1-butanol have identical roles as observed in co-
crystal (12) and (13) i.e. the ternary components acts as a bridge between the furosemide – 
bipyridyl aggregates and the three components are stabilised through the two-dimensional 
network observed in co-crystal (13). The two-dimensional network common to all the ternary 
co-crystals is shown in Scheme 5.1.  
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Scheme 5.1: (a) Representation of the two-dimensional network observed in co-crystals (2) – 
(7) (Abbreviations: TC – Ternary component (DMSO, DMF, MeOH, EtOH, 2-propanol, 1-
butanol), R- Furan ring). (b) conformational flexibility of the furosemide molecules. 
Table 5.3: Geometric aspects of co-crystals (11), (12), (13), (17), (18) and (19): 
Compound Hydrogen bond 
d 
(H···A)/Å 
d 
(D···A)/Å 
  
(D-
H···A)/
o
 
(H···A) vdW 
cutoff 
contraction / % 
11 O(1)-H(1)···N(3) 1.57 2.53(2) 166.5 43 
 N(2)-H(2)···O(1) 2.15 2.97(4) 157.2 21 
 N(2)-H(3)···O(2) 2.04 1.93(3) 169.2 25 
11(intra) N(1)-H(6)···O(2) 2.00 2.67(6) 134.6 26 
12 N(1)-H(6)···N(3) 2.11 2.99(4) 160.9 23 
 N(1)-H(7)···O(6) 2.13 2.91(7) 172.0 22 
 O(1)-H(1)···N(4) 1.75 2.56(3) 174.7 36 
 C(24)-H(28)···O(4) 2.53 3.38(5) 147.0 7 
12 C(23)-H(25)···O(3) 2.51 3.40(6) 166.4 8 
12(intra) N(2)-H(2)···O(2) 2.00 2.69(7) 139.5 26 
13 N(1)-H(6)···N(3) 2.18 2.97(8) 162.4 21 
 N(1)-H(7)···O(6) 2.02 2.89(6) 169.1 26 
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 O(6)-H(25)···O(3) 1.97 2.77(3) 161.4 27 
 O(1)-H(1)···N(4) 1.84 2.62(2) 173.2 33 
13(intra) N(2)-H(2)···O(2) 1.99 2.66(4) 138.5 27 
17 O(1)-H(1)···N(4) 1.69 2.60(3) 150.9 38 
 N(1)-H(6)···N(3) 1.98 2.91(3) 152.7 28 
 N(1)-H(7)···O(6) 2.09 2.93(4) 166.2 23 
 O(6)-H(25)···O(3) 2.02 2.78(6) 153.5 26 
17(intra) N(2)-H(2)···O(2) 2.00 2.66(3) 139.8 26 
18 O(1)-H(1)···N(3) 1.81 2.62(2) 169.5 34 
 N(1)-H(6)···N(4) 2.11 2.97(6) 160.2 23 
 O(6)-H(25)···O(4) 1.89 2.75(4) 176.0 30 
 N(1)-H(7)···O(6) 2.01 2.88(2) 171.7 26 
18(intra) N(2)-H(2)···O(2) 1.97 2.66(5) 137.1 27 
19 O(1)-H(1)···N(4) 1.83 2.61(6) 173.6 33 
 N(1)-H(6)···N(3) 2.12 2.92(6) 162.4 23 
 N(1)-H(7)···O(6) 2.14 2.95(3) 157.9 21 
 O(6)-H(25)···O(3) 1.87 2.70(4) 173.6 31 
19(intra) N(2)-H(2)···O(2) 2.02 2.65(2) 138.1 26 
 
The discovery of the asymmetric two-dimensional hydrogen-bonded network (Scheme 5.1) in 
all the ternary co-crystals, allowed for the prediction of space group and gross structural 
features in related compounds from their molecular structure, the π–π interactions between 
aromatic moieties of furosemide and bipyridyl play significant role in stabilising the crystal 
structures. In addition, to the space group and gross structural features the lattice metrics a, b, 
c and β are depended on the structural features discussed earlier.  
To predict the crystal packing arrangement in other ternary co-crystals and to test the 
robustness of the two-dimensional network, the compounds ethylene glycol, 1,4-butanediol 
and hydroquinone were used as ternary components (Scheme 5.2). The ternary components 
ethylene glycol, 1,4-butanediol and hydroquinone selected possess mirror planes in their 
molecular structure. With no chiral centres in the molecular structures of any of the 
components, the number of possible space groups reduces to P1̅, based on the asymmetric 
two-dimensional network.  
143 
 
 
S
O O
NH2
Cl
NH
O
OH
O
NN
HO
OH
HO
OHfurosemide
4,4'-bipyirdyl hydroquinone
ethyleneglycol
1,4-butanediol
HO OH
 
Scheme 5.2: Molecules used for the prediction of crystal structures. 
 
 
Scheme 5.3: Two-dimensional network as building block and the corresponding extended 
solids network. 
Based on the molecular structure of the three components, the asymmetric two-dimensional 
network and the π–π interactions between furosemide – bipyridyl aggregates observed in co-
+ 
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extended structures 
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crystals (13), one can predict the formation of extended solids, crystallised through the robust 
two-dimensional network discovered earlier. A pictorial representation of the extended solids 
is shown in Scheme 5.3. 
5.6. Co-crystals (17) [(furosemide – 4,4’-bipyridyl – ethylene glycol (1-1-0.5))]; (18) 
[(furosemide – 4,4’-bipyridyl – 1,4-butanediol (1-1-0.5))]; (19) [(furosemide – 4,4’-
bipyridyl – hydroquinone (1-1-0.5))] 
Mechanochemical synthesis of co-crystals (17), (18), (19) 
Co-crystals (17) and (18) were synthesised by grinding furosemide (1mmol, 33.0mg) and 
4,4’-bipyridyl (1mmol, 15.6mg) in the presence of 10μl of ethylene glycol and 1,4-butanediol 
respectively for 5 minutes. Co-crystal (19) (furosemide – 4,4’-bipyridyl – hydroquinone (1-1-
0.5)) is synthesised by grinding furosemide (1mmol, 33.0mg), 4,4’-bipyridyl (1mmol, 
15.6mg) and hydroquinone (0.5mmol, 5.5mg) in presence of 20μl of acetonitrile for 3 
minutes using a mortar and pestle. 
 
Figure 5.19: ORTEP picture of co-crystal (17) (furosemide – bipyridyl – ethylene glycol) (1-
1-0.5).  
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Crystallisation of co-crystals (17), (18) and (19)   
Diffraction quality crystals of co-crystals (17) and (18) were obtained by dissolving 1-1 
molar amounts of furosemide (1 mmol, 33.0 mg) and 4,4’-bipyridyl (1 mmol, 15.6 mg) in 2.0 
ml of ethylene glycol and 2.0 ml of 1,4-butanediol respectively and allowing them crystallise  
through slow evaporation. Single crystals of co-crystals (17) and (18) were obtained after 6 
days. Crystals of co-crystal (19) (furosemide – 4,4’-bipyridyl – hydroquinone (1-1-0.5)) are 
synthesised by dissolving furosemide (1mmol, 33.0mg), 4,4’-bipyridyl (1mmol, 15.6mg) and 
hydroquinone (0.5mmol, 5.5mg) in 3ml of acetonitrile and allowing them to crystallise  
through slow evaporation of solvent. Single crystals of co-crystal (19) were isolated from the 
crystallisation flask after 4 days. 
5.6.1. Crystal structure of co-crystal (17) [(furosemide – 4,4’-bipyridyl – ethylene glycol 
(1-1-0.5))] 
The crystal structure analysis reveals the structural features in co-crystal (17). As anticipated, 
the asymmetric unit of (17) consists of one molecule each of furosemide and 4,4’-bipyridyl 
and half a molecule of ethylene glycol (Figure 5.19). The three components, as predicted 
crystallise in the space group P1̅ and are stabilised through the asymmetric two-dimensional 
hydrogen-bonded network. The full crystallographic details are given in Table 5.4. 
 
Figure 5.20: Interactions between furosemide and ternary component ethylene glycol in co-
crystal (17) viewed along the [001] direction. 
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Analogous to other ternary co-crystals, the anti N-H and syn S=O (syn and anti with respect 
to chlorine) of furosemide are hydrogen-bonded to the acceptor and donor groups of ternary 
components through N(1)-H(7)···O(6) and O(6)-H(25)···O(3) hydrogen bonding interactions 
(Table 5.3) (Figure 5.20). Similar to other ternary co-crystals the hydrogen bonding 
interactions between furosemide and the ternary component, in this case ethylene glycol, 
extend along the a crystallographic axis, since ethylene glycol possess and inversion center, 
similar hydrogen bonding interactions extend on the other end of the molecule (Figure 5.20). 
In addition to these interactions, one end of the bipyridyl is hydrogen-bonded to the syn N-H 
of furosemide through N(1)-H(6)···N(3) interactions while the other end of bipyridyl 
participates in an acid pyridine supramolecular heterosynthon through O(1)-H(1)···N(4) and 
C(22)-H(22)···O(2) interactions (Table 5.3) (Figure 5.21). While the hydrogen bonding 
interactions between the furosemide and the bipyridyl molecules are common in all the 
ternary co-crystals, these interactions in co-crystal (17) propagate almost parallel to the c 
crystallographic axis as shown in Figure 5.21. The three components arrange via the two 
dimensional network as shown in Figure 5.22. In addition to the hydrogen bonding 
interactions, there are strong π–π (3.362(2)Å and 3.285(4)Å) (Figure 5.23) interactions 
between the aromatic moieties of furosemide and bipyridyl. Analogous to other ternary co-
crystals the π–π interactions between the aromatic moieties of furosemide and bipyridyl are 
arranged in a slipped offset face-to-face/ center-to-edge fashion with a slip angle of 5.87
o
.  
 
Figure 5.21: Interactions between furosemide and bipyridyl molecules in co-crystal (17) 
viewed along the [100] direction. 
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Figure 5.22: Two-dimensional network formed by the three components in co-crystal (17), 
viewed along the [010] direction. 
 
 
Figure 5.23: π–π interactions in co-crystal (17). 
  
b 
c a 
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Thermal analysis of co-crystal (17) 
The TGA/ DTA analysis of co-crystal (17) indicate a broad transition with an onset at 69.8
o
C, 
corresponding to a weight loss of around 4.9%. This transition and the corresponding weight 
loss are due to evaporation of surface bound ethylene glycol molecules, which is the solvent 
of crystallisation. This transition is followed by a transition at 116.3
o
C, with an onset of 
110.0
o
C, with a corresponding weight loss of 6.5%. This transition and the corresponding 
weight loss are equal to the loss of half molecule of lattice bound ethylene glycol molecule. 
This is followed by a transition in the DTA curve at 220.5 
o
C with an onset at 216.8 
o
C, 
which is due to the melting of the compound. This transition is immediately followed by 
decomposition. The DTA/ TGA thermograms of (17) are indicated in Figure 5.24. 
 
Figure 5.24: TG/DTA of co-crystal (17). 
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5.6.2. Crystal structure of co-crystal (18) [(furosemide – 4,4’-bipyridyl – 1,4-butanediol 
(1-1-0.5))] 
The single crystal X-ray diffraction analysis of co-crystal (18) reveals that the asymmetric 
unit of (18) consist of one molecule each of furosemide, 4,4’-bipyridyl  and half molecule of 
1,4-butanediol (Figure 5.25).  
 
 
Figure 5.25: ORTEP plot of Co-crystal (18). 
 
Figure 5.26: Hydrogen bonding arrangement between furosemide and bipyridyl molecules in 
co-crystal (18) along the [010] direction. 
The arrangement of the three components in (18) is similar to that observed in other ternary 
co-crystals. The three components in (18) are arranged via the asymmetric two dimensional 
hydrogen-bonded network while crystallizing in space group P1̅. The full crystallographic 
details are given in Table 5.4. The syn N-H (with respect to chlorine) and the carboxylic O-H 
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are hydrogen-bonded to the pyridyl nitrogen’s of 4,4,’-bipyridyl through O(1)-H(1)···N(4) 
and N(1)-H(6)···N(3) interactions (Table 5.3) (Figure 5.26), the anti N-H of furosemide is 
hydrogen-bonded to the oxygen of the 1,4-butanediol to form N(1)-H(7)···O(6) hydrogen 
bonds, while the O-H group of 1,4-butanediol is hydrogen-bonded to the  of the sulphoxide 
group of furosemide though O(6)-H(25)···O(3) interactions (Table 5.3) (Figure 5.27). 
Analogous to co-crystal (17), since the ternary component 1,4-butanediol contains an 
inversion centre in its molecular structure, the three components crystallise  with the 1,4-
butanediol possessing an inversion centre, with the two-dimensional network extending on 
the other end of the molecule. Analogous to other ternary co-crystals the π–π interactions 
between the aromatic moieties of furosemide and bipyridyl are arranged in a slipped offset 
face-to-face/ centre-to-edge fashion with a slip angle of 7.82
o
 (Figure 5.28). The two-
dimensional network in co-crystal (18) is similar to the two-dimensional network observed in 
co-crystal (13). The two-dimensional network extends diagonally in the [010] direction as 
shown in Figure 5.29. 
 
Figure 5.27: Packing arrangement in co-crystal (18) along the [010] direction. 
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Figure 5.28: π–π interactions between aromatic moieties of furosemide and bipyridyl in co-
crystal (18). 
 
Figure 5.29: two-dimensional pattern in co-crystal (18) viewed along the [010] direction. 
DTA/TGA of co-crystal (18) 
The TGA/ DTA thermogram of co-crystal (18) are shown in Figure 5.30. The DTA 
thermogram indicates a transition at around 100.1
o
C, with a corresponding weight loss of 
8.85% in the TG curve. This corresponds to the loss of half mole of 1,4-butanediol from the 
crystal lattice. In addition to this the DTA shows transitions at 159.4
o
C followed by transition 
corresponding to the melting of the material at 207.2
o
C which is followed by decomposition 
of the material. 
b 
c a 
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Figure 5.30: DTA/TGA of co-crystal (18). 
 
Figure 5.31: ORTEP picture of co-crystal (19). 
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5.6.3. Crystal structure of co-crystal (19) [(furosemide – 4,4’-bipyridyl – hydroquinone 
(1-1-0.5))] 
The ternary co-crystal (19) contains one molecule each of furosemide, 4,4’-bipyridyl and half 
molecules of hydroquinone in the asymmetric unit (Figure 5.31). The three components 
stabilised through the two–dimensional network (Figure 5.35) and π–π interactions (Figure 
5.32) crystallise  in P1̅ space group (Table 5.4). Analogous to co-crystals (11)–(18), the 
bipyridyl molecule links two furosemide molecules through acid–pyridine and pyridine–
amine supramolecular synthons (Figure 5.33) to form parallely arranged furosemide – 
bipyridyl aggregates. These furosemide bipyridyl aggregates are linked through N(1)-
H(7)····O(6) and O(6)-H(25)···O(3) hydrogen bonding interactions (Table 5.3) formed by the 
hydroxyl group of hydroquinone (Figure 5.34). The ternary component, hydroquinone holds 
an inversion centre thereby allowing the non-covalent interactions to extend on the other end 
of the molecule (Figure 5.34). The π–π interactions in co-crystal (19) are analogous to other 
ternary co-crystals, arranged in a offset face–to–face / center–to–edge fashion with a slip 
angle of 12.7 
o
. 
 
Figure 5.32: π – π interactions in co-crystal (19). 
 
Figure 5.33: Interactions between furosemide and bipyridyl in co-crystal (19) viewed along  
the [100] direction. 
b 
c a 
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Figure 5.34: Interactions between furosemide and hydroquinone in co-crystal (19) viewed 
along the [001] direction. 
 
Figure 5.35: Two-dimensional hydrogen-bonded network observed in co-crystal (19) viewed 
along the [010] direction. 
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DSC of co-crystal (19) 
The DSC thermogram of co-crystal (19) was performed using 6.152 mg of the sample.  The 
thermogram of (19) reveals a sharp endotherm at 210.8 
o
C with an onset at 207.4 
o
C, which 
corresponds to the melting of (19). The melting temperature of (19) is significantly diferent to 
the melting temperature of the other two components (4,4’-bipyridyl (112-114 oC); 
hydroquinone (170-172 
o
C )) . The DSC thermogram shows that the melting of (19) is 
followed by decomposition (Figure 5.36). 
 
Figure 5.36: DSC of co-crystal (19). 
 
Table 5.4: Crystallographic Data of co-crystals (9), (10) and (11) 
 (9) (10) (11) 
Chemical 
formula 
C24H25Cl1N4O6S2 C24H25Cl1N4O6S2 C24H25Cl1N4O6S2 
Formula weight 518.0 532.0 542.0 
Crystal system Triclinic Triclinic Triclinic 
a / Å 6.7510(5) 7.3972(7) 6.9302(4) 
b / Å 9.5719(6) 9.3373(8) 9.9356(6) 
c / Å 18.6178(13) 18.1141(16) 18.6298(11) 
Temp Cel
250.0200.0150.0100.050.0
D
S
C
 m
W
1.000
0.000
-1.000
-2.000
-3.000
-4.000
-5.000
-6.000
-7.000
D
D
S
C
 m
W
/m
in
210.8Cel
-6.720mW
207.4Cel
-0.149mW
36.5mJ/mg
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α / o 84.977(4) 80.504(4) 83.633(3) 
β / o 89.783(4) 82.039(4) 89.624(3) 
γ / o 73.488(4) 75.173(4) 72.794(3) 
Space group P1̅ P1̅ P1̅ 
V / Å
3
 1148.76(14) 1186.81(19) 1217.34(13) 
Z 2 2 2 
N reflection/ 
Nparameter 
6368/319 7624/325 5405/334 
ρcalc / g cm
-3
 1.497 1.489 1.479 
Radiation type 
Mo Kα (λ 
=0.710173 Å) 
Mo Kα (λ 
=0.710173 Å) 
Mo Kα (λ 
=0.710173 Å) 
T / K 100 100 100 
 range/° 1 – 34 1 – 37 1 – 29 
Range of h -10 – 10 -12 – 12 -9 – 9 
Range of k -14 – 14 -15 – 12 -13 – 12 
Range of l 0 – 29 -30 – 30 -24 – 25 
Rmerge 0.0360 0.0399 0.0239 
R1 / % 6.73 3.76 4.36 
WR2 / % 6.40 4.22 3.66 
Goodness-of-fit 0.965 1.030 1.098 
 
5.7. Conclusion  
In theory an attempted co-crystallisation of molecules containing sulphonamide, carboxylic 
acid, halogen, furan, pyridine, sulphoxide and hydroxyl functional groups could result in the 
formation of several products stabilised through a plethora of intermolecular interactions. 
These functional groups are known to participate in various heteromeric and homomeric 
interactions. However, in the study presented here it has been shown that the supramolecular 
reaction between furosemide, 4,4’-bipyridyl and DMSO resulted in the formation of a solid 
stabilised through an infinitely arranged two-dimensional network as observed in co-crystal 
(12). The space group and the arrangement of the components in co-crystal (12) served as a 
blueprint for the selection and synthesis of co-crystals (13)–(16). Crystal structure 
determination of co-crystal (13) and powder pattern indexing of co-crystals (14)–(16) 
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suggests that the three components in (14)–(16) are stabilised through an analogous 
asymmetric two-dimensional hydrogen-bonded network. The discovery of the asymmetric 
robust-two dimensional network in ternary co-crystals allowed for the prediction of space 
group symmetry and gross structural features in ternary co-crystals (17)–(19). Prediction of 
gross structural features and space group symmetry in (17)–(19) at this level of accuracy is 
unprecedented in organic crystal engineering. We have obtained eight new molecular 
complexes, seven of which involve three components, that are constructed using the identical 
supramolecular synthons involving (a) acid–pyridine, (b) amine–pyridine, (c) arene–arene, 
(d) amine–sulphoxide in co-crystal (12) while (d) amine – hydroxyl and (e) hydroxyl–
sulphoxide in ternary co-crystals (13)–(19). The supramolecular reaction involving the above 
supramolecular synthons results in the formation of a high yielding product stabilised through 
a robust asymmetric two-dimensional hydrogen-bonded network, can be classified as a high-
yielding supramolecular reaction.
186
 Here, robust is defined as the ability of the asymmetric 
two-dimensional hydrogen-bonded network to maintain its dimensionality and general 
structural features when changes occur in the ancillary functional groups. We have shown 
that the robust two-dimensional network serves as a building block for the synthesis of 
extended solids (17)–(19). Extended solids are common in metal-organic frameworks, 
wherein a polyvalent metal ion acts as an effective multi-dimensional hub, between which 
organic linkers are connected to form a three dimensional structure. In such solids, the metal-
coordination bonds stabilize the crystal structures. While, extended solids formed through 
metal-organic frameworks are common, there are very few examples of rationally synthesised 
extended solids stabilised though ionic interactions between organic components. To the best 
of our knowledge, there are no examples of extended solids in the literature stabilised through 
neutral hydrogen bonding interactions, especially in cases containing three or more 
components. While the geometry of all the functional groups are important, the pseudo–
tetrahedral shaped sulphonamide group is central to all the ternary co-crystals, the three 
components hydrogen bond by exploiting the pseudo–tetrahedral geometry of the 
sulphonamide group, based on this we can also conclude that it is essential for all of the 
donors of furosemide to participate in hydrogen bonding interactions. The π–π interactions 
play a significant role in the assembly of the molecules. While in co-crystal (11) the bipyridyl 
molecule crystallises by occupying the inversion centre, in all other ternary co-crystals it acts 
as a ditopic hydrogen bond acceptor by bridging between the furosemide molecules leading 
to the formation of the asymmetric two-dimensional network. Finally it can be concluded that 
solid state architectures formed by neutral hydrogen bonding interactions can be predicted by 
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crystal engineering methods. Identifying such robust hydrogen bonding networks formed by 
different combinations of supramolecular synthons is crucial for effective crystal engineering. 
It has been shown a robust two–dimensional network can serve as a supramolecular 
module
187
 or synthon for directing the assembly of the components in three dimensions. The 
results presented here show that the synthesis of two–dimensional networks through 
hydrogen bonding requires the presence of polyvalent functional groups with three or more 
hydrogen bonding functionalities. The robust two–dimensional hydrogen-bonded networks of 
the type presented here can be considered to be crucial for nano-structural elements.
188
 The 
results presented here also indicate that physical mixtures of two components can be used for 
the synthesis of ternary co-crystals. 
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Chapter 6: Conclusions and Further Work 
6.1. Conclusions 
In the thesis presented here the co-crystallisation of two APIs, paracetamol and furosemide 
are discussed. Co-crystals are molecular complexes containing two or more components in 
the crystal lattice. All the co-crystals presented in the thesis are synthesized by 
mechanochemical and crystallisation methods. The co-crystals are then analysed by X-ray 
diffraction to understand the intermolecular interactions. The following conclusion are drawn 
from the work presented here.  
6.1.1. Molecular complexes of paracetamol 
In chapter 3 the co-crystals of paracetamol are described. The strongest hydrogen bonding 
interactions in paracetamol are formed between the phenolic O-H and the amidic oxygen to 
form O-H∙∙∙O=C interactions. In co-crystals (1)–(3), these interactions are replaced by the O-
H∙∙∙N interactions while in co-crystal (4) they are replaced by the O-H∙∙∙O between the PAC 
and CCF. The interactions observed in (1)–(4) are in accordance with the empirical rules 
followed by Etter. The hierarchical arrangement between the best donors to the best acceptors 
is in agreement with all the previous reported multi-component crystalline forms of 
paracetamol. In addition to the best donor to best acceptor interactions there are additional 
hydrogen bonds in each of the molecular complexes. Co-crystal (2) has additional N−H∙∙∙O 
and O−H∙∙∙O=C interactions due to the incorporation of solvent molecules in the crystal 
lattice. In (3), there are N−H∙∙∙N interactions between the API and CCF. In (4), the 
paracetamol molecules are hydrogen bonded to the carbonate anion through O−H∙∙∙O 
synthon. The cyclam molecules in (4) does not participate in hydrogen bonding interactions 
with the paracetamol molecules and acts as a spacer between the pair of paracetamol and 
carboxylate chains.  
The results presented in chapter 3 suggest that difunctional CCFs are necessary for co-crystal 
formation with paracetamol. While CSD analysis suggests that the carboxylic acids and 
amide groups containing molecules as potential co-crystal formers, the experimental results 
suggest that these are not effective. The study shows that a balance between the retrosynthetic 
approach (synthon method) and database guided co-crystal screening of supramolecular 
synthons provides a useful approach to the targeted co-crystal synthesis. 
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6.1.2. Molecular complexes of furosemide 
Furosemide is a loop diuretic drug, and suffers from both low permeability and solubility. To 
understand the intermolecular interactions and to rationally predict the crystal packing 
arrangements a series of molecular complexes of furosemide were synthesized and presented 
in chapter 4. The study demonstrates that the crystal packing arrangement of the furosemide 
complexes is dependent on the dominant intermolecular interaction in the complex. The 
charge assisted hydrogen bonding interaction (Scheme 6.1(a)) is the dominant interaction in 
the molecular complexes (5) to (9) and drives the crystal packing arrangement leading to the 
formation of isostructural host-guest complexes, thereby allowing to rationally predict the 
crystal packing arrangement of other complexes. However, such persistent crystal packing 
arrangement was not observed in complex (10), where the two components are stabilised 
through a neutral acid-pyridine supramolecular synthon (Scheme 6.1(b)). The results show 
that subtle change in the dominant intermolecular interaction can alter the packing 
arrangement significantly. 
NHN
N
N
N
N
N
H
H
N NH
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N RHO
O
R
N N
NHO
R
O H
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imidazole trans-1,4-di(4-pyridyl) – ethylene
1,2-bis(4-pyridyl) – ethane
piperazine 1,4,8,11-tetraazacyclotetradecane
(a) charge assisted O-H---N
 supramolecular synthon
4,4'-bipyridyl
(b) neutral acid-pyridine
 supramolecular synthon
 
Scheme 6.1: Supramolecular synthons studied in chapter 4. The dotted lines indicate 
hydrogen bonding interactions 
6.1.3. Proton transfer 
The empirical rule for proton transfer based on the pKa values suggests that proton transfer 
will occur from acid to base when the difference in pKa (ΔpKa = pKa(base) - pKa(acid)) is > 
3.5. In the six molecular complexes studies in chapter 4, proton transfer was found to occur in 
complexes (5)–(9). Based on the results observed in complexes (8) and (9) it could be 
predicted that molecular complex (10) would be stabilised through charge transfer 
interaction. However, this was not the case; the two components in (10) are held together 
through neutral acid-pyridine heterosynthon when crystallised under similar solvent and 
temperature conditions. There is no question that further work is required on this aspect, with 
a wider range of pH levels and co-molecules, whilst controlling other experimental 
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conditions. However these limited results add another set of examples that call into question 
the robustness of the pKa rule.  
 
6.1.4. The asymmetric two-dimensional hydrogen bonded network 
In chapter 4, it was shown that the charge assisted hydrogen bonding interaction drives the 
crystal packing. In chapter 5 the work on predicting the crystal packing arrangement was 
further extended whilst working with furosemide. In theory an attempted co-crystallization of 
FUR, BIPY and DMSO could result in the formation of several products stabilised through a 
plethora of intermolecular interactions. However, the study shows that the supramolecular 
reaction between furosemide, 4,4’-bipyridyl and DMSO results in the formation of a solid 
stabilised through an infinitely arranged two-dimensional network as observed in co-crystal 
(12).  
The space group and the crystal packing arrangement in co-crystal (12) served as a blueprint 
for the selection and synthesis of other ternary co-crystals (13)–(16). Crystal structure 
determination of co-crystal (13) and powder pattern indexing of co-crystals (14)–(16) 
suggests that the three components in (14)–(16) are stabilised through an analogous 
asymmetric two-dimensional hydrogen-bonded network (Scheme 6.2). The discovery of the 
asymmetric robust-two dimensional network in ternary co-crystals allowed for the prediction 
of space group symmetry and gross structural features in other ternary co-crystals (17)–(19). 
The pseudo-tetrahedral shape of the sulphonamide group and the planarity of the carboxylic 
acid groups are central to all of the ternary co-crystals presented in chapter 5. The study 
demonstrates that networks that can maintain their dimensionality and integrity when changes 
occur in the ancillary functional groups provide a degree of predictability in the crystal 
packing arrangements in the solid state. Identification of similar robust n-dimensional 
networks may therefore offer a means of improving the effectiveness of crystal engineering. 
The study also shows that physical mixtures of components can be used for the synthesis of 
new higher order co-crystals. 
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Scheme 6.2: Schematic illustration of the two-dimensional network observed in all 
ternary co-crystals (12)–(19). R = furfuryl group, TC = ternary component ( DMSO; 
MeOH; ethanol; 2-propanol; 1-butanol; ethylene glycol; 1,4-butanediol; 
hydroquinone). The dotted lines indicate hydrogen bonding interactions. 
 
6.2. Further work 
The compounds presented in the thesis are fully characterised. However, given further time 
and extensive investigation, other novel co-crystals of paracetamol or related molecules can 
be produced by utilizing the robust O-H∙∙∙N supramolecular synthon identified in Chapter 3. 
The work on co-crystals of paracetamol can be extended for the synthesis of other ternary co-
crystals. The understanding of intermolecular interactions in co-crystal (2) serves as a good 
starting point for this purpose. It can be anticipated that other ternary co-crystals can be 
synthesised by replacing the methanol in (2) with other hydroxyl group containing molecules.  
Furosemide is a diuretic drug with low permeability and water solubility, the CCFs used in 
molecular complexes (5) and (6) belong to the class of materials categorised as generally 
recognised as safe (GRAS). The complexes (5) and (6) can serve as an alternative for oral 
dosage of furosemide. However, further work is necessary to study the stability, 
bioavailability and dissolution profiles of these molecular complexes. In addition, the charge 
assisted hydrogen bonding interaction can be used as a rationale for the synthesis of other 
molecular complexes whilst using GRAS listed CCFs. 
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The synthesis of ternary or higher order crystals remains to be a challenge in organic crystal 
engineering. The robust 2-D network identified in chapter 5 can serve as a rationale for the 
synthesis of ternary co-crystals in molecules containing similar functional groups. 
6.3. Concluding remarks. 
The prediction of crystal packing arrangements of a molecular complex from the molecular 
structure under a defined set of conditions remains a challenge in organic crystal engineering. 
The work presented here identifies empirical based strategies to predict the crystal packing 
arrangements in molecular complexes of active pharmaceutical ingredients. One such 
strategy is based on utilizing the dominant hydrogen bonding interaction in molecular 
complexes, i.e. the charge-assisted hydrogen bonding interactions. The other is based on 
identifying robust supramolecular synthons which lead to the formation of extended motifs in 
molecular complexes. The two strategies were found to be promising to make reasonable 
predictions on the likely molecular association and packing of molecular complexes in the 
families of compounds presented here.  
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